PhIRDA
中国药促会

中國医药工业科研开发促進会

CHINA PHARMACEUTICAL INDUSTRY RESEARCH AND DEVELOPMENT ASSOCIATION

2013-2014 会刊
ASSOCIATION JOURNAL

IN

NOVATION

DUSTRIALIZATION

TERNATIONALIZATION

contents

简 介
BRIEF INTRODUCTION

中国医药工业科研开发促进会（简称中国药促会，英文名称为China Pharmaceutical Industry Research and Development Association，英文缩写为SINO-PhIRDA）成立于1988年，是经国家民政部登记注册的非营利性全国性一级社会团体组织。

目前，中国药促会有会长及会员单位60多家，主要由三方面的成员构成：一是，在医药创新方面具有代表性的民族医药企业；二是，从事医药研发的高等院校和科研院所；三是，在新药临床研究领域具有较高水平、特别是承担“重大新药创制”科技重大专项新药临床评价研究（GCP）技术平台的临床医疗机构。中国药促会将努力建设成为以研发为核心，以创新为宗旨，以临床需求为导向，“产学研用”紧密结合的促进医药科研开发的社会团体。

中国药促会的工作内容主要包括：一是，通过举办各种论坛、发布会、大型会议等促进会员单位乃至整个医药产业互相交流、创新发展；二是，通过与美国药品研发和制造商协会（PhRMA）等国外协会和外国驻华使馆合作，共同寻求推动中外医药产业领域的合作交流，为会员单位搭建国际交流平台；三是，为会员单位提供医药信息搜集、整理、评价、咨询的服务，包括编辑双月刊刊物《医药科研开发信息》和每日《医药信息简报》、每周《国际医药产业发展动态与研发信息简报》、《行业热点评析》等内部电子刊物以及建设中国药促会官方网站等内容；四是，开展医药政策研究工作，在卫生计生委、商务部、工信部、国家食品药品监督管理总局等有关政府部门和医药科研学术机构和企业的支持下，为医改事业和医药产业发展建言献策。

中国药促会将围绕 “创新、产业化、国际化”的宗旨，加强行业自律，推动我国医药行业的技术进步，促进我国医药产业健康发展，为加快我国经济社会发展、保障人民群众健康不断做出贡献！

Founded in 1988, China Pharmaceutical Industry Research and Development Association (SINO-PhIRDA) is registered as a non-profitorganization by the Ministry of Civil Affair of China at the first national level.

At current stage, SINO-PhIRDA has more than 60 members which are three major categories: First, national pharmaceuticalenterprises excelling at medical innovation; Second, universities, colleges and research institutions conducting pharmaceutical research and development;Third, clinical institutions featuring high skills in applicable research on new drugs,especially those undertake “major new drug innovation” technological platform for good clinical practice. SINO-PhIRDA will exert great effort to grow into a social organization featuring “university-industry collaboration”, an organization which centers on research and development, persists in innovation to achieve unmet clinical requirements.

Major work of SINO-PhIRDA includes: First, to promote communication and innovative development of our member units and even the whole pharmaceutical industry through forums, press-conferences, summits, etc; Second, to make efforts to establish an international exchange platform for our member units through cooperation with foreign embassies and foreign associations such as PhRMA to stimulate communication between China and foreign countries in pharmaceutical field; Third, to improve the website of SINO-PhIRDA and provide collecting, arranging, revising and consulting service of pharmaceutical information, which includes the following internal e-magazines such as the bimonthly journal Scientific and Technological Development Information on Pharmacy, Daily Pharmaceutical Information Brief, Weekly International Pharmaceutical Development Tendency and Research Information Brief; Fourth, to conduct pharmaceutical policy research, propose valuable suggestions on healthcare reform and the development of pharmaceutical industry , with the help from the National Health and Family Planning Commission(of the people’s Republic of China) Ministry of Commerce, Ministry of Industry and Information Technology, CFDA and other concerned government departments.

Focusing on the principle of “innovation,industrialization,internationalization”, SINO-PhIRDA will strengthen self-discipline, promote technological progress for and enhance healthy development of our national pharmaceutical industry, making constant contributions to the greater economic development of our country and public health.

机构设置
ORGANIZATIONAL STRUCTURE OF ASSOCIATION



致中国医药工业科研开发促进会第九届会员大会第四次会议的贺信

十一届全国人大常委会副委员长
中国工程院院士
中国药促会荣誉会长
桑国卫

各位代表：

在中国医药工业科研开发促进会第九届会员大会第四次会议召开之际，我向大会表示热烈的祝贺！由于国家安排我于本月15至23日率团访问巴西，无法到会与大家见面，衷心希望大家能够谅解。

中国药促会九届三次会员大会以来，秉承“创新、产业化、国际化”宗旨，坚持民主决策，实行科学规范管理，得到了会员单位和医药界的肯定。我和大家都感到很欣慰。

在过去的一年里，中国药促会围绕“创新药物的审批政策研究”和“创新药物的市场环境建设”两大工作重点，配合政府有关部门开展专项研究工作，研究领域涉及“重大新药创制”知识产权保护、创新药物审批机制、仿制药一致性评价政策、医保用药管理、基本药物法律制度等多个方面。通过开展课题探究、专题研讨会、地方调研等方式，为完善和构建我国医药政策环境体系作出了不懈的努力。同时还加强国际交流活动和提高信息服务水平，探索更多渠道、采用更多样化的方式，不断提升会员的服务质量。这是十分值得肯定的！

同时，中国药促会为维护行业的利益，不断为医药产业健康发展发出声音。先后针对广东省药品交易规则征求意见稿和上海市医保药品试行“带量采购”实施方案征求意见稿提出修改建议，得到了业界的广泛关注和积极响应，已经产生了一定的影响作用。

党的十八大明确提出“实施创新驱动发展战略”和“加快建设国家创新体系，着力构建以企业为主体、市场为导向、产学研相结合的技术创新体系”。增强新药创制能力被列为医药工业“十二五”规划中的首要任务。在前不久举行的第九次中共中央政治局集体学习会，专门以实施创新驱动发展战略为主题，习近平总书记在会上提出了如何加强创新发展的5个方面的任务。十二五期间是我国医药创新发展的重要时期，是落实十八大精神的开局之时。在新的一年里，希望中国药促会乘着国家鼓励创新的东风，继续围绕“创新、产业化、国际化”的宗旨，顺应形势，真正成为中国民族医药产业创新企业的代表性团体。

我也衷心希望中国药促会的各个会员单位认真贯彻落实十八大创新驱动发展战略，加强创新，加强自律，积极参与中国药促会的各项工作，为改善我国医药创新市场环境与促进我国医药创新发展、提高人民的健康保障水平做出应有的贡献！

祝会员大会取得圆满成功！

桑国卫

二〇一三年十月十七日

致“2013国际医药创新大会”的贺信

十一届全国人大常委会副委员长、中国工程院院士 中国药促会荣誉会长 桑国卫

参加“2013国际医药创新大会”的各位嘉宾：

在由中国国际商会、中国医药工业科研开发促进会、药物信息协会、中国医疗保险研究会、北京市卫生局、北京市食品药品监督管理局主办的“2013国际医药创新大会”召开之际，我向大会表示热烈的祝贺！我已经为本次大会认真准备了关于我国创新医药产业发展的报告。但是，由于我根据国家安排,本月15至23日率团出访巴西，无法到会，衷心希望大家能够谅解。

本次大会的主题是鼓励医药创新，优化医药创新的生态环境。中国政府一直重视医药产业的创新发展，中国共产党十八大作出了实施创新驱动发展战略的重大部署，十八大报告中也明确：“科技创新是提高社会生产力和综合国力的战略支撑，必须摆在国家发展全局的核心位置”，“把全社会智慧和力量凝聚到创新发展上来”。9月30日，国家主席习近平强调，要敏锐把握世界科技创新发展趋势，切实把创新驱动发展战略实施好。他就此还为发展科技创新提出了五方面任务：一是着力推动科技创新与经济社会发展紧密结合；二是着力增强自主创新能力；三是着力完善人才发展机制；四是着力营造良好政策环境；五是着力扩大科技开放合作。

医药科技创新能够提升医药产业健康可持续发展的核心竞争力和根本驱动力。我们都很高兴地了解到，这次大会将为医药创新活动提供一个非常好的沟通和合作的平台。大会不仅设立药物政策专题讨论，从药品审批、医疗保险、定价、招标、知识产权保护等医药创新相关的多个环节提供政府、企业、专家交流互动的机会，而且还设立了药物研发技术分论坛和商业桥，让参会者了解到临床试验设计、临床数据管理、生物仿制药等相关问题的国际前沿动态，并为参会企业提供了来自加拿大、波兰、丹麦等国家的几十个研发项目。会议内容可谓丰富，实用。

促进医药技术创新，加快培育健康可持续发展的医药产业，已经成为全球的共识。2013国际医药创新大会的召开，将极大鼓舞和促进中外医药产业界的交流与合作！我衷心地希望与会的医药界同仁能够都有所得，共同努力，为改善全球医药创新市场环境与促进全球医药创新发展、提高人类的健康保障水平做出应有的贡献！祝大会取得圆满成功！

桑国卫

二〇一三年十月十八日

Congratulatory Letter to The Fourth Meeting of 9th SINO-PhIRDA General Assembly

Sang Guowei
Vice Chairman of the Standing Committee of Eleventh National People's Congress
Honorary Chairman of SINO-PhIRDA, Academician of Chinese Academy of Engineering
October 17,2013

Dear Representatives:

I would like to express my sincere congratulations to the Fourth Meeting of 9th SINO-PhIRDA General Assembly. According to the nation's arrangements, I have to lead a delegation to visit Brazil during October 15-23, and I sincerely thank your understanding on my absence.

Since the Third Meeting of 9th SINO-PhIRDA General Assembly, we are happy to see that the association focuses on the goal of "Innovation, Industrialization, Internationalization", adheres to the principle of democratic decision-making, implements scientific and standardized management, which received good recognition from the members and the pharmaceutical industry.

During last year, SINO-PhIRDA focuses on two major areas "research on the approval policies on innovative drugs" and "market environment construction for innovative drugs", cooperated with relevant government departments to carry out research projects on Major New Drug Innovation IP protection, approval mechanism of innovative drugs, consistency evaluation policy of generics, healthcare insurance medicine management, essential drug policy, etc. SINO-PhIRDA has made unremitting efforts to improve and construct the healthcare policy eco-system in China by conducting research, workshops/ seminars, local investigations, etc. Meanwhile, the Association promotes international exchange and cooperation, as well as information service standard to constantly improve the quality of member services in more diversified manners and approaches. This is worthy of recognition.

At the same time, SINO-PhIRDA continues to make suggestions to promote the healthy development of pharmaceutical industry in order to safeguard the interests of the industry. The association suggested changes to "Pharmaceutical Trading Rules in Guangdong Province (Draft)" and "Implementation Plan for Drug Purchase with Required Amount in Shanghai (Draft)", which attracted great attention and positive response from the industry and generate certain effects.

The 18th National Congress of the Communist Party of China has pointed out "To implement the innovation-driven development strategy" and "To accelerate the construction progress to build the national innovation system into an enterprises-centered, market-oriented combination of industry, academia and research institutions." To improve the new drug innovation capacity has been listed as the most important task during the Twelfth Five-Year Plan period for pharmaceutical industry in China. During the recent meeting of CPC Central Committee, General-Secretary Xi Jinping has pointed out five tasks to promote the innovation-driven developments. The Twelfth Five-Year Plan period is an important time for the innovative development of Chinese pharmaceutical industry and to implement the spirit of the 18th National Congress of the Communist Party of China. In next year, I hope SINO-PhIRDA will take advantage of the encouraging policies for innovation, continue to focus on the goal of "Innovation, Industrialization, Internationalization" and become the organization representing China's domestic innovative pharmaceutical enterprises.

Hereby, I also hope that all of SINO-PhIRDA members will carefully implement the innovation-driven development strategy stated by the 18th National Congress of the Communist Party of China, promote innovation and strengthen self-discipline, actively participate in the association's activities, making great contributions to improve pharmaceutical market environment and innovative developments, meanwhile, providing a better healthcare standard for the nation!

I hope this meeting a great success!

Congratulatory Letter to 2013 International Pharmaceutical Innovation Forum

Sang Guowei
Vice Chairman of the Standing Committee of Eleventh National People's Congress
Honorary Chairman of SINO-PhIRDA, Academician of Chinese Academy of Engineering
October 18,2013

Dear Distinguished Guests at 2013 International Pharmaceutical Innovation Forum:

I would like to express my sincere congratulations to the 2013 International Pharmaceutical Innovation Forum co-hosted by China Chamber of International Commerce (CCOIC), China Pharmaceutical Industry Research and Development Association (SINO-PhIRDA), Drug Information Association (DIA), China Health Insurance Research Association (CHIRA), Beijing Municipal Health Bureau and Beijing Food and Drug Administration. I carefully prepared a speech on the development and innovation of Chinese pharmaceutical industry for this forum. However, according to the nation's arrangements, I have to lead a delegation to visit Brazil during October 15-23, and I sincerely thank your understanding on my absence.

The theme of this forum is to encourage pharmaceutical innovation and optimize innovative eco-system. The Chinese government has always attached great importance to the innovation and development of pharmaceutical industry. The 18th National Congress of the Communist Party of China has made important arrangement on implementing the innovation-driven development strategy; the congress report also stated "Science and technology innovation is the strategic support to improve the social productive forces and the comprehensive national strength. It must be placed in the core position during the nation's overall developments." "To gather the entire society's wisdom and force onto innovation and development." On September 30, President Xi Jinping emphasized on keeping keen focus on the development trend of worldwide science and technology innovation, implementing the innovation-driven development strategy in a good and practical manner. He also listed five tasks for the development of science and technology innovation: First, to enhance the close combination of science/ technology innovation and economic/ social development; Second, to strengthen the independent innovation capability; Third, to improve the talent development mechanism; Fourth, to create a favorable policy environment; Fifth, to expand the science and technology cooperation scope.

Pharmaceutical science and technology innovation can improve the core competitiveness and fundamental driving force of sustainable development of pharmaceutical industry. We are delighted to know that this forum will provide an excellent communication/ cooperation platform for pharmaceutical innovation. There are not only sessions on drug policies, providing exchange opportunities among government, enterprises and scholars on drug approval, healthcare insurance, pricing and bidding, IPR protection, etc.; but also R&D technology session and business collaboration bridge session, giving the participants valuable understanding on international forefront of issues related to clinical trial design, clinical data management, biosimilars, etc., meanwhile introducing dozens of innovation projects from Canada, Poland, Denmark, etc. The content is definitely rich and practical.

It has become a global consensus to promote the pharmaceutical technology innovation and accelerate the healthy and sustainable development of pharmaceutical industry. The 2013 International Pharmaceutical Innovation Forum will greatly encourage and promote the worldwide pharmaceutical communication and cooperation. I sincerely hope that all participants will feel this forum beneficial and make joint efforts and contributions together to improve the global market environment and promote the development of pharmaceutical innovation, as well as to improve the healthcare standards of mankind. I hope this forum a great success!

2012-2013中国医药工业科研开发促进会工作报告（摘要）

—2013年10月17日在第九届会员大会第四次会议上

中国药促会执行会长
宋瑞霖

第一部分
2012-2013年度的主要工作回顾

中国药促会自去年6月份召开九届三次会员大会以来，按照会员大会确定的工作要求与重点，主要做了三方面的工作：

一是，加强制度建设，坚持民主办会，规范管理；

二是，将工作重心调整到为医药产业的创新服务上来；

三是，运用全球视野开展国际交流活动。

一、加强协会建设

（一）切实发挥会长会议的作用，坚持民主决策。

今年2月21日召开的2013年第一次会长会议上，我会荣誉会长桑国卫院士到会并发表了重要讲话。会议审议并原则通过了《中国医药工业科研开发促进会秘书处薪酬改革方案》、《中国医药工业科研开发促进会年度轮值会长选举办法（暂行）》、《中国医药工业科研开发促进会会员管理办法（暂行）》等三个文件，并审议了企业的入会申请。会长会议制度为中国药促会的发展和运转发挥了重大作用。

（二）充分依靠会员单位的联络秘书。

我们通过电子邮件、短信平台、QQ群、电话会议和召开现场会等多种方式与联系秘书进行沟通。

（三）加强规章制度建设，实行科学规范管理。

我会秘书处制定了人事、财务、课题研究项目管理、办公室管理等22项规章制度，涵盖了秘书处内部管理的各个方面，使协会内部管理进一步规范化、科学化。

二、开展的重点工作

去年会员大会确定了2012年-2013年度的两大工作重点：创新药物的审批政策研究和创新药物的市场环境建设。围绕这两个重点，我们主要做了以下工作：

（一）配合政府有关部门开展工作

1、撰写了关于保护国家“重大新药创制”科技重大专项的知识产权成果的研究报告，报请桑国卫院士转送国务院有关领导，时任副总理李克强、国务委员刘延东分别作出重要批示，要求有关部门采取措施加强国家“重大新药创制”科技重大专项的知识产权保护。重大新药创制专项办召集卫生部、科技部等部门专门召开会议，落实国务院领导批示。

2、开展创新药物的审批机制改革问题研究。我们多次与食品药品监管总局的有关负责同志进行面谈、沟通，并于去年9月22日召开了由食品药品监管总局的相关负责同志及有关部门负责同志和我会创新企业代表参加的座谈会。我们

根据座谈会和调研的情况撰写了《关于完善药品审评机制，促进医改事业和医药产业创新发展的报告》。

3、针对食品药品监管总局发布征求意见的关于仿制药质量一致性评价政策，我们专门召开企业座谈会，并撰写研究意见报给总局的有关司局。

4、 今年8月1日-2日我会主办了“药品注册审评工作座谈会”。此次会议加强了药品监管部门和管理相对人之间的理解，搭建起企业与注册及审评机构的互动平台。

5、协助国家食品药品监管总局药品审评中心开展化药新药注册申请电子递交工作。

6、关于创新药物的市场环境建设问题，我们加强了与发展改革委、人力资源社会保障部、卫生计生委等有关部门的沟通，并接受了人力资源社会保障部和卫生计生委委托的有关医保用药管理和基本药物法律制度的研究课题。

（二）通过研讨会、调研等方式促进医药健康产业创新发展

1、2013年1月11日，在北京举行“创新药物市场环境建设政策研讨会”。北京市卫生局方来英局长、青岛市社会保险事业局刘军帅处长、上海复旦大学陈文教授在会上分别作了主题报告。通过此次座谈会，政府、专家与产业界进行了深入交流，在如何制定科学、合理的政策，促进疗效好的创新药物进入医保目录、医院采购目录，让患者及时用得上，提高人民群众健康保障水平等问题上增进了理解，达成了共识。

2、2013年4月16日，我会主办“国家重大新药创制专项项目成果应用汇报会—凯美纳Ⅳ期临床研究总结会”。全国人大常委会副委员长陈竺院士为大会发来贺信。国家“重大新药创制”科技重大专项技术总师、我会荣誉会长桑国卫院士出席汇报会并发表重要讲话。

3、2013年6月13—14日，我会组织调研组赴青岛开展调研活动，考察了青岛市护理保险制度的基本内容和取得的成效。我会将与青岛市社会保险事业局开展紧密合作，对医保支付制度改革和护理保险制度创新进行深入研究，通过评估其实施效果，研究如何完善这一制度并为全国的社会保障事业提供借鉴。

4、2013年8月9日，我会会同中国药学会举办了第四届中国医院药学政策论坛，来自全国各省市的300多名医院药师出席会议。本次论坛集中研讨了药师在医疗服务中的责任与地位。

（三）强化研究功能，开展课题研究

1、为进一步强化研究功能，更多地汇聚正能量，为药物政策及医药经济健康发展提供智力支持，中国药促会与中国药科大学、中国药学会于今年4月28日共同发起成立了“国家药物政策与医药产业经济研究中心”。研究中心邀请了来自国家发改委、工信部、科技部、人力资源和社会保障部、卫生计生委、食品药品监管总局、社会科学院、北京大学、复旦大学、中国药科大学、沈阳药科大学等权威部门和机构的领导、专家担任研究员，组成了国家顶级药物政策研究团队。桑国卫院士担任中心主任。

中心将建立全新的机制，以中国药科大学为依托，面向国内外招聘一流的专家学者作为研究员组建专家团队，重点做好医药政策等方面的研究。

2、始终坚持围绕我国医药政策领域热点问题进行专题研究，为我国民族医药产业的健康创新发展、国家医药卫生体制改革建言献策。近一年多来，我会秘书处研究部已结题项目8个，正在开展课题8个，拟开展课题4个。

（四）维护行业利益，为医药产业健康发展发出声音

1、对广东省卫生厅的药品交易规则征求意见稿提出修改建议。

2013年5月17日，广东省卫生厅在其网上挂出了《广东省药品交易规则（试行）（征求意见稿）》等5个医药交易新政征求意见的文件，重拾药品招标采购“唯低价是取”的旧弊，引起广大药品企业的强烈不满。为此，中国药促会迅速反应，以最快速度召开由有关专家和部分药品生产企业参加的座谈会，对广东省卫生厅征求意见稿中多处问题提出尖锐批评，5月23日，以“关于《广东省药品交易规则（试行）（征求意见稿）》相关文件的研究意见”为题，向广东省药品集中采购工作领导小组办公室、国务院医改办，卫生计生委，工业和信息化部，食品药品监管总局等部门反映了广大企业的诉求并提出了明确的修改意见，引起了媒体和有关部门的重视。

2、对上海市医保药品试行“带量采购”的实施方案（征求意见稿）提出修改建议。

今年7月，上海市药招办制定了《关于本市医保药品试行“带量采购”的实施方案（征求意见稿）》，此方案存在给予原研药特殊政策、仿制药最低价中标、对带量采购的药品，医保结算价格按照采购价加成15%计算等问题。我会在充分研究和征求意见的基础上，及时向上海市医保办提出了书面意见。随后，我们又专程到上海与有关领导进行面对面沟通。上海市医保办原则上接受了我会的意见并将我们的意见上报上海市政府。目前，上海市已暂停执行此实施方案。

三、加强国际交流活动

2012年我会的国际交流活动更加注重与国内外产业界的联系，搭建中外企业商业合作的平台，提供直接合作的机会。主要的活动有：

（一）国际交流活动

1、2012年6月25至7月4日，由我会会员单位组成的代表团对丹麦、瑞士、波兰进行访问，与当地的政府有关部门、行业协会、医药企业开展交流活动，并就双方今后的合作进行深入探讨。

2、2013年7月6日-21日，我会代表团赴美国、加拿大进行考察访问。在美期间，就美国医药产业创新发展问题进行考察，专门访问了美国商务部、专利商标局等部门，与美国药品研究与制造商协会（PhRMA）、美国食品药品研究所（FDLI）、哥伦比亚大学等机构的专家进行座谈，详细研究了美国医药产业的发展历程、美国促进医药产业创新发展的主要法律制度，特别是美国如何从医药大国发展为医药强国的关键政策路径，取得了较好成果。

在加期间，代表团走访了加拿大的2个省级政府机构和行业协会、2所大学、4个科研机构，并对接了50余项医药创新项目。通过出访，协会与加拿大的政府、行业组织、医药企业和科研机构间建立起了紧密联系。

（二）培训交流

2012年7月16日至25日，由北京市医院管理局牵头，我会在澳大利亚悉尼大学举办了医院高级管理人员赴外培训活动。本次培训项目为期12天，由我会负责人带队，北京同仁医院等12名北京三甲医院院长参加，内容包括课堂授课、与当地卫生部门座谈和走访医院等。此次活动非常成功，得到了参加培训的院长们的好评和北京市领导的肯定。

（三）召开峰会

1、2012年11月30日，我会与中国外商投资企业协会药品研制和开发行业委员会（RDPAC）、PhRMA联合举办的“2012国际医药创新峰会”，峰会的主题为“全面提升中国生物医药产业创新能力”。

2、2012年11月30日中午，PhRMA主席、美国礼来公司首席执行官李励达(John C Lechleiter)博士在北京举行午餐会，宴请我会会员企业的企业家。双方就产业发展与合作问题进行了深入的交流。

（四）与有关国家驻华使领馆的联系与合作

先后与丹麦、波兰、印度、巴西、加拿大等近30个国家的驻华使领馆建立了联系。2012年10月和11月，分别与丹麦、波兰使馆共同举办投资、药品监管体制等方面的洽谈活动，提供机会和信息让会员企业走出去，取得良好效果。

四、医药信息服务水平不断提高

为会员单位提供医药信息服务一直是我会的一项重点工作。这项工作主要分为五部分：一是网站服务，中国药促会的门户网站即时刊登我会的重大活动新闻、国内外的重要医药政策和研发信息，每天都更新；二是信息简报，每天编辑并给会员单位和合作伙伴发送国内外当天重要的医药政策和产业信息；三是每周编辑国际医药政策和产业动态；四是每周撰写医药行业热点评析；五是每个季度编辑医药工业科研开发信息。

第二部分
关于2013-2014年度的工作建议

结合2012-2013年度工作的体会，现针对2013-2014年度的工作提出以下建议。

（一）加强与政府、药物研发专家、临床专家、药学专家的联系与沟通

力争在相关医药政策出台之前充分了解情况，深入进行研究，提出建议和意见，与政府有关部门进行有效地接触与交流，反映会员企业的心声。搭建平台，加强会员企业与药物研发专家、临床医学专家、药学专家的联系与互动。

（二）提高政策研究水平

我们要围绕我会的中心工作，关注国家有关医药卫生的政策走向和大政方针，借助行业、学术界的资源，研究行业的重点问题，为政府决策提供参考，谏有用之言，献可行之策，优化医药产业发展的政策环境。

（三）拓宽国际交流渠道

我们要在已有的国际交流基础上，利用国外驻华使馆、国外行业协会、大专院校等科研机构，为会员企业的新药研发、上市等方面的洽谈、合作提供优质服务。

（四）提升医药信息服务水平

我们要围绕中国药促会的中心工作，通过与药物信息协会（DIA）的合作和有关方面专家的帮助，进一步提升医药信息服务的水平，拓宽信息渠道，提高信息质量，满足会员单位在信息方面的需求。

具体而言，计划开展以下几项重点工作。

一、举办“2013国际医药创新大会”

经与各方充分协商，决定将一年一度的中美医药产业峰会拓展为“国际医药创新大会”，从过去单纯与PhRMA的政策研讨，扩展到与更多国家的新药技术项目交流与合作，搭建国际化的医药交流与合作平台。

二、加入博鳌亚洲论坛的相关工作

经认真研究并与博鳌亚洲论坛秘书处沟通，我会已获准加入亚洲博鳌论坛，成为论坛会员。我会将协助论坛组委会在明年四月召开的博鳌论坛年会上主办医药行业CEO圆桌会议。会议将邀请国际机构、跨国制药企业主要负责人、投资界知名企业和我会成员企业参会，并将邀请卫生计生委、人力资源和社会保障部的主要负责同志就商业伦理与市场环境等问题进行讨论。这将是自博鳌亚洲论坛成立十三年来第一次为医药板块举行闭门会议。

三、与青岛社保局的合作

我会与青岛社保局建立了战略合作关系，在推动国内企业的优质仿制药、创新药进入医保方面政策研究方面加强合作。经双方协商，初步定于今年12月中旬由青岛市政府、中国药促会、中国医疗保险研究会共同主办“中国医保改革地方经验交流会”。论坛将邀请人力资源和社会保障部以及各地方医保部门等部门的官员、专家学者及相关创新型企业对医疗保险体制改革中的有关问题做深入交流研讨，力图推进我国医保管理制度改革，相信将对进一步完善我国医保制度改革起到非常重要的意义。

过去的一年里，我会在桑国卫院士的指导下，在陈启宇会长的领导下，在各会员单位的支持与配合下，做了一些事情，取得了一些成绩。在接下来的一年里，中国药促会将更加注重创新发展，一方面，加强治理结构的创新，提高为会员单位的服务能力；另一方面，促进会员企业医药科技的创新，促进我国医药产业的整体发展。

SINO-PhIRDA Annual Work Report (Abstract)

Song Ruilin, Executive President of SINO-PhIRDA
The Fourth Meeting of 9th SINO-PhIRDA General Assembly October 17, 2013

Session One. Review of Major Work during 2012-2013

According to the requirements and decisions by the Third Meeting of 9th SINO-PhIRDA General Assembly in June 2012, the association carried out work mainly in three areas:

First, to strengthen system construction, adhere to democratic and standardized management;

Second, to adjust our focus point into services for the pharmaceutical industry innovation;

Third, to promote international exchange activities with a global vision.

Part One. To enhance the construction of association

I. Effectively perform the role of Chairman Board Meeting, insist on democratic decision-making.

On February 21 this year, The 1st Chairman Board Meeting was held. Academician Sang Guowei, Honorary Chairman of SINO-PhIRDA attended the meeting and delivered an important speech. The meeting approved in principle the "China Pharmaceutical Industry Research and Development Association Secretariat Salary Reform Plan", "China Pharmaceutical Industry Research and Development Association Annual Rotating Chairman Election Method (Provisional)" and "China Pharmaceutical Industry Research and Development Association Membership Management Methods (Provisional)", meanwhile considered several applications for membership. The Chairman Board Meeting mechanism will greatly promote the development and operation of SINO-PhIRDA.

II. Rely on the contact secretaries of members

The association utilized e-mail, text messaging platform, QQ group, tel-conference call and on-site meeting to communicate with the contact secretaries.

III. To strengthen rule and regulation constructions, implement scientific and standardized management

The secretariat has developed 22 rules including Management Rules of Staffs, Finance, Research projects, General Office, etc., covering all aspects of management within the Secretariat to make internal management more standardized and scientific.

Part Two. Major areas of work

The 2012 General Assembly Meeting set two focusing points for work in 2012-2013: research on approval policy of innovative drugs, market environment construction for innovative drugs. Centering on these two pinots, the following work has been carried out:

I. Work with relevant government and departments

1. Research on protection of intellectual property achievements of National Major Science and Technology Project "Innovation and Development of New Drug", and reported to Academician Sang Guowei and forwarded to relevant officials in the State Council. Former Vice Premier Li Keqiang, State Councilor Liu Yandong have made important instructions, demanding relevant departments to take actions to strengthen the protection of related intellectual property achievements. General Expert Committee of National Major Science and Technology Project "Innovation and Development of New Drug" convened Ministry of Health, Ministry of Technology to held meetings and implement the instructions of officials of State Council.

2. Research on innovative drug approval mechanism issues. We had face-to-face communication with related officials in China Food and Drug Administration frequently. On Sep 22, SINO-PhIRDA held a seminar with invited comrades from relevant regulatory departments and innovative enterprises. According to the investigation and the seminar, SINO-PhIRDA has accomplished the report on "Improving the mechanism of drug evaluation and promoting innovative development of healthcare reform and pharmaceutical industry".

3. According to the consistency evaluation policy on generic drugs published by China Food and Drug Administration, SINO-PhIRDA held a conference and

proposed suggestions to relevant departments.

4. SINO-PhIRDA held the working symposium on drug registration and approval, which strengthened the understanding between drug administrative departments and enterprises, built a dialogue platform between the industry and government.

5. Assisted Center of Drug Evaluation of China Food and Drug Administration on the electronic submission work of new chemical drug applications for registration.

6. In regards to construction of innovative medicine market environment, SINO-PhIRDA strengthened the communication with National Development and Reform Commission, Ministry of Human Resource and Social Security and National Health and Family Planning Commission, and accepted the relevant research projects on healthcare insurance management and law system of essential drugs set by Ministry of Human Resource and Social Security and National Health and Family Planning Commission.

II. Promote innovative development of pharmaceutical health industry through seminars and investigations

1. On January 11, 2013, Seminar on Construction of Innovative Drugs Market Environment was held in Beijing. Fang Laiying, Secretary of Party Leadership Group and Director of Beijing Municipal Health Bureau, Liu Junshuai, Director of Health Insurance Division of Qingdao Social Insurance Bureau and Professor Chen Wen from Fudan University made keynote speeches in the seminar. Representatives from government and industry had discussions on many issues including how to establish scientific and reasonable policies, how to promote effective innovative drugs to be listed in the Medicine Insurance Directory and Procurement Catalogue, to promote patients' access to the necessary medicines and improve public healthcare insurance standard.

2. On April 16, 2013, SINO-PhIRDA hosted the Report Meeting of National Major New Drug Innovation Project - Summary of Conmana Phase IV Clinical Research. Academician Chen Zhu, Vice President of the Standing Committee of National People's Congress, sent a congratulatory message to the conference. Academician Sang Guowei, Chairman of the General Expert Committee of National Major Science and Technology Project "Major New Drug Innovation" delivered a speech at this event and.

3. During June 13-14, SINO-PhIRDA had an investigation on essential content and achievements of nursing and insurance system in Qingdao. SINO-PhIRDA will carry out close collaboration with Qingdao Social Insurance Bureau, and make a in-depth research on medicare payment system reform and the nursing care insurance system innovation. By assessing its effectiveness, we made a study on improvement of social insurance system in China.

4. On August 9, 2013, "4th Forum of China's Hospital & Pharmacy" co-hosted by SINO-PhIRDA and Chinese Pharmaceutical Association was held. More than 200 pharmacists from hospitals around China attend this meeting. Representatives had an in-depth discussion on the role and responsibility of pharmacists in medical services.

III. Strengthen capabilities of study, and carry out project research

1. In order to further strengthen the capability of research, better converge positive energy, provide intellectual support for drug policies and healthy economic development of the industry. SINO-PhIRDA co-established the Research Center of National Drug Policy & Ecosystem with China Pharmaceutical University and Chinese Pharmaceutical Association on April 28, 2013. The center consists of officials and experts from NDRC, MIIT, MST, MHRSS, NHFPC, CFDA, Academy of Social Sciences, Peking University, Fudan University, China Pharmaceutical University and Shenyang Pharmaceutical University, becoming national top team in researches on pharmaceutical policies. Academician Sang Guowei is the Director of this center.

Relying on China Pharmaceutical University, the center will establish a new mechanism to recruit first-class experts worldwide to build a team emphasizing on drug policy research.

2. Adhering to project research surrounding the hot issues on the national healthy development of pharmaceutical industry innovation in China, and making suggestions to national healthcare reform, SINO-PhIRDA has accomplished 8 subjects, with another 8 ongoing and 4 to initiate in the near future.

IV. Protect interests of industry, expressing the demands for the healthy development of pharmaceutical industry

1. Make suggestions on "Pharmaceutical Trading Rules in Guangdong Province (Draft)"

On May 17, 2013, "Pharmaceutical Trading Rules in Guangdong Province (Draft)" and five other documents about new regulations on medicine trading

was published on the website of Health Department of Guangdong Province, which caused strong resentment among the majority of the pharmaceutical enterprises. Thus, SINO-PhIRDA gave a quick response, and rapidly organized relevant experts and some pharmaceutical manufacturing enterprises for a seminar to discuss the problems existed in "Pharmaceutical Trading Rules in Guangdong Province (Draft)" and proposed sharp criticisms. On May 23, SINO-PhIRDA wrote an article of research and opinions on the relevant documents of "Pharmaceutical Trading Rules in Guangdong Province (Draft)", and submitted it to Guangdong Provincial Drug Centralized Purchasing Work Leading Group Office, Healthcare Reform Office of State Council, NHFPC, MIIT, CFDA to reflect appeals of enterprises and put forward clear amendments, which attracted great attention from media and relevant sectors.

2. In July this year, Drugs Biding Office of Shanghai published "Implementation Plan for Drug Purchase with Required Amount in Shanghai (Draft)". There were many problems existed in this document, such as: provide special policy to original drugs, bid the drugs in the lowest price among generic drugs, as for drugs with required amount, the medical insurance settlement price will be the purchase price plus 15%. Based on adequate research and comments, SINO-PhIRDA proposed to Shanghai medical insurance office in written. After that, we visited Shanghai and have a face-to-face communication with related officials. Shanghai Medical Insurance Office accepted our suggestions in principal and reported to Shanghai Municipal Government. So far, Shanghai has suspended its implementation.

Part Three. To promote international cooperation activities

In 2012, SINO-PhIRDA's international exchange activities paid more attention on the domestic and international industry communication to build business cooperation platform for Chinese and foreign enterprises and provide direct opportunities for cooperation. Major events include:

I. International exchange activities

1. SINO-PhIRDA delegation visited related governments, organizations and enterprises in Denmark, Switzerland and Poland during June 25 -July 4, 2012.

2. SINO-PhIRDA delegation visited US and Canada during July 6 21, 2013. During the visit to US, the delegation met with representatives from US Department of Commerce, US Patent and Trademark Office, PhRMA, FDLI, University of Columbia, etc., discussing common interests on the development history of US Pharmaceutical industry and major laws and regulations, as well as the main factors to promote the innovative development of the industry.

During the visit to Canada, the delegation visited governments and industry organizations in Ontario and British Columbia, University of Western Ontario, University of British Columbia, four research institutes with more than 50 innovative projects introduced. A strong partnership has been established with the Canadian side through these activities.

II. Training and Exchange

Led by Beijing Hospital Management Bureau, SINO-PhIRDA held Executive Training Program for Hospital Management in University of Sydney, Australia during July 16 25, 2012. Presidents of 12 Three-A level hospitals attended this program. This 12-day training included lectures, meetings with local authorities and visit to hospitals. It received positive comments and feedbacks from both participants and leaders of Beijing municipal government.

III. 2012 International Pharmaceutical Innovation Summit

1. 2012 International Pharmaceutical Innovation Summit was co-hosted by SINO-PhIRDA, RDPAC and PhRMA on October 30, 2012. The theme of the summit was to promote the innovation capability of pharmaceutical industry in China.

2. Dr. John C. Lechleiter, Chairman of PhRMA and CEO of Eli Lily, hosted a breakfast meeting with SINO-PhIRDA representatives in Beijing on November 30, 2012 to discuss common interest on industrial development and cooperation.

IV. Cooperation with foreign embassies and consulates in China

The association has established partnership with more than 30 foreign embassies and consulates in China, such as Denmark, Poland, India, Brazil, Canada, etc. Conferences and seminars on innovative projects and drug regulations have been held together with Danish Consulate in October 2012 and Polish Embassy in November 2012.

Part Four. To improve information service standard

It is one of the association's tasks to provide information service to our members. This task mainly consists of five major parts: First, website service for important industry news and association activities; Second, daily newsletter to summarize and publish important policy and R&D updates; Third, weekly newsletter to summarize and publish international news of the industry;

Fourth, weekly review and analysis on hot topics; Fifth, pharmaceutical industry R&D information journal in each quarter.

Session Two. Proposal of Work during 2013-2014

According the experience during 2012-2013, proposals on work plan during 2013-2014 are made as follows:

I. To strengthen the communication with governments, experts on new drug R&D, clinical research and pharmacy

We should endeavor to fully understand the background before relevant healthcare policies are published, make in-depth research, put forward proposals and suggestions, and effectively communicate with related government departments in order to reflect the needs of enterprises. Build a platform to strengthen the contact and interaction between member companies and experts on new drug R&D, clinical research and pharmacy.

II. To improve the capability of policy research

We should concentrate on our core task, pay close attention to policies on national healthcare, take advantages of the resources from industry and academia, provide useful and practical suggestions to the government, in order to optimize policy environment for pharmaceutical development.

III. To broaden channels of international cooperation

Based on existing international cooperation scope, we should work together with embassies, foreign industry associations, colleges and institutions, in order to provide excellent service for member companies on new drug R&D and marketing, etc.

IV. To improve service of pharmaceutical information

Concentrated on SINO-PhIRDA's core tasks, through the cooperation with Drug Information Association and experts in related areas, we should further improve service of pharmaceutical information, broaden the channels of information, improve the quality of information, to meet our member companies' needs.

Especially, our major work focuses on the following items:

Part One. International Pharmaceutical Innovation Forum

After discussing with partners, we decided to expand the Annual Sino-US Pharmaceutical Industry Summit to "Pharmaceutical International Innovation Forum", broaden the discussion scope from US to more countries to build an international platform for communication and collaboration in pharmaceutical industry.

Part Two. To prepare for Boao Forum for Asia

After discussing with Secretariat of Boao, we are admitted to become a member of Boao Forum for Asia (BFA). SINO-PhIRDA will organize a Pharmaceutical CEO Round-table Conference during BFA Annual Conference in April 2014. We will invite the principals of international agencies, multinational pharmaceutical enterprises, investment firms, and our members to attend this event. Meanwhile, officials from National Health and Family Planning Commission and Ministry of Human Resources and Social Security will be invited have discussions on pharmaceutical business ethics and market environment. This is the first time for BFA to hold such a conference in pharmaceutical field since its establishment 13 years ago.

Part Three. Collaboration with Qingdao Bureau of Human Resources and Social Security

SINO-PhIRDA has established a partnership with Qingdao Bureau of Human Resources and Social Security to strengthen the collaboration on promoting high-value generic and innovative drugs to be listed for healthcare insurance. According our agreement, The Conference of Economic Exchanges on Chinese Healthcare Insurance Reform, co-hosted by SINO-PhIRDA and CHIRA will be held in Qingdao during mid-December. Officials, experts and scholars from Ministry of Human Resource and Social Security and local governments will be invited and have deep discussions on issues of innovative enterprises encountering during healthcare insurance reform, strive to promote medical insurance administrative management reform in China. This will be of great significance in the process of improving the healthcare system in China.

During last year, under the leadership by Academician Sang Guowei and Chairman Chen Qiyu, the association made some achievements with the joint efforts and supports from all members. In next year, SINO-PhIRDA will further focus on innovative developments, on one hand, enhance the management structure innovation to improve our service capability; on the other hand, enhance members' innovation of pharmaceutical technology to promote the overall development of healthcare industry in China.

中国医药工业科研开发促进会
第九届会员大会第四次会议纪要

为进一步促进医药企业科研开发及创新能力建设，体现我会“创新、产业化、国际化”的办会宗旨，优化医药创新生态环境，使会员单位更好地抓住机遇，迎接挑战，2013年10月17日，中国医药工业科研开发促进会（简称中国药促会）在北京召开了第九届会员大会第四次会议。本次大会，应到会员数65家，实到会员数53家，符合本会章程第十五条关于“会员大会须有2/3以上会员出席方能召开”的规定。

会议主要内容如下：

一、第十一届全国人大常委会副委员长桑国卫的贺信

第十一届全国人大常委会副委员长、中国药促会荣誉会长桑国卫院士为本届大会发来了贺信。

桑国卫院士在贺信中对中国药促会过去一年来的工作给予高度评价和肯定。桑国卫院士结合中央提出的鼓励创新的精神，指出：十二五期间是我国医药创新发展的重要时期，是落实十八大精神的开局之时；在新的一年里，希望中国药促会乘着国家鼓励创新的东风，继续围绕“创新、产业化、国际化”的宗旨，顺应形势，真正成为中国民族医药产业创新企业的代表性团体。他希望中国药促会各会员单位加强创新，加强自律，积极参与中国药促会的各项工作，为改善我国医药创新市场环境与促进我国医药创新发展、提高人民的健康保障水平做出应有的贡献。

二、大会审议事项

本次大会，对中国药促会2012-2013年度工作报告、2012-2013年度收支情况报告、中国药促会更名的议案等进行了审议。

1、大会审议通过了宋瑞霖执行会长做的《中国医药工业科研开发促进会工作报告》。

工作报告总结了2012-2013年度中国药促会在加强制度建设、坚持民主办会、规范管理；为医药产业的创新发展服务；运用全球视野开展国际交流活动等三个方面所做的工作。在过去的一年里，中国药促会围绕“创新药物的审批政策研究”和“创新药物的市场环境建设”两大工作重点，配合政府有关部门开展专项研究工作，研究领域涉及“重大新药创制”知识产权保护、创新药物审批机制、仿制药一致性评价政策、医保用药管理、基本药物法律制度等多个方面。通过开展课题探究、专题研讨会、地方调研等方式，为完善和构建我国医药政策环境体系作出了不懈的努力。同时还加强国际交流活动和提高信息服务水平，探索更多渠道、采用更多样化的方式，不断提升会员的服务质量。

同时，中国药促会为维护行业的利益，不断为医药产业健康发展发出声音，先后针对广东省药品交易规则征求意见稿和上海市医保药品试行“带量采购”实施方案征求意见稿提出修改建议。中国药促会的意见受到了相关政府部门的重视，得到了业界的广泛关注和积极响应，产生了一定的影响作用。

工作报告提出2013-2014年度中国药促会的工作将集中在四个方面：一是，加强与政府、药物研发专家、临床专家、药学专家的联系与沟通；二是，提高政策研究水平，借助行业、学术界的资源，研究行业的重点问题，为政府决策提供参考；三是，拓宽国际交流渠道，进一步提升医药企业的国际化水平；四是，提升医药信息服务水平，拓宽信息渠道，提高信息质量，满足会员单位在信息方面的需求。中国药促会将集中精力，与有关单位共同努力，办好“中国医保改革地方经验交流会”和2014年博鳌亚洲论坛年会上的“医药产业领袖闭门会议”。

2、大会审议通过了《2012-2013年度收支情况报告》。

3、大会审议通过了《关于优化我国医药创新生态环境的建议书》。建议书分为四部分：一是，准确认识我国医药产业发展的现状；二是，清晰界定药品审评性质，完善药品审评机制；三是，厘清药品监管部门与专利管理部门、司法机关的职责，加强药品专利保护；四是，鼓励创新药物进入医保目录等四个方面的内容。建议书经会议审议通过后，中国药促会将报送国家发改委、卫计委、社保部、药监总局等国家有关部门。

4、大会用无记名投票方式审议通过了中国药促会更名议案。此次投票，共发出表决票54张（含到会的53家会员单位和执行会长宋瑞霖的选票，下同），收回54张，有效票数54张，其中赞成票53张，反对票1张，通过了我会由原名称“中国医药工业科研开发促进会”变更为“中国医药创新促进会”的议案。会议要求秘书处在会后按照国家有关规定和要求，办理相关更名手续。

5、大会听取了齐鲁制药等四家新入会企业的情况。根据《章程》的相关规定和中国药促会会长会议的决议，齐鲁制药有限公司、北京科信必成医药科技发展有限公司、上海中信国健药业股份有限公司、深圳微芯生物科技有限责任公司四家企业今年获准加入我会。

三、选举轮值会长、候任轮值会长候选人

1、大会通过无记名投票方式选举2013-2014年度轮值会长一名。按照国资委和民政部相关文件的要求，大会以无记名投票的方式选举

天士力控股集团董事局主席闫希军为中国药促会2013-2014年度轮值会长。选举过程如下：大会共发出选票54张，收回54张，有效票54张，赞成票53张，反对票1张，选举合法有效。

2、大会通过无记名投票方式选举2014-2015年度轮值会长候选人一名。选举江苏恒瑞医药股份有限公司董事长孙飘扬为2014-2015年度轮值会长候选人。选举过程如下：大会共发出选票54张，收回54张，有效票54张，赞成票53张，反对票1张，选举合法有效。

四、学术讲座

为了使会员单位更好地了解和掌握宏观经济形势，把握企业发展和改革大趋势，会议特邀请著名经济学家、清华大学教授李稻葵做了“国内宏观经济形势及发展趋势”的专题报告，并与参会代表进行互动。

此次会员大会参与度高，内容丰富，程序规范，完成了既定的各项议程，取得了圆满成功。

Summary of The Fourth Meeting of 9th SINO-PhIRDA General Assembly

To further promote the R&D and innovation capacity of pharmaceutical enterprises, implement our goal of “Innovation, Industrialization, Internationalization”, optimize the pharmaceutical innovation eco-system, enable the members to seize opportunities and overcome challenges, China Pharmaceutical Industry Research and Development Association (SINO-PhIRDA) held the Fourth Meeting of 9th SINO-PhIRDA General Assembly in Beijing on October 17, 2013. Representatives from 53 members out of 65 in total attended this meeting, which met the requirement by Article 15 of SINO-PhIRDA Constitution.

The main contents of the meeting were summarized as follows:

Part One. Congratulatory Letter from Mr. Sang Guowei, Vice-Chairman of the Standing Committee of Eleventh National People’s Congress

Academician Sang Guowei, Vice-Chairman of the Standing Committee of Eleventh National People’s Congress, Honorary Chairman of SINO-PhIRDA has sent congratulatory letter to this meeting.

In the congratulatory letter, Academician Sang Guowei expressed highly positive comments on SINO-PhIRDA’s work during last year. According to the spirit encouraging innovation stated by CPC Central Committee, Academician Sang Guowei pointed out that The Twelfth Five-Year Plan period is an important time for the innovative development of Chinese pharmaceutical industry and to implement the spirit of the 18th National Congress of the Communist Party of China. In next year, I hope SINO-PhIRDA will take advantage of the encouraging policies for innovation, continue to focus on the goal of “Innovation, Industrialization, Internationalization” and become the organization representing China’s domestic innovative pharmaceutical enterprises. He hopes SINO-PhIRDA members will promote innovation and strengthen self-discipline, actively participant in the association’s activities, making great contributions to improve pharmaceutical market environment and innovative developments, meanwhile, providing a better healthcare standard for the nation.

Part Two. Topics of the Meeting

Topics discussed during the meeting included 2012-2013 Annual Work Report, 2012-2013 Annual Financial Report, SINO-PhIRDA Rename Proposal, etc.

1. The meeting approved 2012-2013 Annual Work Report by Executive President Song Ruilin.

The report reviewed SINO-PhIRDA’s work in three areas during Year 2012-2013, including regulatory construction, democratic management, serving the innovative development of pharmaceutical industry and carrying out international cooperation activities on a worldwide view. During last year, SINO-PhIRDA focuses on two major areas “research on the approval policies on innovative drugs” and “market environment construction for innovative drugs”, cooperated with relevant government departments to carry out research projects on Major New Drug Innovation IP protection, approval mechanism of innovative drugs, consistency evaluation policy of generics, healthcare insurance medicine management, essential drug policy, etc. SINO-PhIRDA has made

unremitting efforts to improve and construct the healthcare policy eco-system in China by conducting research, workshops/ seminars, local investigations, etc. Meanwhile, the Association promotes international exchange and cooperation, as well as information service standard to constantly improve the quality of member services in more diversified manners and approaches. This is worthy of recognition.

At the same time, SINO-PhIRDA continues to make suggestions to promote the healthy development of pharmaceutical industry in order to safeguard the interests of the industry. The association suggested changes to "Pharmaceutical Trading Rules in Guangdong Province (Draft)" and "Implementation Plan for Drug Purchase with Required Amount in Shanghai (Draft)", which attracted great attention and positive response from the industry and generate certain effects.

The work report put up forward that during 2013-2014, SINO-PhIRDA will make efforts on the following four areas: First, to strengthen the communication with government and experts on drug discovery, clinical and pharmacy; Second, to improve the capability on policy research, conduct studies on the important issues in pharmaceutical industry, utilizing resources from industry, academia in order to provide references to government on decision-making; Third, to expand the scope of international cooperation, further improve the internationalization in pharmaceutical industry; Fourth, to improve the service of information, expand information channels, promote its quality to meet member's needs. SINO-PhIRDA will make joint efforts with related member companies to held the "Experience Exchange Meeting on Chinese Healthcare Insurance Reform" and "Pharmaceutical CEO Round-table Conference on Boao Forum for Asia Annual Conference 2014".

2. The meeting approved 2012-2013 Annual Financial Report.

3. The meeting adopted Proposal on Optimizing Pharmaceutical Innovative Eco-system in China, which consists of four parts: First, to have a precise understanding on current development of pharmaceutical industry in China; Second, to clearly define quality of drug evaluation, improve drug medicine approval mechanism; Third, to figure out the obligation of supervisory department, patent administrative department and judicial authority, in order to strengthen drug patent protection; Fourth, to encourage innovative drugs to be listed for healthcare insurance reimbursement. The proposal was adopted and SINO-PhIRDA will submit report to National Development and Reform Commission, National Health and Family Planning Commission, Ministry of Human Resources and Social Security, China Food and Drug Administration and other related departments.

4. The meeting approved the SINO-PhIRDA Rename Proposal by secret vote. A total of 54 votes (including 53 members to the meeting and Executive President Song Ruilin) were issued with 54 valid votes returned, 53 of which were favored votes. The vote approved to change the association's name from "China Pharmaceutical Industry Research and Development Association" into "China Pharmaceutical Innovation Association". The Secretariat was requested to proceed with the rename procedure in accordance with relevant state regulations and requirements.

5. According to relevant articles in SINO-PhIRDA Constitution and the decision by SINO-PhIRDA President Meeting, the meeting accepted Qilu Pharmaceutical Co., Ltd., Beijing CoSci Med-Tech Co., Ltd, Shanghai CP Guojian Pharmaceutical Co., Ltd. and Shenzhen Chipscreen Biosciences Co., Ltd. as new members of the association.

Part Three. Election of Annual Chairman 2013-2014 and Annual Chairman Candidate 2014-2015

1. According to relevant laws and regulations by SASAC and MOCA, the meeting elected Mr. Yan Xijun, Chairman of Tasly Holding Group, as the Annual Chairman 2013-2014 by secret vote. A total of 54 votes were issued with 54 valid votes returned, 53 of which were favored votes.

2. According to relevant laws and regulations by SASAC and MOCA, the meeting elected Mr. Sun Piaoyang, Chairman of Jiangsu Hengrui Medicine Co., Ltd., as the Annual Chairman Candidate 2014-2015 by secret vote. A total of 54 votes were issued with 54 valid votes returned, 53 of which were favored votes.

Part Four. Academic Lecture

In order to provide the members a better understanding on the macroeconomic situation, the trend of corporate development and reform, the meeting invited Prof. Li Daokui, a well-known economist from Tsinghua University to give a lecture on "Domestic Macroeconomic Situation and Development Trend" and have interactive discussion with the participants.

The meeting with high participation rate and rich contents completed all items on the agenda and was a great success.

会领导介绍
Introduction about SINO-PhIRDA Leadership

荣誉会长 桑国卫

十一届全国人大常委会副委员长
中国工程院院士

Sang Guowei
Honorary Chairman of SINO-PhIRDA
Vice Chairman of the Standing Committee of
Eleventh National People's Congress
Academician of Chinese Academy of Engineering

年度会长(2013-2014) 闫希军

天士力控股集团董事局主席
Yan Xijun Annual Chairman(2013-2014)
Chairman of the Board,Tasly Holding Group

执行会长兼秘书长 宋瑞霖

Song Ruilin,
Executive President Secretary-General

副会长 佘鲁林

中国医药集团总公司总经理
She Lulin, CEO , China National Pharmaceutical Group Corporation

副会长 陈启宇

上海复星医药（集团）股份有限公司董事长
(2012-2013年度会长）
Chen Qiyu , Chairman of the Board, Chairman of the Board, Shanghai Fosun Pharmaceutical(Group) Co.,Ltd
(2012-2013 Annual Chairman)

副会长 孙飘扬

江苏恒瑞医药股份有限公司董事长
Sun Piaoyang , Chairman of the Board , Jiangsu Hengrui Medicine Co.,Ltd

副会长 丁　健

中国科学院上海药物研究所所长、
中国工程院院士
Ding Jian, Director , Shanghai Institute of Materia Medica , Academician of Chinese Academy of Engineering

副会长 徐镜人

扬子江药业集团董事长
Xu Jingren , Chairman of the Board , Yangtze River Pharmaceutical Group

副会长 蔡东晨

石药集团有限公司董事长
Cai Dongchen , Chairman of the Board ,
CSPC Pharmaceutical Group Ltd.

副会长 楼定波

上海医药集团股份有限公司董事长
Lou Dingbo , Chairman of the Board ,
Shanghai Pharmaceuticals Holding Co., Ltd.

副会长 白礼西

太极集团有限公司董事长
Bai Lixi ,
Chairman of the Board , Taiji Group Co., Ltd.

副会长 任晋生

先声药业董事长
Ren Jinsheng , Chairman of the Board ,
Simcere Pharmaceutical Group

副会长 石晟怡

中国医药集团总公司董事会秘书
《中国新药杂志》有限公司董事长
Shi Shengyi , Secretary of the Board of Sinopharma Group Corporation Chairman of the Board of Chinese Journal of New Drugs

中国医药工业科研开发促进会章程

第一章 总 则

第一条 本团体的名称是：中国医药工业科研开发促进会，英文名称： China Pharmaceutical Industry Research and Development Association ，缩写：SINO-PhIRDA。

第二条 本团体是由医药生产企业、相关的科研单位及大专院校等自愿结成的全国性、专业性、非营利性社会组织。

第三条 本团体的宗旨:

高举中国特色社会主义伟大旗帜,以邓小平理论、三个代表重要思想、科学发展观为指导,贯彻国家有关方针、政策和改革精神，提高中国医药工业的科研创新能力，加强医药科研与生产的紧密结合，推动中国医药工业科研开发的国际合作，加快中国医药及相关行业的技术进步，提高经济效益,维护会员单位的合法权益，为医药卫生事业、经济社会发展做出更大的贡献。

本团体遵守宪法、法律、法规和国家政策，遵守社会道德风尚。

第四条 本团体接受社团登记管理机关中华人民共和国民政部和业务主管单位国务院国有资产监督管理委员会的业务指导和监督管理。

第五条 本团体的住所：北京市。

第二章 业务范围

第六条 本团体的业务范围：

（一）认真贯彻执行党中央、国务院有关中国医药工业科研开发政策，深入研究新药研发政策和中国医药体系创新的相关问题，科学预测新药研发的走向，及时提出中国医药工业发展的政策建议，切实反映会员单位合理的愿望和要求，协助会员单位解决实际问题；

（二）组织和参加有关医药行业发展的交流活动，增强中国医药行业的创新能力。组织和参加有关学术交流，组建中国医药行业发展、创新智库，推动医药行业产学研的结合，积极开展新药科研和技术协作及科技成果的推广，组织技术转让与协作，促进医药高科技的产业化，专业化；

（三）发挥自身优势、充分利用现代化手段，搜集、整理、研究、传递医药科技研发信息，聚焦医药行业重点问题，并开展咨询服务；

（四）推动中国医药行业的国际交流，组织开展各种形式的中外医药行业信息、技术、人员的交流与合作。

第三章 会 员

第七条 本团体的会员种类:单位会员。

第八条 申请加入本团体的会员，必须具备下列条件：

（一）拥护本团体的章程；

（二）有加入本团体的意愿；

（三）在本团体的业务领域内具有一定的影响。

第九条 会员入会的程序是：

（一）提交入会申请书；

（二）经会员大会讨论通过；

（三）由会员大会或会员大会授权的机构发给会员证。

第十条 会员享有下列权利：

（一）本团体的选举权、被选举权和表决权；

（二）参加本团体的活动；

（三）获得本团体服务的优先权；

（四）对本团体工作的批评建议权和监督权；

（五）按规定有获得本团体发出的信息资料和刊物权；

（六）有对本团体提出保护合法权益不受侵害的权利；

（七）入会自愿，退会自由。

第十一条 会员履行下列义务：

（一）遵守本团体章程，执行本团体决议；

（二）维护本团体合法权益；

（三）完成本团体交办的工作；

（四）按规定交纳会费；

（五）向本团体反映情况，提供有关资料。

第十二条 会员退会应书面通知本团体，并交回会员证。会员如果2年不履行义务，视为自动退会。

第十三条 会员如有严重违反本章程的行为，经会员大会或者会员大会授权的机构表决通过，予以除名。

第四章 组织机构和负责人产生、罢免

第十四条 本团体的最高权力机构是会员大会。会员大会的职权是：

（一）制定和修改章程；

（二）选举和罢免会长、副会长和秘书长；

（三）审议本团体的工作报告和财务报告；

（四）制定并修改会费标准；

（五）决定名誉职务的设立和人选；

（六）决定办事机构、分支机构、代表机构和实体机构的设立、变更和注销；

（七）决定聘任副秘书长以及各机构主要负责人；

（八）决定本团体终止事宜；

（九）决定其他重大事宜。

会员大会可以在副会长中选举一人，负责本会日常管理工作。

第十五条 会员大会须有2／3以上的会员出席方能召开，其决议须经到会会员半数以上表决通过方能生效。

会员大会每年至少召开一次。特殊情况下，也可以采用通讯方式召开，但修改章程、负责人变更及会费标准等重大事项不得以通讯方式表决。

第十六条 本团体的会长 、副会长 、秘书长必须具备下列条件：

（一）坚持党的路线、方针、政策、政治素质好；

（二）在本团体业务领域内有较大影响；

（三）会长、副会长最高任职年龄不超过70周岁，秘书长最高任职年龄不超过60周岁且为专职；

（四）身体健康，能坚持正常工作；

（五）未受过剥夺政治权利的刑事处罚；

（六）具有完全民事行为能力。

第十七条 本团体实行年度轮值会长制度；会长从会员中经选举产生，任期1年。

副会长、秘书长每届任期4年，连任不超过两届。

第十八条 会长为本团体法定代表人。因特殊情况，经会长委托，会员大会同意，报业务主管单位审查、社团登记管理机关批准后，可以指定一名副会长或秘书长担任法定代表人。

法定代表人代表本团体签署有关重要文件。

本团体法定代表人不兼任其他团体的法定代表人。

本团体会长、副会长、会员代表离开所属单位的，自动失去会长、副会长、会员代表资格，由原单位推荐新的人选，报会员大会选举备案。

第十九条 本团体会长行使下列职权：

（一）召集和主持会员大会；

（二）检查会员大会决议的落实情况。

副会长受会长的委托，可以代行会长的部分职权。

第二十条 本团体设立秘书处，在秘书长的领导下履行下列职责：

（一）开展日常工作，组织实施年度工作计划；

（二）协调各分支机构、代表机构、实体机构开展工作；

（三）提名副秘书长以及各机构主要负责人，交会员大会决定；

（四）决定办事机构、代表机构、实体机构专职工作人员的聘用；

（五）处理其他日常事务。

第五章 资产管理、使用原则

第二十一条 本团体经费来源：

（一）会费；

（二）捐赠；

（三）政府资助；

（四）在核准的业务范围内开展活动和服务的收入；

（五）利息；

（六）其他合法收入。

第二十二条 本团体按照国家有关规定收取会员会费。

会费由秘书处负责管理，并在会员大会期间向全体会员单位公布经费使用情况。

第二十三条 本团体经费必须用于本章程规定的业务范围和事业的发展，不得在会员中分配。

第二十四条 本团体建立严格的财务管理制度，保证会计资料合法、真实、准确、完整。

第二十五条 本团体配备具有专业资格的会计人员。会计不得兼任出纳。会计人员必须进行会计核算，实行会计监督。会计人员调动工作或离职时，必须与接管人员办清交接手续。

第二十六条 本团体的资产管理必须执行国家规定的财务管理制度，接受会员大会和财政部门的监督。资产来源属于国家拨款或者社会捐赠、资助的，必须接受审计机关的监督，并将有关情况以适当方式向社会公布。

第二十七条 本团体换届或更换法定代表人之前必须接受社团登记管理机关和业务主管单位认可的审计机构组织的财务审计。

第二十八条 本团体的资产，任何单位、个人不得侵占、私分和挪用。

第二十九条 本团体专职工作人员的工资和保险、福利待遇，参照国家对事业单位的有关规定执行。

第六章 章程的修改程序

第三十条 对本团体章程的修改，须经会员大会审议。

第三十一条 本团体修改的章程，须在会员大会通过后15日内，报业务主管单位审查，经同意，报社团登记管理机关核准后生效。

第七章 终止程序及终止后的财产处理

第三十二条 本团体完成宗旨或自行解散或由于分立、合并等原因需要注销的，由会员大会提出终止动议。

第三十三条 本团体终止动议须经会员大会表决通过，并报业务主管单位审查同意。

第三十四条 本团体终止前，须在业务主管单位及有关机关指导下成立清算组织，清理债权债务，处理善后事宜。清算期间，不开展清算以外的活动。

第三十五条 本团体经社团登记管理机关办理注销登记手续后即为终止。

第三十六条 本团体终止后的剩余财产，在业务主管单位和社团登记管理机关的监督下，按照国家有关规定，用于发展与本团体宗旨相关的事业。

第八章 附则

第三十七条 本章程经2012年6月1日第九届会员大会第三次会议表决通过。

第三十八条 本章程的解释权属本团体的会员大会。

第三十九条 本章程自社团登记管理机关核准之日起生效。

Constitution of SINO-PhIRDA

Chapter One: General Principle

Article 1. Name of the Association: China Pharmaceutical Industry Research and Development Association (the abbreviated name is SINO-PhIRDA).

Article 2. SINO-PhIRDA is a nationwide non-governmental and non-profit industrial organization composed of pharmaceutical scientific research institutions, enterprises, relevant universities and colleges on the basis of voluntariness.

Article 3. The objectives of the Association include:

to implement the relevant general and specific policies and the reform spirit of the government, strengthen the combination between the scientific research institutions and pharmaceutical enterprises, promote international cooperation on research and development of China's pharmaceutical industry, expedite the technological development in pharmaceutical industry, enhance the economic efficiency in enterprises and provide better service for healthcare and economic developments.

The Association follows the China's related constitution, laws, regulations and policies, as well as the ethical code of the society.

Article 4. The Association undertakes administration by State-owned Assets Supervision and Administration Commission of the State Council and Ministry of Civil Affairs.

Article 5. The Association's residence is in Beijing.

Chapter Two: Business Range

Article 6. Business range of the Association

(1) To carry out and implement relevant general and specific policies on Chinese pharmaceutical industry development made by the Central Committee of CPC and the State Council, perform in-depth research on new drug development and Chinese pharmaceutical innovation system, scientifically forecast the direction of new drug development, timely propose the recommendations for development of Chinese pharmaceutical industry, reflect members' reasonable wishes and demands, and assists members to solve practical problems.

(2) To organize and participate in the relevant exchange programs to enhance Chinese pharmaceutical industry development. To organize and participate in the relevant academic exchanges, set up a think tank for Chinese pharmaceutical industry development and innovation, promote the pharmaceutical industry combination of scientific research and practices, operate the relevant research cooperation and academic-achieve promotion, and assist to industrialization and specification of the high technology.

(3) Using our advantages and modern technologies to collect, study and publish the medical information, to focus on the key issues of industry and provide consultancy.

(4) To promote the international communication of Chinese pharmaceutical industry, and organize different kinds of cooperation and exchanges on information, technologies and personnels.

Chapter Three: Members

Article 7. Member type of the Association: Institutional member.

Article 8. Applicant members should fulfill the following requirements:

(1) Upholding the constitution of the Association;

(2) Be willing to join the Association;

(3) Possessing certain influences in the professional (industrial, academic) realm of our Association.

Article 9. Procedure of joining the Association

(1) Submitting application;

(2) Being approved through discussion on SINO-PhIRDA General Assembly;

(3) SINO-PhIRDA General Assembly or authorized agency issuing certificate to approved members.

Article 10. Rights and duties of members

(1) The rights of election, being elected and vote;

(2) Participate in the Association activities;

(3) The priorities of obtaining services from Association;

(4) The rights of supervision, suggestion and criticizing the issues of Association;

(5) The rights of obtaining the information and publications by Association;

(6) The right of protecting legitimate rights and interests.

(7) Enjoying freedom of joining and quitting the Association;

Article 11. Duties of the members

(1) Follow the Constitution of SINO-PhIRDA, implement the decision of the Association;

(2) Protect the legal rights and interests of the Association;

(3) Complete the work entrusted by the Association;

(4) Pay membership dues on time as per the stipulation;

(5) Provide various information requested by the Association.

Article 12. Quitted members should notify the Association with a written statement and return the membership certificates. If members don't carry out their duties for 2 years, they are regarded as withdrawing from the Association automatically.

Article 13. Members with serious breach of the Constitution will be cancelled with their membership by vote of the Board of Directors on the basis of consensus.

Chapter Four: Organization and Generation of Recall of Leading Staffs

Article 14. The SINO-PhIRDA General Assembly is the highest powerful organization of the Association. Functions of the SINO-PhIRDA General Assembly include:

(1) Composing and revising the Constitution of the association;

(2) Electing and recalling of the Chairman, Vice-President and Secretary-General;

(3) Reviewing working report and financial report of this association;

(4) Establishing and modifying the membership fee standard;

(5) Making decision on the establishment and nomination of honorary position;

(6) Deciding the establishment, alteration and cancellation of offices, branches, agencies and entities of the Association;

(7) Appointing Deputy Secretary-General and other major responsible persons;

(8) Deciding termination of the Association;

(9) Deciding other important issues.

Through the SINO-PhIRDA General Assembly, a Vice-President can be elected to take charge of daily management work.

Article 15. The SINO-PhIRDA General Assembly should require a participation of more than two thirds of all members. The effectiveness of its decision should require acquire approval vote of more than half members.

The SINO-PhIRDA General Assembly shall be convened at least once a year; it can be convened through telecommunication under certain conditions, except the decisions on important issues, including constitution emendation, major responsible person and fee standard changes, etc.

Article 16. The Chairman, Vice Presidents and Secretary-General of the association must meet the following requirements:

(1) Persist in the CCP political direction, decisions, policies.

(2) Strong influence in the professional work field.

(3) An age of no more than 70 for the Chairman, Vice President. An age of no more than 60 for the Secretary-General. The Secretary-General should be in full-time position.

(4) Being healthy enough to do normal daily work.

(5) Never deprived of political rights for criminal punishment.

(6) With ability of complete civil behavior.

Article 17. The Association applies system of annual Chairman rotation; the Chairman shall be elected from association members, and the term lasts for 1 year.

The Vice-President and Secretary-General are in position for a 4-year term, while their maximum tenure in office shall not surpass 2 terms.

Article 18. The Chairman is the legal representative of the Association. Under special circumstances, with the Chairman's commission and approval from Members General Assembly, subject to the review and approval from the related registration and administration authority, a Vice-President or the Secretary-General can be appointed as the legal representative.

The legal representative is not allowed to hold a concurrent post in other associations.

The Chairman, Vice-President and members of the Association will automatically lose their representative qualification when leaving their member units, and new election from candidates for their posts will be invoked.

Article 19. Function and powers executed by the President:

(1) Calling for and hosting the General Assembly.

(2) Examining the implementation of decisions made by General Assembly.

In the case of being authorized by the Chairman, Vice-Presidents can perform parts of Chairman's responsibilities.

Article 20. The Association Secretariat is established to perform the following duties under the leadership of Secretary-General.

(1) In charge and to organize routine work to implement annual work plan.

(2) To coordinate the work of sub-branches, representative and entity.

(3) To nominate the Deputy Secretary-General and representatives of sub-branches for the General Assembly's approval.

(4) To manage the employment of full-time working staffs for the Association.

(5) In charge of executing other routine affairs.

Chapter Five: Principle of Assets Management and Utilization

Article 21. Funds resources of the Association:

(1) Member annual fee;

(2) Donation;

(3) Government subsidies;

(4) Income from approved business activities and services;

(5) Interests;

(6) Other income from legitimate sources.

Article 22. Members pay fees to the Association according to the relevant state regulation.

The secretariat is responsible to manage the dues and the financial revenue and expenditure will be reported to all members during the General Assembly.

Article 23. The funds of the Association shall be used in the business range and career development regulated in the constitution and shall not be distributed among members.

Article 24. The Association sets up strict financial management rules and regulations, in order to ensure that the accounting data is legitimate, true, accurate and complete.

Article 25. The Association employs accounting staff with professional qualifications. An accountant cannot be a cashier at the same time. Accountants must perform accounting and accounting supervision. If accountants leave the posts or are transferred to other work, they must go through connecting procedures with the managing staff and shifting persons.

Article 26. Management of assets of the Association shall be executed according to the financial regulations stipulated by the state, and shall accept supervision of the members' Conference and the financial department. The assets that come from the government subsidies and social contribution shall be subjected to supervision by the audit organ, and shall be also promulgated to the public by the proper means.

Article 27. Before the legal person of the Association is replaced or is at the expiration of his term of office, he must be subjected to the financial audit by the relevant registration administration organ and the professional administration unit.

Article 28. The assets of the Association cannot be embezzled, diverted and distributed in private by any unit or any person.

Article 29. The wages, insurance and welfare of full-time staffs should comply with relevant regulations for government institutions in China.

Chapter Six: Revision Procedure of the Constitution

Article 30. The right of interpreting this Constitution belongs to the General Assembly.

Article 31. The Constitution comes into force on the date when it is ratified by social registration administration organ.

Chapter Seven: Procedure of disbanding the Association and handling the Assets

Article 32. Association cancelled due to organization structure changes or other reasons will be firstly proposed by the General Assembly.

Article 33. The proposal needs to be submitted and passed by the General Assembly and approved by administration department.

Article 34. Before disbanding the Association a clearing group shall be formed, under the direction of the professional administrative unit and the relevant organ, settle claims and debts, and to deal with the aftermath. During the clearing period any activities except clearing work will not be in progress.

Article 35. The Association is terminated after cancelling its registration in Social Organization Registration Administration.

Article 36. The left assets, after the Association is terminated, will be used to develop the business concerned about the Association's aim under the supervision of the professional administrative unit and the mass organization registration administration, in accordance with the relevant state regulations.

Chapter Eight: Appendix

Article 37. This Constitution was approved by 3rd Meeting of 9th SINO-PhIRDA General Assembly on June 1st, 2012.

Article 38. The right of interpreting this Constitution belongs to SINO-PhIRDA General Assembly.

Article 39. The Constitution comes into force on the date when it is approved by the authority of social organization registration & administration.

会员单位及其代表
Members & their Representatives

闫希军 Yan Xijun	天士力控股集团董事局主席 Chairman of the Board, Tasly Holding Group
佘鲁林 She Lulin	中国医药集团总公司总经理 CEO,China National Pharmaceutical Group Corporation
陈启宇 Chen Qiyu	上海复星医药（集团）股份有限公司董事长 Chairman of the Board, Shanghai Fosun Pharmaceutical(Group) Co.,Ltd
孙飘扬 Sun Piaoyang	江苏恒瑞医药股份有限公司董事长 Chairman of the Board, Jiangsu Hengrui Medicine Co.,Ltd
丁 健 Ding Jian	中国科学院上海药物研究所所长、中国工程院院士 Director, Shanghai Institute of Materia Medica , Academician Chinese Academy of Engineering
徐镜人 Xu Jingren	扬子江药业集团董事长 Chairman of the Board, Yangtze River Pharmaceutical Group
蔡东晨 Cai Dongchen	石药集团有限公司董事长 Chairman of the Board, CSPC Pharmaceutical Group Ltd
楼定波 Lou Dingbo	上海医药集团股份有限公司董事长 Chairman of the Board, Shanghai Pharmaceuticals Holding Co., Ltd.
白礼西 Bai Lixi	太极集团有限公司董事长 Chairman of the Board, Taiji Group Co., Ltd.
任晋生 Ren Jinsheng	先声药业有限公司董事长 Chairman of the Board,Simcere Pharmaceutical Group
石晟怡 Shi Shengyi	中国医药集团总公司董事会秘书、《中国新药杂志》有限公司董事长 Secretary of the Board of Sinopharma Group Corporation Chairman of the Board of Chinese Journal of New Drugs
胡季强 Hu Jiqiang	浙江康恩贝制药股份有限公司董事长 Chairman of the Board, Zhejiang CONBA Pharmaceutical Co., Ltd.
李振江 Li Zhenjiang	神威药业集团有限公司董事长 Chairman of the Board, Shineway Pharmaceutical Co.,Ltd
李春波 Li Chunbo	浙江医药股份有限公司董事长 Chairman of the Board, Zhejiang Medicine Co.,Ltd
白 骅 Bai Hua	浙江海正药业股份有限公司董事长 Chairman of the Board, Zhejiang Hisun Pharmaceutical Co., Ltd.
张千兵 Zhang Qianbing	华北制药集团有限责任公司总经理 General Manager, North China Pharmaceutical Group Corporation
汲 涌 Ji Yong	东北制药集团股份有限公司总经理 General Manager, Northeast Pharmaceutical Group Co.,Ltd
郭毅民 Guo Yimin	中国医药工业有限公司总经理 General Manager, China National Pharmaceutical Industry Co,Ltd
刘革新 Liu Gexin	四川科伦药业股份有限公司董事长 Chairman of the Board,, Sichuan Kelun Pharmaceutical Co,Ltd
李 聪 Li Cong	通化东宝药业股份有限公司总经理 General Manager, Tong Hua Dong Bao Group
李安平 Li Anping	山西振东制药股份有限公司董事长 Chairman of the Board, Shanxi Zhendong Pharmceutical Co.,Ltd
刘殿波 Liu Dianbo	绿叶制药集团有限公司董事长 Chairman of the Board, LUYE Pharmaceutical Co., Ltd.
张成海 Zhang Chenghai	美罗药业股份有限公司董事长 Chairman of the Board, Merro Pharmaceutical Co.,Ltd
闫志刚 Yan Zhigang	国药集团一致药业股份有限公司总经理 General Manager, China National Accord Medicines Corporation Ltd.
顾浩亮 Gu Haoliang	上海信谊药厂有限公司总经理 General Manager, Shanghai Sine Pharmaceutical Laboratories Co.,Ltd
李 昕 Li Xin	华润双鹤药业股份有限公司总裁 President,China Resources Double-Crane Pharmaceutical Co., Ltd
陶德胜 Tao Desheng	丽珠医药集团股份有限公司副总裁 Vice President , LIVZON Pharmaceutical Group Inc
郭殿武 Guo Dianwu	杭州民生药业有限公司副总经理 Deputy General Manager, Hangzhou Minsheng Pharmaceutical Co.,Ltd
董弘宇 Dong Hongyu	浙江佐力药业股份有限公司总经理 General Manager, Zhejiang Jolly Pharmaceutical Co.Ltd
许淑清 Xu Shuqing	广西梧州中恒集团股份有限公司董事长 Chairman of the Board,GuangXi WuZhou ZhongHeng Group.Co.Ltd
王 勇 Wang Yong	南京圣和药业有限公司董事长 Chairman of the Board, Nanjing Sanhome Pharmaceutical Co., Ltd
张观福 Zhang Guanfu	贵州信邦制药股份有限公司董事长 Chairman of the Board ,Guizhou Xinbang Pharmaceutical Co.,Ltd.
赵 涛 Zhao Tao	山东步长制药股份有限公司总裁 President,Shandong Buchang Pharmaceutical Co.,Ltd.
于伟仕 Yu Weishi	悦康药业集团有限公司董事长 Chairman of the Board,YouCare Pharmaceutical.Group Co.Ltd
陈庆才 Chen Qingcai	江苏奥赛康药业股份有限公司董事长 Chairman of the Board, Jiangsu Aosaikang Pharmaceutical Co.,Ltd

王晓琳
Wang Xiaolin
重庆植恩药业有限公司副总经理
Deputy General Manager,ZHIEN pharmaceutical.Co.Ltd

冯　鹤
Feng He
正大青春宝药业有限公司总裁
President, CHIATAI QINGCHUN BAO Pharmaceutical.Co.Ltd

丁列明
Ding Lieming
贝达药业股份有限公司董事长
Chairman of the Board,Betta Pharmaceutical Co.,Ltd

徐希平
Xu Xiping
深圳奥萨医药有限公司董事长
Chairman of the Board, Shenzhen Ausa Pharma Co.,Ltd

娄　竞
Lou Jing
沈阳三生制药有限责任公司总裁
President, Shenyang Sunshine Pharmaceutical Co.,Ltd

曹　飞
Cao Fei
百济神州（北京）生物科技有限公司公共事务部高级总监
Senior Director of Public Affairs, BeiGene (Beijing) Co., Ltd

王永辉
Wang Yonghui
广州市香雪制药股份有限公司董事长
Chairman of the Board, Xiangxue Pharmaceutical Co.,Ltd.

任武贤
Ren Wuxian
亚宝药业集团股份有限公司董事长
Chairman of the Board,Yabao Pharmaceutical Group Co., Ltd

葛啸虎
Ge Xiaohu
常州方圆制药有限公司董事长
Chairman of the Board, Changzhou Fangyuan Pharmaceutical Co., Ltd

李景亮
Li Jingliang
河南太龙药业股份有限公司副董事长
vice-Chairman of the Board, Henan Taloph Pharmaceutical Stock Co.,Ltd

郑效东
Zheng Xiaodong
上海东富龙科技股份有限公司董事长
Chairman of the Board, Shanghai Tofflon Science and Technology Co.,Ltd

李伯涛
Li Botao
齐鲁制药有限公司总经理
General Manager, Qilu Pharmaceutical Co.,Ltd

王锦刚
Wang Jingang
北京科信必成医药科技有限公司总经理
General Manager, Cosci Med-Tech Co.,Ltd

王俊林
Wang Junlin
上海中信国健药业股份有限公司总经理
General Manager, Shanghai CP Guojian Pharmaceutical Co.,Ltd

鲁先平
Lu Xianping
深圳微芯生物科技有限责任公司总裁
President, Shenzhen Chips Creen Bioscien Co.,Ltd

柯尊洪
Ke Zunhong
成都康弘药业集团股份有限公司董事长
Chairman of the Board, Kanghong Pharmaceutical Group Co.,Ltd

张伯礼
Zhang Boli
天津中医药大学校长、中国工程院院士
President,Tianjin University of Traditional Chinese Medicine
Academician , Chinese Academy of Engineering

黄璐琦
Huang Luqi
中国中医科学院副院长
Vice President, China Academy of Chinese Medical Sciences

吴晓明
Wu Xiaoming
中国药科大学原校长
Former President,China Pharmaceutical University

高思华
Gao Sihua
北京中医药大学校长
President, Beijing University of Chinese Medicine

吴春福
Wu Chunfu
沈阳药科大学党委书记
Party Secretary, Shenyang Pharmaceutical University

刘俊义
Liu Junyi
北京大学药学院院长
Dean, Peking University School of Pharmaceutical Sciences

陆伟跃
Lu Weiyue
复旦大学药学院党委书记
Party Secretary, School of Pharmacy Fudan University

蒋建东
Jiang Jiandong
中国医学科学院药物研究所所长
Director, Insititute of Materia Medica, Chinese Academy of Medical Sciences

刘克良
Liu Keliang
军事医学科学院毒物药物研究所所长
Director, Institute of Pharmacology and Toxicology Academy of Military Medical Sciences

汤立达
Tang Lida
天津药物研究院院长
Director, Tianjin Institute of Pharmaceutical Research

俞　雄
Yu Xiong
中国医药工业研究总院副院长
Vice President,China State Institute of Pharmaceutical Industry

李卓荣
Li Zhuorong
中国医学科学院医药生物技术研究所所长助理
Assistant Director, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences

王拥军
Wang Yongjun
北京天坛医院副院长
Deputy Dean ,Beijing Tiantan Hospital

苗志敏
Miao Zhimin
青岛大学医学院附属医院院长
President of the Affiliated Hospital of Medical College at Qingdao University

曾进胜
Zeng Jinsheng
中山大学附属第一医院神经科主任
Director of the Department of Neurology, The First Affiliated Hospital of Sun Yat-Sen University

董　强
Dong Qiang
上海华山医院神经内科主任
Director of the Department of Neurology, Huashan Hospital in Shanghai

会员单位简介:(排名不分先后)
Brief Introduction of SINO-PhIRDA Members

天士力控股集团
Tasly Holding Group

天士力集团成立于1994年，是以大健康产业为主线，以生物医药产业为核心，以保健品、功能食品等健康产业以及健康管理与服务业为两翼的高科技跨国企业集团。

天士力始终秉承“追求天人合一，提高生命质量”的企业理念，坚持打造现代中药第一品牌，不断推进大健康产业持续快速发展。

天士力以现代中药奠基立业，立足于现代科技创新，以组分中药为主导，形成了组分中药产业化开发的技术平台和先进制造平台。大力推进标准化管理的创新和系统化建设，形成了一条将药物研发、药材种植、中药提取、制剂生产和市场营销各环节集于一体的现代中药产业链，开发培育了一批疗效确切、市场信誉度高的现代中药产品群，其中最具代表的复方丹参滴丸2010年顺利通过了FDA（美国食品和药品管理局）Ⅱ期临床试验，现在正在全球开展三期临床试验。

近年来，特色化学药和高端生物药也获得快速发展。化学药建立了获得欧美和中国的GMP认证生产基地，达到国际先进水平，产品全部面向国际市场。生物药以溶栓制剂尿激酶原和亚单位流感疫苗为龙头，形成了治疗用药与预防用药相结合的研发平台和产业平台。

借助于生物医药领域的技术优势，紧密结合食品、饮品等生活核心要素，向生命健康产业扩展。经过近年来的精心打造，形成了以“国台”为品牌的现代白酒产供销体系；“帝泊洱”生物茶、饮用水以及保健品、功能食品等产业领域，以科技创新为先导，以优势资源开发为基础，形成了规模化产能和品牌化营销。

面向未来，天士力集团将继续发展壮大“一个核心带两翼”的大健康产业格局，为实现“创造健康，人人共享”的目标，锐意创新，科学发展。

Tasly Holding Group. Co., Ltd, was founded on May 1994. Through decades of development with Great Health industry as guideline and pharmaceutical industry as its center, Tasly has become a hi-tech group whose scope of business includes modern TCM, chemical medicine, biological medicine, healthcare products, functional food, covering the fields of research and development, planting, manufacturing and distribution.

Tasly has been upholding the concept of “Pursue the integral of man and the nature, and improve the quality of life”. Its goal is to create the No. 1 brand of the modern TCM and continuously promote the fast development of the Great Heath industry.

Tasly’s development is rooted from the modern TCM, and based on the innovation of modern technology. With component TCM as its leading factor, Tasly has formed a platform both for the industrial development of component TCM and for the advanced manufacturing. Tasly has greatly promoted the innovation of standardized management and the construction of systematization. A modern TCM industry chain, which ranges from the research and the development, the plantation, the extraction, the manufacturing, and the marketing, has been established. It has developed a host of modern TCM products which have curative effects and market reputation. The Compound Danshen Dripping Pills,one of the most renowned products of Tasly, successfully completed the FDA Phase II in 2010, and undergoes the FDA Phase III now.

In recent years, the chemical pharmaceutical sector and the high-end bio-pharmaceuticals have developed quickly. The manufacturing plant of chemical pharmaceutical, which has reached the international standardization, was approved

by the European, the US and the Chinese GMP standard. The products are sold to the global market. The bio-pharmaceuticals are headed by the Recombinant Human Prourokinase which is used for thrombolysis and the subunit influenza vaccine. They have set up the platform of research, development and manufacturing to treat and prevent the disease.

With the technical advantage of pharmaceutical industry, and focusing on the core elements of live such as food and drink, Tasly has expanded its business into the area of health industry. It includes the Guotai modern Chinese spirit, Deepure instant tea and drinking water and the health and functional products. Guided by the scientific innovation and based on the advantaged resources, it has achieved large scale production and brand marketing.

Looking into the future, Tasly Holding Group will continuously develop the great health industry with the biopharmaceutical industry as a core as well as healthy life and healthcare management and service as two-sided wings for its business development strategy. People at Tasly today, bare with the spirit as a pioneer innovator, are fully dedicated in carry alone their great mission of creating and sharing the health for all human being.

中国医药集团总公司
China National Pharmaceutical Group Corporation (SINOPHARM)

中国医药集团是由国务院国资委直接管理的中国规模最大、产业链最全、综合实力最强的医药健康产业集团。以预防治疗和诊断护理等健康相关产品的分销、零售、研发及生产为主业。旗下拥有11家全资或控股子公司和国药控股、国药股份、天坛生物、现代制药、一致药业5家上市公司。2003年至2012年，集团营业收入年平均增幅32%，利润总额年平均增幅45%，总资产年平均增幅32%。2012年营业收入1650亿元，其中工业销售规模超130亿元，是中国唯一一家超千亿医药健康产业集团。

中国医药集团正全力推进集团五大平台——现代物流分销一体化运营平台、产学研一体化科技创新平台、国际经营一体化平台、医疗健康产业平台和高效管控与融合协同一体化平台的全面建设，形成五大全覆盖网络——全国医药物流分销配送网络、全国医药零售连锁网络、全国麻醉药品配送网络、全国生物制品营销及冷链配送网络、全国医疗器械耗材产品配送网络，促进集团十一大业务——医药现代物流分销、医药零售、生物制品、化学制药、现代中药、诊断试剂与化学试剂、科学仪器与医疗器械、医药科研与工程设计、医药国际经营与海外实业、医药会展与传媒、医疗健康产业的全面发展，构成了一个以医药健康产业为核心竞争力的创新型企业。

中国医药集团拥有覆盖全国31个省、自治区、直辖市的医药流通配送网络和与国际水平接轨的30个配送中心，是国内最大的生物医药研发、生产企业，承担了80%以上的国家免疫规划用疫苗的生产任务。集团建立了生物制药、麻醉精神药品、抗感染药、抗肿瘤药、心脑血管用药、呼吸系统用药等生产基地和药材基地，拥有国内实力最强的应用性医药研究机构和工程设计院。2010年，中国医药集团被评为国家创新型企业。

中国医药集团是我国医药行业与外资合作最早、最多和最成功的企业。从1980年开始先后与多个国际著名医药企业建立了中国大冢制药有限公司、华瑞制药有限公司、西安杨森制药有限公司、中美施贵宝制药有限公司、苏州胶囊有限公司等20家合资企业，与世界上100多个国家和地区建立了贸易合作关系，开展了多项国际技术合作，国际化步伐不断加快。

中国医药集团的发展目标是，“十二五”期间，建成涵盖医药行业全产业链的，具有行业带动力和国际竞争力的大型医药健康产业集团，成为进入世界500强的第一家中国医药健康企业。

China National Pharmaceutical Group Corporation, (Sinopharm) is the largest medical and healthcare group in China which is directly managed by State-owned Assets Supervision and Administration Commission of the State Council (SASAC), with the core businesses of distribution, logistics, retail, scientific research and manufacture of healthcare related products. Associated built on the basis of the four state-owned companies: China National Pharmaceutical (Group) Corporation, China National Pharmaceutical Industry Corporation, China National Pharmaceutical Foreign Trade Corporation and China National Medical Equipment Industry Corporation, Sinopharm was established in 1998. In 2003, China National Group Corporation of Traditional & Herbal Medicine joined Sinopharm. In 2009, Sinophrm restructured with China National Bio-tech Group (CNBG). As well as in 2010, Shanghai Institute of Pharmaceutical Industry (SIPI) and China National Service Corporation for Chinese Personnel Working Abroad (CNSC) joined Sinopharm. So far, Sinopharm owns 11 wholly owned or holding subsidiaries, and 5 listed companies including Sinopharm Group Co., Ltd. (01099.HK), China National Medicines Co., Ltd. (600511.SH), Beijing Tiantan Biological Products Co., Ltd. (600161.SH), Shyndec Pharmaceutical Co., Ltd. (600420.SH) and Shenzhen Accord Pharmaceutical Co., Ltd. (200028.SZ). The sales revenue of Sinopharm exceeded RMB 160 billion in 2012. It is the only Chinese pharmaceutical company whose sales revenue exceeds RMB 100 billion.

With all-out efforts, Sinopharm is promoting the overall construction of five major platforms the modern integrated distribution and logistics platform, the integrated manufacturing and R&D platform

for scientific and technological innovation, the integrated globally operational platform, the health care industry platform and the highly efficient control and integration services platform, to comprehensively advance the joint development of the eleven core business sectors of modern pharmaceutical logistics and distribution; medicine retail; biological products; chemical pharmaceuticals; modern TCM; diagnosis reagents and chemical reagents; scientific instruments and medical equipments; medical scientific research and engineering design; pharmaceutical international trade and overseas industry, pharmaceutical exhibitions and media; health care industry. So far, Sinopharm has formed an immense and complete pharmaceutical industrial platform, realized the scale effect and promote a high-speed growth. Since Year 2003 to Year 2011, the annual average growth rate of revenue was 33%, the annual average growth rate of gross profit was 44% and the annual average growth rate of total assets was 35%. Besides the largest pharmaceutical and medical distribution network covering 31 provinces, autonomous regions and municipalities and 30 international standard distribution centers and production bases, Sinopharm also owns the first-class manufacturers for medicines, vaccines, blood products, high-level scientific and technological institutes, massive planting bases for medicinal herbs and most of domestic medicine and health care related professional exhibition brands in China. Since 1980s, Sinopharm has cooperated with renowned multinationals, established dozens of Sino-foreign pharmaceutical joint ventures, e.g. China Otsuka Pharmaceutical Co., Ltd. (COP) and Sino-Swed Pharmaceutical Co., Ltd. (SSPC), jointly conducted international technologic programs with companies from U.S.A., Japan, France, UK., Germany, Italy and Korea, built up collaborative relationship with the clients from over 100 countries and regions. The broad international cooperation has energetically promoted the operation and management ability of the industry in China.

Sinopharm is aiming to be an international pharmaceutical and healthcare group which covering the whole industrial chain, giving strong impetus to the industry, becoming the first Chinese pharmaceutical company of the Global Top 500 Corporations during the period of "the 12th Five-Year-Plan".

FOSUNPHARMA 复星医药

上海复星医药（集团）股份有限公司
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

上海复星医药（集团）股份有限公司（简称“复星医药”）成立于1994年，1998年8月和2012年10月分别在上海证券交易所和香港联合交易所主板挂牌上市（股票代码：600196-SH，02196-HK），是在中国医药行业处于领先地位的上市公司。

复星医药专注现代生物医药健康产业，抓住中国医药市场的快速成长和中国企业进军世界主流医药市场的巨大机遇，战略性地覆盖研发制造、分销及终端等医药健康产业链的多个重要环节，形成了以药品研发制造为核心，同时在医药流通、医疗服务、医学诊断和医疗器械等领域拥有领先的市场地位，在研发创新、市场营销、并购整合、人才建设等方面形成竞争优势的大型专业医药健康产业集团。

复星医药注重创新研发，拥有国家级企业技术中心，并在上海、重庆、美国建立了高效的国际化研发团队。公司研发专注于心血管、抗肿瘤、中枢神经系统、血液系统、新陈代谢及消化道及抗感染等治疗领域，且主要产品均在各自细分市场占据领先地位。在中国，复星医药已取得肝病、糖尿病、结核病、临床诊断产品等细分市场的竞争优势；在全球市场，复星医药也已成为抗疟药物的领先者。

复星医药在聚焦发展核心制药业务的同时，积极发展医疗服务领域，并进一步巩固在医学诊断、医疗器械等领域的竞争优势。目前，复星医药已在国内高端和专科医疗服务领域建立坚实基础。复星医药亦是中国最大药品分销企业国药控股的第二大股东，并拥有复美大药房、金象大药房等区域领先零售连锁品牌，形成以上海、北京为中心，面向全国发展的医药零售格局。

复星医药奉行可持续发展的原则，将履行社会责任纳入到企业发展的长期战略。在企业的经营发展过程中，复星医药始终怀着感恩的心态，努力做一个让社会、政府、员工和股东满意的企业。

持续创新，共享健康。面向未来，复星医药将继续以促进人类健康为使命，采取“内生式增长、外延式扩张和整合式发展”的战略发展模式，不断提高创新能力、服务能力、整合能力以及国际化能力，高效运营、管理和投资行业优秀企业，以成为提供健康产品和服务的领导性公司。

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“FosunPharma”), a leading healthcare company in China,which was established in 1994 ,has been listed on Shanghai Stock Exchange since August 1998 and on the Main Board of the Stock Exchange of Hong Kong Limited (stock code: 600196-SH,02196-HK).

Specializing in modern biopharmaceutical and healthcare industry, FosunPharma has captured opportunities within the rapidly developing Chinese healthcare industry as well as from the globalization of Chinese healthcare companies in general. FosunPharma's operations strategically cover several important segments of the healthcare industry value-chain, including: pharmaceutical manufacturing, distribution and retail. In particular, the Company has a leading market position and unmatched advantages in pharmaceutical distribution and retail, healthcare services, diagnostic products and medical devices, and maintains a strong focus on research and development, and manufacturing. As one of the largest healthcare companies in China, FosunPharma enjoys a competitive advantage in research and development, innovation, marketing, integration of mergers and acquisitions, as well as human resources.

As a result of its focus on innovation, research and development, FosunPharma maintains a highly capable international R&D team with operations in Shanghai and Chongqing and United States in addition to its National Recognized Enterprise Technology Centre. FosunPharma's research and development activities cover therapeutic areas such as metabolism and alimentary tract, the cardiovascular system, anti-tumor,centralnervous system and anti-infective drug. The Company has market-leading products in China in such segments as liver diseases, diabetes, tuberculosis and diagnostic products; and is the leading provider of anti-malaria medicines globally.

While focusing on pharmaceutical manufacturing, FosunPharma has built a leading position in diagnostic products and medical devices while actively developing its presence in healthcare services, where it has a solid foundation for domestic high-end and specialty services. FosunPharma is the second largest shareholder of Sinopharm, China's largest pharmaceutical distributor. The Company also operates leading local pharmacy chains such as For Me Pharmacy and Golden Elephant Pharmacy, which, from their bases in Shanghai and Beijing, provide it with a nationwide retail network.

FosunPharma strongly believes in the principle of sustainable development and has incorporated social responsibility into its long-term business strategy. In full recognition of its social role, FosunPharma endeavors to meet the needs of its community, customers, employees and shareholders throughout conducting its business and its future development.

With its commitment to innovation for good health and creating a better future, FosunPharma remains on its mission to promote health and well-being. The Company's strategic development approach of “Organic Growth, Coupled with M&A and Integration” allows it to continue to enhance creativity and service, drive integration and achieve global capabilities. As a result, FosunPharma will emerge with effective operation, world-class management, sound investments and as a leading provider of healthcare products and services.

江苏恒瑞医药股份有限公司
Jiangsu Hengrui Medicine Co., Ltd.

江苏恒瑞医药股份有限公司(Jiangsu Hengrui Medicine Co., Ltd.)始建于1970年，前身是连云港制药厂，1997年改制成为股份公司，2000年在上海证券交易所上市（股票代码600276）。目前是国内最具创新能力的现代化制药企业之一，销售额和利税均位居行业前五强。

自成立以来，恒瑞医药本着“诚实守信，质量第一”的经营原则，致力于在抗肿瘤药、手术用药、内分泌治疗药、心血管药及抗感染药物等领域的创新发展，并逐步形成了品牌优势。公司主要研发中心在美国新泽西和中国上海，生产基地在中国连云港和上海。公司销售网络覆盖全国，部分产品远销欧美，其中抗肿瘤药、手术用药销售已连续多年在国内排名第一，其他产品的销售在国内也名列前茅。

在未来发展中，公司将始终秉承“科研为本创造健康生活”的理念，以建设“中国专利制药企业”为目标，拼搏进取，勇于创新，不断实现企业发展的新跨越和新突破。

Jiangsu Hengrui Medicine Co., Ltd., founded in 1970, was listed Shanghai Stock Exchange since 2000 (code: 600276). At present, HRH medicine has become one of the largest production bases of key oncology products and manufacturers of narcotic drugs in China.

Over the years, HRH medicine under the spirit of "honest and trustworthy, quality first" business principles, is committed to oncology, surgery and anti-infective drug classes and other areas of innovation and research and development. After decades of development, not only the sales network covering the whole country, and along with R & D capacity increasing year by year, its market is gradually extending tentacles into Europe , United States and other countries.

In future development, HRH medicine will continue adhering to the "research-oriented, healthy life" concept, in order to create "brand-name pharmaceutical companies in China" as the goal, achieving a new leap in development.

中国科学院上海药物研究所
Shanghai Institute of Materia Medica of Chinese Academy of Sciences

中国科学院上海药物研究所是我国历史最悠久的药物研究机构，她的前身是国立北平研究院药物研究所，创建于1932年，1933年迁至上海，2003年又搬迁至浦东张江高科技园区。

上海药物研究所是以创新药物的基础研究、应用基础和应用开发研究为主的综合性研究所。通过生物学和化学两大学科的密切合作，阐明生物活性物质的结构、活性及其相互关系；探索药物作用的新机理、新靶点；完成新药临床前综合评价及研究；大力推进新药成果转化；为我国创新药物能力的全面提升起到引领、骨干和辐射作用。

上海药物研究所的主要研究领域包括：天然活性物质的发现；化合物的合成、结构修饰；药物作用的细胞和分子机制；药效评价新动物模型；新靶标的确证；药物－靶标相互作用和构效关系；分子药物设计；高通量和高内涵药物筛选；药物的早期代谢特征和安全性评价；药物新型传递系统等。重点研究治疗严重危害我国人民健康的恶性肿瘤、心血管疾病、神经退行性疾病、代谢性疾病的新药；同时对严重影响公共卫生和社会安全的感染性及突发性疾病等开展新药研发；并加强现代中药的研发，发掘祖国医药宝库，为中药走向世界不断作出基础性、战略性的贡献。

上海药物研究所设有新药研究国家重点实验室、国家新药筛选中心、中药标准化技术国家工程实验室三个国家级研究中心，六个研究室，以及一系列新药研发技术平台；主办了英文学术杂志《Asian Journal of Andrology》和《Acta Pharmacologica Sinica》，并主办以非处方药物为主的科普杂志《家庭用药》。

经过几代科研人员的努力，上海药物研究所已发展成为学科齐全、成就卓著、人才荟萃、在国内外享有较高声誉的国立药物研究机构。成为我国新药研究最重要的中心之一。

Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences (CAS) evolved from the Institute of Materia Medica of Peking Academy of Sciences founded in 1932. Its current location is within the heart of Zhang Jiang Hi-Tech Park, Pudong New District.

SIMM's mission is to provide a comprehensive solution in drug discovery and development. By combining basic and applied research efforts and through cross-fostering between chemistry and biology, scientists at SIMM carry out studies toward the elucidation of the structural basis of bioactive substances, discovery of new targets or mechanisms of action, comprehensive pre-clinical evaluation of drug candidates, and promotion of commercialization, thereby playing an indispensable role in building China's drug innovation capabilities. The major research directions of SIMM include drugs against diseases seriously endangering the health of Chinese people like tumors, cardiovascular diseases, neurological diseases, metabolic diseases, autoimmune diseases as well as infectious diseases. Another task for SIMM is to strengthen research and development of Traditional Chinese Medicine (TCM).

SIMM consists of the following functional divisions: three national research centers which include State Key Laboratory of Drug Research, National Center for Drug Screening, and National Engineering Laboratory for TCM Standardization Technology; six research departments and six drug discovery and development platforms.Two English journals, namely, Acta Pharmacologica Sinica and Asian Journal of Andrology, and one Chinese journal Family Medicines are published by SIMM.

Through several generations of efforts, SIMM has become one of the leading interdisciplinary research centers in China . It is recognized worldwide by its outstanding achievements in both basic and applied research fields.

扬子江药业集团
Yangtze River Pharmaceutical Group

求索进取 护佑众生

—— 奋进中的扬子江药业集团

扬子江药业集团创建于1971年，是一家跨地区、产学研相结合、科工贸一体化的国家大型医药企业集团，也是科技部命名的全国首批创新型企业。集团总部位于江苏省泰州市，旗下20多家成员公司分布北京、上海、南京、广州、成都等地；营销网络覆盖全国各省、市、自治区。

多年来，集团始终秉承“求索进取，护佑众生”的理念，践行“高质惠民，创新为民”发展宗旨。企业综合经济效益自1996年起，连续十多年排名江苏省和全国医药行业前列，并跻身“中国企业500强”、“中国民营企业500强”、“全国纳税500强”。据国家工信部公布的数据，2009年以来，扬子江药业集团有限公司主营业务收入连续四年名列全国医药工业企业百强榜前三甲。

集团坚持以创新引领发展，加快实施“三药并举”研发创新战略。依托产学研联合建成设施一流的江苏省（扬子江）新药研究院，拥有国家级企业技术中心、药物制剂新技术国家重点实验室、中药国家工程研究中心等创新研发平台。经过多年的持续积累和创新，产品体系中西药并举，覆盖10多个领域、20多种剂型、200多个品规。

集团视质量为企业的生命。现有20多个产品被评为“江苏省名牌产品”，11个产品获“中国名优产品”称号，9个产品被列入“国家中药保护品种”，2个产品获“国家科技进步二等奖”；另有20多个产品质量达到欧美药典标准，3个车间已通过欧盟GMP认证。集团自2005年以来蝉联全国医药行业QC成果评比一等奖总数“九连冠”，并被中国食品药品检定研究院、江苏省食品药品监督管理局指定为实训基地。

面向未来，奋进中的扬子江药业集团以振兴民族医药为己任，怀着科学、严谨、负责的态度，竭诚为全人类的健康服务。

Seeking Progress At All Times and Safeguarding All Human Beings

—— YRPG on its Road of Progress

Established in 1971, YRPG is a large cross-regional pharmaceutical group that features industry-university-institute cooperation and integrates scientific research, industrial production and sale. It is among the first group of Innovative Enterprises named by the Ministry of Science and Technology. Headquartered in Taizhou (Jiangsu Province), The sales network spans all of China. YRPG has over 20 subsidiary companies.

Since its inception, YRPG follows its philosophy of "seeking progress at all times and safeguarding all human beings" and principle of "benefiting the general public through quality products and innovation". Since 1996, the group's overall

economic strength has topped the list of pharmaceutical industry in Jiangsu as well as in China. According to figures from the Ministry of Industry and Information, YRPG's prime operating income was among the top three of the Chinese pharmaceutical companies since 2009.

YRGP upholds the principle of developing through innovation,. It is now stepping up the R&D strategy of "three medicines in one go". it has built the Jiangsu (YRPG) New Medicine Institute through industry-university-institution cooperation. Its R&D platforms include a nation-level class enterprise technological center, a key state-level laboratory of pharmaceutical preparation,and an engineering R&D center for traditional Chinese medicine.With these platforms .Through years of work, its products include both Chinese and Western medicines, encompassing over 10 fields, 20 preparations and 200 sizes for medicine.

YRPG sees quality as the life of our company. It now has over 20 products awarded "Jiangsu Well-known Brands", 11 "Chinese Excellent Products" and 9 "National Protected TCM Medicine". Two of YRPG's products won Second Prize for National Science and Technology Progress.More than 20 products meet the pharmacopeia standards in the U.S.A and EU.,and three facilities have gained EU GMP qualification. Since 2005, it has consecutively won first-place prizes year after year from the National Pharmaceutical Industry QC. It was also designated a training center by the Chinese Food and Drug Administration and Jiangsu Food and Drug Agency.

Looking forward, YRPG will continue working to help build up the Chinese pharmaceutical industry, and serve all human beings scientifically, rigorously and responsibly.

石药集团有限公司
CSPC Pharmaceutical Group Co.,Ltd.

石药集团始建于1938年5月，现有资产总额200亿元，员工18000人，主要从事医药产品的开发、生产和销售。产品包括抗生素、维生素、心脑血管、解热镇痛、消化系统用药、呼吸系统用药和中成药等七大系列近千个品种，主导产品的产量、规模、实力在全国均名列前茅。

石药集团坚持以科技创新为驱动，新药研发实力位居全国药企领先水平。目前在研新药项目170个，其中拥有自主知识产权的国家一类新药10余项，涉及生物技术、手性合成药物、脂质体、透皮制剂、分子微囊剂等多种领域。已成功上市的国家一类新药“恩必普”是脑卒中治疗领域的全球领先药物，也是我国第三个拥有自主知识产权的一类新药，在86个国家受到专利保护。近五年来，石药集团先后承担了国家863、973、重大新药创制等项目40余项。

石药集团拥有“石药”“欧意”“果维康”“恩必普”四个中国驰名商标，六度入选“中国500最具价值品牌”。石药集团生产的药品安全有效、质量可靠、享誉全国，已经培育出了恩必普、玄宁、欧来宁、维宏、固邦、多美素等一大批品牌药，产品疗效得到广大医患的一致好评，为缓解患者的病痛和推动我国医疗卫生事业发展做出了突出贡献。

2012年，石药集团实现销售收入164亿元。2012年，创新药、品牌药等制剂销售为石药集团贡献的毛利已经占集团总毛利的90%以上。未来，石药集团将通过现有产品快速增长及收购兼并发展成为国际型领先制药企业。

CSPC Pharmaceutical Group was established in May 1938, and now has 18,000 employees and RMB 20 billion of total assets. CSPC is primarily engaged in development, manufacturing, and sales of pharmaceutical products. Its product offerings include seven categories and nearly a thousand product varieties, such as antibiotic, vitamin, cardiovascular, anti-inflammatory, gastrointestinal, respiratory, and traditional Chinese medicine. CSPC’s key products rank the best in sales volume, revenue, and profit in China.

CSPC, driven by scientific and technological innovation, has been leading the Chinese pharmaceutical industry in new drug research and development. Currently there are 170 new drugs in development. More than 10 drugs have independent intellectual property rights and are granted Class I new drugs by CFDA. These drugs cover biologic, chiral synthetic, liposomal, transdermal, molecular microcapsule technologies. Among these innovative drugs, NBP is successfully marketed as the third national Class I new drug and is considered a global leading medicine in the treatment of stroke. Currently, NBP has been granted patent protection in 86 countries. In the past five years, CSPC has undertaken more than 40 projects that are sponsored by the national 863, 973, and other major new drug development programs.

CSPC owns four well-known trademarks, "CSPC", " Ouyi" , "Guowei C", " NBP ". CSPC is named for six times as one of the "500 most valuable brands in China". CSPC is nationally recognized for manufacturing high-quality, safe and effective drug, including NBP, Xuan Ning, Oxiracetam, Gubang, Weihong , Doxorubicin Hydrochloride Liposome Injection. These products are praised by doctors and patients for making significant contribution to the advancement of China’s health care.

In 2012 CSPC achieved RMB 16.4 billion in sales. The innovative and branded drugs contributed to over 90% of the total gross profit. Into the future, CSPC is aspired to become a leading international pharmaceutical company through accelerating organic growth and pursuing external mergers and acquisitions.

上海医药集团股份有限公司
Shanghai Pharmaceuticals Holding Co.,Ltd.

上海医药集团股份有限公司（港交所股票代号：02607；上交所股票代号：601607）是一家总部位于上海的全国性医药产业集团。公司主营业务覆盖医药研发与制造、分销与零售全产业链，产品聚焦心脑血管类、全身性抗感染类、消化系统和免疫代谢类、神经精神类、抗肿瘤类五大治疗领域。公司综合排名位居全国医药行业第二，是中国为数不多的在医药产品和分销市场方面均居领先地位的医药上市公司，2012年营业收入680亿元，位列中国企业500强，入选上证180指数、沪深300指数样本股，H股入选恒生指数成分股、摩根斯坦利中国指数（MSCI）。公司倡导“创新、诚信、合作、包容、责任”的企业核心价值观，致力于持之以恒，提升民众的健康生活品质，努力打造受人尊敬、具有行业美誉度的领先品牌药制造商和健康领域服务商。

Shanghai Pharmaceuticals Holding Co., Ltd (HKEx Stock Code: 02607 and SSE Stock Code: 601607) is a national pharmaceutical industrial group located in Shanghai. The Company’s major businesses cover the whole industrial chain ranging from pharmaceutical R&D and manufacturing, distribution and retailing, with its product focusing on such five major therapeutic areas as the cardiovascular, systemic anti-infection, digestive system and immune-metabolism, neuropsychopathy and antineoplastic. Ranked No. 2 in domestic pharmaceutical industry in terms of comprehensive capacity in China,the company is the one of the few listed pharmaceutical companies which holds aleading position in both pharmaceutical manufacturing and distribution in China. As one of the top 500 companies in China, Shanghai Pharma had the business revenues of RMB 68 billion yuan in 2012. The Company has been listed in SSE 180 Index, CSI 300 Index sampled stocks and listed by H stock in the composite stocks of Hang Seng Index and MSCI China Index. The Company advocates such core value conceptions as “innovation, integrity, cooperation, compatibility and responsibility” and is committed to constantly improve the quality of healthy life for the public, while endeavoring to be arespectable leading branded pharmaceutical producer and health service provider with industry reputation.

太极集团有限公司
Taiji Group Co., Ltd.

太极集团有限公司是中国企业500强之一，中国医药工业10强，资产200亿元，拥有“太极集团”、“西南药业”、“桐君阁”三家上市公司。“太极”（TAIJI）为中国驰名商标，2012年集团销售总额达180亿元，2021年太极集团将跨越千亿大关。

太极集团拥有10000家药房、13000名员工、20多家医药商业公司、13家制药厂及太极医药研究院、重庆中药研究院和太极博士后工作站三大研发机构。太极集团现有中西药品种1500多个、全国独家生产品种50多个、专利产品120个、获得国家中药保护品种50多个、年销售额逾亿元的品种6个。

习近平、张德江、江泽民、李鹏、温家宝、吴邦国、曾庆红、邹家华等党和国家领导人多次亲临太极集团视察，充分肯定太极集团的发展壮大之路，江泽民同志亲笔书写“太极集团”四个金光闪闪的大字予以鼓励。

健康世界，太极无限！

Taiji Group Co., Ltd. is one of the Top 500 Chinese enterprises and Top 10 Chinese pharmaceutical companies, having 20 billion yuan assets, with three listed companies. ——“Taiji Group”, “Southwest Pharmaceutical”, "Tong Junge ". "Tai Ji" (TAIJI) has been a well-known trademark in China. In 2012, the gross sale was 1.8 billion yuan. We plan to reach 10 billion yuan in 2021.

Taiji Group owns 10,000 pharmacies, 13,000 employees, more than 20 commercial pharmaceutical companies, 13 pharmaceutical manufacturing plants. The three R & D institutions ——Taiji Institute of Traditional Chinese Medicine, Chongqing Institute of Chinese Medicine and post-doctoral workstation, provide great support for the company. Taiji Group has more than 1500 varieties of Chinese and Western medicines, 50 exclusive products, 120 patented products, as well as more than 50 protected species, 6 of which Single product sales reach one billion per year.

Xi Jinping, Zhang Dejiang, Jiang Zeming, Wen Jiabao and other state leaders have visited Taiji and all gave affirmation to our company. Moreover, Jiang Zeming sent a inscription with his handwriting “tai ji ji tuan” four glittering characters to encourage Taiji Group.

We will always dedicate to the health of people around the world!


太极工业园区



千亿太极航母

先声药业有限公司
Simcere Pharmaceutical Group

先声药业成立于1995年，当时是仅有几十名员工、注册资金200多万元的小型药品经销公司，至2011年公司，先声药业集团拥有6个生产企业，2个销售企业，一个研究院，员工人数增加到4200人，2011年销售31.8亿元，年利税6.1亿元，净资产37亿元，2011年医药行业排名39位，近三年均被中国医药工业信息中心评为“十大创新力最佳医药工业”，2011年排名第3名。

先声药业17年的创业成长过程，也是不断转型升级的历史。公司根据实际情况，先后作出了放弃普药经销、变更为制药企业、开始首仿药开发、并购创新药、成立研究院自主研发、引进海外人才、与国际巨头联合研发等一系列循序渐进的战略选择，这些探索已初见成效。

2007年4月，公司成功登录纽约证券交易所，募集资金2.62亿美元，成为中国第一家在纽交所上市的化学生物药公司。公司上市以来的5年中，年研发投入占销售收入的占比均在6%～10%,同时公司注重在海外和跨国公司引进研发和管理人才，这2年引进的人才总数超过过去15年的总和。

先声药业于2003年获准设立国家企业博士后工作站，2005年批准为“国家认定企业技术中心”；2008年批准设立“江苏省抗肿瘤分子靶向药物重点实验室”；2009年被认定为“国家高新技术企业”；同时2009年获准设立“江苏省企业院士工作站”。2011年，先声药业累计26000平方米全新的实验室投入使用，成为国内医药企业中设施最先进、功能最齐全的研发基地之一，并承担了多个国家“重大新药创制”项目。

2010年11月，跨国公司百时美施贵宝与先声药业同时宣布开展抗肿瘤药领域的国际合作研发；2011年7月，全球第二大制药公司默克与先声药业在美国新泽西州签署协议，在中国成立二家合资企业，企资公司获得默克糖尿病新药西格列汀（该药品2011年全球销售额40亿美元）专利授权；2011年8月，先声治疗类风湿关节炎一类创新药艾拉莫德在全球第一家获准上市，比日本卫材富山化学在日本获批提早了10个多月。2011年先声的必奇原料和制剂产品通过欧盟GMP认证，标志着先声质量管理水平提升到了一个新的高度。

2010～2012年间，先声药业共有7个一类创新药进入和即将进入临床研究阶段，这是中国4000多家制药公司中第一家取得如此进展的企业；2011年，先声治疗脑卒中的创新药在澳大利亚完成一期临床，这也是第一个来自中国的创新药注射剂在澳大利亚开展临床研究。过去的5年，先声药业研究院共提交了200多项国内和PCT专利申请。先声药业因此被南方医药经济研究所评为2011年中国医药行业最具创新力公司。

先声药业的发展过程，得到了我国各级政府的大力帮助和支持，党和国家领导人胡锦涛、吴邦国、张德江、吴官正、贾庆林、桑国卫、李源潮、周光召、李金华、李智勇、李铁映等先后亲临先声药业视察，对先声药业的发展作出了重要指示。未来，先声药业的企业目标是成为中国创新药物开发的领先者，在重大疾病挑战领域创造革命性药物。先声人信守：也许许多患者的生命仅剩几个月、几天，先声的使命是寻求更有效的药物，为了患者的期待，我们不能懈待！

Founded in 1995, Simcere swiftly evolved from being a pure distributor of pharmaceutical products to become a leading manufacturer and supplier of drugs in China's rapidly growing pharmaceutical market. Simcere currently operates five GMP-certified manufacturing facilities, two nationwide sales and marketing subsidiaries, a research and development center and manages over 4,200 employees. We are the first Chinese chemical and biological drug company to list on the New York Stock Exchange with IPO proceeds reaching US$ 261 million.

Innovation is the key driver of our progress towards excellence. In recent years, we have refined our strategy to focus on the development of first-to-market generic

and innovative pharmaceuticals.

We currently manufacture and sell over 45 principal pharmaceutical products, which treat a range of medical conditions such as tumors and cardiocerebral vascular diseases and infections.

Bicun, an Edaravone Injection providing treatment for strokes, the first synthetic free radical scavenger available on Chinese market.

Endu, our innovative anti-angiogenic drug used in the treatment of Non-Small Cell Lung Cancer was the world's first listed recombinant human endostatin and has acquired patent protection in China and the United States. It is also gold medal winner of the '10th Outstanding Chinese Patent Invention Award' and second prize winner of the '2008 National Tech & Invention Award.'

In recent years,Simcere has brought Anxin, China's first Biapenem Injection used in the treatment of severe infections, to market. We also launched Sinofuan, the world's first anti-cancer sustained-release fluorouracil implant and Jiebaisu, China's first marketable Nedaplatin injection.

In 2009, Simcere's acquisition of 35% equity stake in Shanghai Celgen Bio-Pharmaceutical Co., Ltd. marked our entry in to the field of antibody development. Following the acquisition, Qiangke, a Recombinant Human TNF Receptor-IgG Fusion Protein for Injection and manufactured by Shanghai Celgen, receive new drug registration approval from SFDA and in October 2011 was successfully launched on the Chinese market.

In 2011, we received a new drug approval from SFDA for Iremod, a new drug in the category of Disease Modifying Anti-rheumatic Drugs ("DMARDS"). It was independently developed by Simcere and will be the first Iguratimod drug on the global market.

In July 2011, we reached a framework agreement with Merck to establish a pioneering joint venture, which will focus on serving China's rapidly expanding healthcare needs by providing significantly improved access to quality medicines in major therapeutic areas.

Our brands are widely recognized throughout China and Simcere currently holds four Trademarks in China: Simcere, Zailin, Yingtaiqing and Bicun.

Simcere's branded antidiarrheal drug Biqi smectite powder passed the Eu-GMP inspection and received international GMP-certification from the Finnish Medicines Agency.

To fuel our sustained growth and demonstrate our commitment to research and development, we established the Simcere Pharmaceutical Research Institute. In recent years, Simcere has averaged a 6-8% reinvestment of the company's annual revenue in R&D activities.

We also actively collaborate with domestic and international companies and research institutes to develop new chemical and biological drugs with strong market potential. We have a successful track record of agreements with international partners including OSI, Epitomic and BMS.

Currently, we have over twenty candidate products in various stages of development. In 2010, Simcere submitted applications to the SFDA to conduct clinical trials of five innovative drugs. This is exciting progress and a tremendous step forwards.

Simcere will continue on its path as a leading Chinese pharmaceutical company. Through the development of innovative medicines we will reshape the future of the pharmaceutical industry in China. We are working tirelessly to provide more effective medicines for our patients and to earn the respect from our clients and society.

康恩贝 CONBA

浙江康恩贝制药股份有限公司
ZHEJIANG CONBA PHARMACEUTICAL CO.LTD

浙江康恩贝制药股份有限公司是一家集研发、生产、销售为一体的药业企业，注册资本80960万元，总资产45.39亿元，净资产21.74亿元，员工8000余名。公司于二OO四年四月在上海证券交易所上市，股票代码600572。

公司总部设在浙江省杭州市，在浙江杭州、兰溪、金华、云南、江西、内蒙等地拥有先进规范的药品生产基地，并在兰溪建立起了国内最大的康恩贝植物药产业园基地。旗下拥有浙江金华康恩贝生物制药有限公司、杭州康恩贝制药有限公司、浙江康恩贝药品研究开发有限公司、江西天施康中药股份有限公司、云南希陶绿色药业有限公司、云南康恩贝植物药有限公司、上海康恩贝医药有限公司、内蒙康恩贝制药有限公司等颇具规模和实力的全资及控股子公司。

公司为国家火炬计划重点高新技术企业、国家创新型试点企业、是国家中药五十强企业，建有国家认定企业技术中心、国家博士后科研工作站。公司专注于现代植物药和特色化学药研发，与国内外科研机构、大专院校建立了长期的战略合作关系，已建立新药研发的多个技术平台，在心脑血管系统用药、泌尿系统用药、糖尿病用药、呼吸道系统用药、消化系统用药和抗感染药等药物的研发，以及植物提取分离和结构改造、新型药物释放系统应用等诸多方面，研发具有自主知识产权的新药。

公司重视产品品牌和企业品牌培育和保护，在泌尿系统及心脑血管系统领域树立了强势品牌，已培育出了“前列康”、“天保宁”、“可达灵”、“咳停片”等植物药品牌以及“阿乐欣”、“金奥康”等化学药知名产品品牌，在同类竞争产品中已建立领导地位，“康恩贝”、“前列康”被认定为中国驰名商标。

Zhejiang CONBA Pharmaceutical Co., Ltd. was established in 1969. It is one of the largest listed pharmaceutical companies in China with over 8000 staffs.

The headquarters of CONBA is located in Hangzhou, Zhejiang Province. There are many subsidiaries including R &D, bio-pharma manufacturing, botanical-pharma manufacturing, botanical extracts, health food manufacturing and marketing networks. The state-of-the-art production facilities are based in cities such as Hangzhou, Lanxi and Jinhua, all parts of Zhejiang province. The Lanxi facility is among the largest modernized botanical medicine facilities in China. Zhejiang Jinhua Conba Bio-pharmaceuticals Co., Ltd., one of the subsidiaries of CONBA, has cGMP certificate and recently obtained US FDA certificate for pharmaceutical ingredients.

We specialize in R&D of both modern and traditional botanical medicine along with new drug delivery systems through long-term strategic partnership with institutions and universities such as Ethypharm Company, Zhejiang University, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences (CAS), etc. In addition, we focus on herbal extraction technology, molecular structure transformation, new molecule medicine and pharmaceutical ingredients. Furthermore, we also focus on developing new patent protected medicines for the following areas: neurology, cardiovascular, urinary, anti-diabetic, respiratory, digestive and anti-microbial. CONBA has established an efficient system for R&D and production for both international and domestic markets.

For almost 40 years, CONBA has consistently provided our customers high-quality products with great value. Our very dedicated staff is committed to ensuring the satisfaction of every customer.

神威药业集团有限公司
Shineway Pharmaceutical Group Ltd.

神威药业集团创建于1992年，是以现代中药为主业的大型综合性企业集团，综合竞争力在医药行业居前二十强，在中药行业位列第四，是香港联合交易所市值最大的中药企业，拥有“神威”、“五福”、“神苗”三个中国驰名商标。

神威药业集团产品主要针对中老年用药、儿童用药、抗病毒用药等高速增长的目标市场，形成了现代中药注射液、现代中药软胶囊、现代中药颗粒剂三大特色剂型，拥有多个超亿元现代中药大品种，神威清开灵注射液、神威参麦注射液、神威舒血宁注射液为“全国百姓放心药”，占据了国内同品种70%以上市场份额，神威牌藿香正气软胶囊、清开灵软胶囊等多个品种被列为国家中药保护品种，五福心脑清软胶囊、小儿清肺化痰颗粒等知名产品畅销全国。

Shineway Pharmaceutical Group Ltd., founded since 1992, is a large comprehensive group with modern Chinese medicine as its dominant business. Shineway’s comprehensive competitiveness ranks among top 20 of pharmaceutical industry, taking fourth place in traditional Chinese medicine industry. As the largest traditional Chinese medicine manufacturer by market capitalization in Hong Kong stock exchange, Shineway owns “SHINEWAY” “WUFU” and “SHENMIAO” as three famous trademarks in China.

Targeting on rapidly growing pharmaceutical markets for the middle-aged, elderly, children and anti-virus, Shineway has formed three featured products, including dose forms-modern TCM injection, modern TCM soft capsules, modern TCM granules. Shineway also owns several large categories of modern TCM, with annual sales of more than 100 million RMB. Shineway Qingkailing Injection, Shineway Shenmai Injection and Shineway Shuxuening Injection are awarded “Worth Trusting Medicine of China”, which take over 70% market shares of other similar products. Shineway Huoxiangzhengqi soft capsules, Shineway Qingkailing capsules and other several products are listed as national protected TCM. Famous products including Shineway “Wufu” Xinnaoqing soft capsules and Xiao’er Qingfei Huatan granules are famous products across the country.

浙江医药股份有限公司
Zhejiang Medical Co., Ltd.

浙江医药股份有限公司（以下简称“浙江医药”）是由原浙江新昌制药股份有限公司，浙江仙居药业集团股份有限公司和浙江省医药有限公司等企业以新设合并的方式组建于1997年5月16日的大型股份制制药企业。1999年8月经中国证监会核准，公司向社会公开发行了人民币普通股A股5800万股，同年10月公司股票在上海证券交易所挂牌上市。目前，公司注册资本为45006万元，资产总值25亿元，为浙江省政府重点培育的十八家大型集团（公司）。

浙江医药现拥有新昌制药厂，维生素厂，商业公司，浙江来益生物技术有限公司，上海来益生物药物研究开发中心等多家企业和子公司。公司现有员工4000余人，其中各类专业技术人员1600余人，占40%以上，有中高级职称的300多人，占8%以上。浙江医药倡导“以人为本”的理念，注重科技创新和机制创新，是省区外高新技术企业，2007年公司技术中心晋升国家级

企业技术中心，国家人事部颁发的博士后流动工作站也在此落户。

目前，浙江医药已经形成了脂溶性维生素，类维生素，喹诺酮类抗生素，抗耐药菌抗生素等系列产品的专业化，规模化生产。维生素H产销量全球第一，辅酶Q10、合成维生素E产销量全球第三，已成为一家规模庞大，资金及技术实力雄厚，对全球市场具有影响力的医药制造企业。

公司全部产品通过了国家级GMP认证，商业分公司首批通过了国家级GSP认证。2005年8月公司产品本芴醇通过了澳大利亚TGA认证，2007年9月盐酸万古霉素通过美国FDA的现场审计。同时，公司把节约资源，保护环境，走可持续发展道路作为企业百年大计来抓，大力推行清洁生产，发展循环经济，近几年累计投入环保经费8000多万元，并早在2001年就通过了ISO140001环保国际认证。今后，浙江医药股份有限公司将继续坚持走创新高效、发展循环经济路子，这已经不是局部、单一的工作任务，而是企业生存、发展观、凝聚力和向心力的体现。

浙江医药以“关爱人类健康”为己任，确立了2010年远景目标，即实施“三高两低一结合”的产品竞争策略，“开发具有高技术含量、高市场占有率、高附加值、低污染、低消耗的新产品。制剂产品要创品牌，原料药要上规模”。

浙江医药经过数年的励精图治，已是轻装上阵、厚积薄发，全体员工正奋勇开拓，与时俱进，努力实现公司的再次腾飞。

Combined by former Zhejiang Xinchang Pharmaceutical Co., Ltd., Zhejiang Xianju Pharmaceutical Co., Ltd., and Zhejiang Medical and Pharmaceutical Co., Ltd., Zhejiang Medicine Co., Ltd. was founded on May 16, 1997, approved by China's Securities Supervision Commission. The corporation issued 58 million RMB ordinary shares in August, 1999. In October, the corporation's shares went public in Shanghai Stock Market. As one of the largest 18 key group corporations in Zhejiang Province, Zhejiang Pharmaceutical's registered assets value 450.06 million yuan,and its total value reaches 2 billion yuan in present.

Zhejiang Medicine Co., Ltd. consists of several enterprises and trading companies, such as Xinchang Pharmaceutical Factory, Vitamin Factory, Trading Company, Zhejiang Health Creation Bio-technology Co., Ltd., Shanghai Health Creation Bio-Pharmaceutical R&D Center. The corporation has more than 4000 employees, over 1600 of whom(above 40%)are technicians, and over 300 of whom are experts(above 8%).Zhejiang Medicine takes the "human-centered" principle and strives to make innovations in technology and management. It is a high-tech enterprise authenticated as the provincial technology center. It has a post-doctorate station authorized by Ministry of Human Resources.

By the end of 2003, all of the corporation's products had passed national GMP certification, and its trading company is among the first group of companies passing national GSP authentication. Meanwhile, the corporation attaches a vital importance to resource economy, environmental protection, and sustainable development. Laying stress on clean production and recycling system, it passed ISO140001 Environmental.

Nowadays, Zhejiang Medicine has its professional and large-scale production of various kinds of vitamins and antibiotics, among which its vitamin H and Kitasamycin are the world's best in production and sales, and its coenzyme Q10 and vitamin E are the world's No.3. Zhejiang Medicine is a globally influential enterprise with large scale, solid finance, and advanced technology.

Zhejiang Medicine gives its top priority to "human health", and has set its 2010 goal, viz." three highs, tow lows, one combination" competition strategy. It aims to offer new products with hi-tech proportion, high market shares, high added value, low pollution, and low consumption. It also tries to create excellent brands for preparations and enlarge the scale for raw medicine.

With year's efforts and a solid base, Zhejiang Medicine is striving to achieve the second great development and growth.

浙江海正药业股份有限公司
Zhejiang Hisun Pharmaceuticals Co.,Ltd.

始创于1956年的浙江海正药业股份有限公司（股票代码600267，以下简称“海正药业”）秉承“执著药物创新，成就健康梦想”的使命和“成为广受尊重的全球化制药业企业”的愿景，致力于整合药物研发与生产资源，为全球客户提供更好的产品和服务，通过美国FDA、欧盟EDQM、澳大利亚TGA、韩国KFDA等官方认证的品种达到40多个，销信全球30多个国家的地区。

2009年，公司荣获“全国五一劳动奖状“，海正、HISUN及图形被认定为”中国驰名商标”，入选“中国万种微生物基因组计划”和“国家重大（磅）级药物品种产业化技术创新联盟”。因圆满完成“抗甲流药物中间体生产”的国家任务，受到省政府的通令嘉奖。

Founded in 1956,the mission for Zhejiang HISUN Pharmaceuticals Co.,Ltd. (stock code 600267)hereinafter called ‘HISUN’)is committed to be persistent in pharmaceutical innovation for humans‘well-being’.The company’s vision is to become ‘a widely respected global pharmaceutical provider’.It focuses on the integration of pharmaceutical research and development (R&D)with production resources in order to provide its global customers with outstanding products and services.To date,over 40 of the company’s products have passed certification by the FDA(U.S),EDQM(EU),TGA(Australia),KFDA(Korea),etc.,and are sold to more than 30 countries worldwide.

Over the years.HISUN has received numerous commendations and accolades. For example,in 2009 the company received the “May 1st Labor Award”. The company’s name in Chinese and English(HISUN)and its logo were recognized as” Famous Brands in China”.The company was also selected to participate in “China’s Genome Project for 10,000 Micro-organisms” and “National Technical Innovation Alliance for Commercialization of Major New Drugs”.As a result of its successful completion of the Central Government’s assignment with respect to the production of” anti-H1H1 pharmaceutical intermediate agents”,the company received great compliments by the Zhejiang Provincial Government.

华北制药集团有限责任公司
North China Pharmaceutical Group Corporation

华药集团是目前中国最大的化学制药企业之一，是最大的抗生素和半合抗生产基地。其前身华北制药厂是中国“一五”计划期间重点建设项目，1953年筹建，1958年建成投产，目前拥有四十多家子（分）公司。2009年6月，经省委、省政府批准，冀中能源集团对华药集团实施了重组。截至2012年底，华药集团资产总额150多亿元，职工2万余人。

华药集团先后在国内率先开发成功杆菌肽、春雷霉素、平阳霉素、两性霉素B、林可霉素、克林霉素、克林霉素磷酸酯、去甲基万古霉素、甲钴胺、EPO等十余种产品，并先后获得国家发明奖5项、国家科技进步奖18项。主要产品包括抗生素与半合成抗生素、生物技术药物、生物农兽药、维生素营养保健品、制剂5个系列700多个品种；其中，青霉素、链霉素、阿莫西林、维生素C等产品的产销量居世界前列。总投资20亿元新型头孢项目和总投资40亿元的新制剂项目已竣工投产，使华药集团的转型升级迈出标志性一步。

未来几年，华药集团将秉承“人类健康至上，质量永远第一”的企业宗旨，按照“统筹整合、力主创新、优化升级、做精做强”的发展战略，努力实施“三步走”，实现“一二三”目标，力争通过三至五年的努力，把华药建设成为紧密型、高效能、可持续的国内领先世界一流的现代制药集团。

东北制药集团股份有限公司
Northeast Pharmaceutical Group Co.,Ltd.

东北制药集团股份有限公司（简称“东北制药”），是全国大型综合性制药企业。公司总资产59.98亿元，年销售收入逾百亿。公司始建于1946年，1996年深交所上市，股票代码：000597。

企业主要生产抗生素类、维生素类、心脑血管类、消化系统类、抗病毒类、天然药物类、解热镇痛类、抗艾滋病类、麻醉精神药品类、计划生育药品类、保健品类、化妆品类等12大系列、800多种化学原料药、医药中间体和制剂产品,产品远销100多个国家和地区。

目前，企业拥有制剂产品国家批准文号352个，244个品种进入《国家基本医疗保险、工伤保险和生育保险药品目录》，其中2012年版《国家基本药物目录》中，企业共有81个品种123个品规在目录中。规模化、低成本及市场份额扩张，推动东北制药制剂产业迅速发展。

Northeast Pharmaceutical Group Co., Ltd (NE Pharm) is a national large-scale comprehensive pharmaceutical enterprise. The total asset is RMB 5.998 billion, the annual sales revenue is more then 10 billion. NE Pharm was founded in 1964. In 1996 NE Pharm stock was listed on the Shenzhen Exchange, stock NO.000597.

NE Pharm mainly produces 12 major series of medicines, more than 800 kinds of Active Pharmaceutical Ingredients (API), intermediates and preparation products, including antibiotics, vitamins, cardiovascular and cerebrovascular medicine, digestives drug, anti-virus, natural medicine, antipyretic and analgesic medicine, anti-AIDS, narcotic medicine, categories of family planning drugs, health care products, cosmetics, etc. The products are exported to more than 100 countries and regions.

At present, there are 352 preparation products approved by SFDA, together with 244 drugs included in “National Basic Medical Care Insurance, Work Injury Insurance and Maternity Insurance drug list”, and 81 drugs, 123 strengthens and dose forms included in 2012 "National Essential Drugs List". Large-scale, low-cost and market share expansion will promote the rapid development of NE Pharm preparation industry.

中国医药工业有限公司
China National Pharmaceutical Industry Co.,Ltd.

中国医药工业有限公司是中国医药集团总公司的全资子公司，是集科研、生产、经营、投资为一体的经济实体。

公司的前身中国医药工业公司成立于1964年，是当时国家试办的12个全国性专业公司（托拉斯）之一。1978年国家医药管理局成立后，中国医药工业公司成为分管全国化学医药工业的专业性公司。1986年在国家工商行政管理局登记，转变为企业性公司。2004年9月，经国务院国有资产监督管理委员会批准，中国医药工业公司改制为有限公司。

中国医药工业有限公司注册资本9.56亿元，资产总额31.36亿元，业务涉及医药生产、销售、投资、国际贸易等领域。公司与国际知名医药企业合作建立了西安杨森制药有限公司、中国大冢制药有限公司、华瑞制药有限公司、中美上海施贵宝制药有限公司、苏州胶囊有限公司等十几家中外合资企业。公司还发起成立了中国化学制药工业协会、中国医药科研开发促进会、全国麻醉药品联合体（中国麻醉药品协会前身）等三家社团组织。现有国药集团威奇达药业有限公司、国药集团工业有限公司、国药集团新疆制药有限公司等20多家控股、参股医药生产企业。

中国医药工业有限公司在“十一五”期间成功实现了以商业与投资为核心向以工业为核心的产业结构调整，完成了工业转型的跨越式发展，2010年公司自主工业产品销售收入13.23亿元。“十二五”期间，公司将建成进入全国前三的抗感染药物产业基地和麻醉药品产业基地，销售总额超过90亿元，成为有规模、有专业、有特色、具备核心竞争力的国药集团医药工业产业平台，提高公司在化学制药领域的影响力。

四川科伦药业股份有限公司
Sichuan Kelun Pharmaceutical Co., Ltd.

科伦药业创立于1996年，17年产业疾行，现已成为拥有省内外32家子(分)公司的现代化药业集团。由于输液行业物流的特殊性，科伦药业的生产基地分布于四川、湖南、黑龙江和云南等14个省区，总计为上万名员工提供了就业岗位。2012年科伦药业营业收入超过58亿元、利税超过19亿元人民币。2010年6月3日，科伦药业在深圳证券交易所成功上市。

科伦药业生产和销售包括输液、粉针、冻干粉针、小水针、片剂、胶囊剂、颗粒剂、口服液、透析液，以及原料药、医药包材、医疗器械等产品。其中，拥有109个品种共256种规格的大容量注射剂产品，是中国输液行业中品种最为齐全和包装形式最为完备的医药制造企业之一。以具体产品计，公司有119个品种纳入《国家基本药物目录》，是目前国内产业链最为完善的大型医药集团。

2009年，科学技术部批准公司组建“国家大容量注射剂工程技术研究中心”，并被列入2009年国家工程技术研究中心首批组建项目计划；同年，公司经国家发展与改革委员会、科学技术部、财政部、海关总署、国家税务总局联合审定为“国家认定企业技术中心”；2011年4月，被国家科技部、国务院国资委、中华全国总工会联合审定为“国家第三批创新型企业”； 6月，被工业和信息化部、财政部联合认定为首批“国家技术创新示范企业”； 11月，被国家发改委认定为“国家地方联合工程实验室”，同年还组建了企业院士工作站。

科伦药业与资本市场深度融合以后，必将创造更加波澜壮阔的后续业绩，力争成为中国医药行业规模最大、品规最全、竞争力最强的医药制造商之一。

Founded in 1996, Kelun Pharmaceutical has grown into a modern pharmaceutical group, owning 32 subsidiaries (branches) within and outside Sichuan Province after a rapid development for 17 years. Due to the special features of logistics of IV solution industry, the production bases of Kelun Pharmaceutical are located in 14 provinces and regions of China, such as Sichuan, Hunan, Heilongjiang and Yunnan, totally offering employment opportunities to more than 10 thousand employees. The sales revenue of Kelun Pharmaceutical in 2012 exceeded RMB 5.8 billion Yuan, with profits tax exceeded RMB 1.9 billion Yuan. On June 3, 2010, the bell at Shenzhen Stock Exchange rang to declare the listing of Kelun Pharmaceutical.

Kelun Pharmaceutical manufactures and sells medical products, including IV solutions, sterile powder for injection, lyophilized powder for injection, small volume injection, tablets, capsules, granules, oral solutions, APIs, pharmaceutical packaging

materials, and medical devices, among which 256 products in 109 varieties belongs to IV solutions. It has the largest number of product varieties as well as packaging forms in the IV solution industry of China. Calculated on the specific products, there are totally 119 products brought into National Essential Drugs List, being large pharmaceutical group with the most complete industrial chain in China.

In 2009, Ministry of Science and Technology approved Kelun Pharmaceutical to set up the 'National Large Volume Injection Engineering Technology Research Center' and listed the project into the first batch programs of National Engineering Technology Research Center in the same year. Also in 2009, Kelun Pharmaceutical was recognized to be the 'State Recognized Enterprise Technology Center' by National Development and Reform Commission (NDRC), Ministry of Science and Technology (MOST), Ministry of Finance, National General Customs Administration and State Administration of Taxation jointly. In April 2011, Kelun Pharmaceutical was recognized to be 'The Third Batch of State Innovative Enterprises' by Ministry of Science and Technology, State-Owned Assets Supervision and Administration Commission of the State Council and All China Federation of Trade Unions jointly. In June 2011, Kelun Pharmaceutical was identified as the first batch of 'State Innovation Demonstration Enterprise' by Ministry of Industry and Information Technology, Ministry of Finance jointly. In November 2011, it was identified as 'National Local United Engineering Laboratory' by the National Development and Reform Commission. An enterprise academician workstation was established in 2011.

Through the deep and sufficient integration with the capital market, Kelun Pharmaceutical will definitely create more wealth and make more significant achievements in the future; and strive to be one of the biggest pharmaceutical manufacturers in China, featuring widest range of products as well as the strongest competitiveness.

通化东宝药业股份有限公司
Tonghua Dongbao Pharmaceutical Co., Ltd.

通化东宝药业股份有限公司是一家以生产中、西成药和生物药品的大型制药企业，始建于1985年12月1日，1992年11月改制为股份有限公司，1994年在上海证券交易所挂牌上市。注册资本3.24亿元，现有资产总额18.06亿元。

公司现有60余种产品，其中："基因重组人胰岛素原料药"、"基因重组人胰岛素注射液"（甘舒霖R、甘舒霖N、甘舒霖30R等）、"东宝笔"、"东宝针"、"镇脑宁胶囊"、"东宝甘泰"（复方蛋氨酸胆碱片）、"复方苦参肠炎康片"、"多层共挤膜软袋输液"为公司目前主导产品。"重组人胰岛素注射液"、"粉针剂"、"冻干粉针剂"、"片剂"、"硬胶囊剂"、"大容量注射剂"和"小容量注射剂"、"原料药（重组人胰岛素）"已获国家GMP认定证书。

"基因重组人胰岛素"研发项目是国家"九五"重点科技攻关项目和"国家863火炬计划"项目，该项目于1998年在通化东宝研发成功。同年，该成果被587名两院院士评选为"中国十大科技进展新闻"之一，并荣获2002年度"国家科学技术进步二等奖"；东宝人胰岛素科研成果，拥有我国自主知识产权，并申报了国际专利（专利号为ZL988139413）。

2002年，"东宝"牌商标被国家工商总局认定为"中国驰名商标"，同年，公司一次性通过ISO14001环境管理体系国际国内的双认证，2004年，被科学技术部火炬高技术产业开发中心认定为"国家火炬计划重点高新技术企业"。

Tonghua Dongbao Pharmaceutical Co., Ltd. is a large pharmaceutical company, which mainly produces Chinese traditional medicine, western medicine and biologic medicine, and was set up on December 1, 1985. The company changed its system to stock company in November, 1992, and came into market in the stock exchange of Shanghai in 1994. The registered capital is 324 million Yuan, and the existing property total amount is 1.806 billion Yuan.

The company now has more than 60 kinds of products. Among them, "The raw material of Gene Recombination Human Insulin", "Gene Recombination Human Insulin Injection" series product (Gansulin R, Gansulin N, Gansulin 30Retc.), "Dongbao pen", "Dongbao pinhead series products", "Zhen Nao Ning Capsule", "Dongbao Gan Tai "(Compound methionine-choline Tablet). "Compound Kushen Changyan Kang Tablet and Co-extrusion Film Flexible Bags Transfusion are currently the leading

products of the company. The product lines of 6 kinds of dosage forms such as tablets, capsules, big volume injections, small volume injections, powder injections, and freeze-dried powder injections…etc. have already got the national GMP affirming certificates.

The research and development of "Gene Recombination Human Insulin" project is one of the projects in national 9th "Five-year-plan" important science and technology programs and "National 863 Torch Plans", which was excogitated successfully in Tonghua Dongbao in 1998. In the same year, the project was chosen for one of "the Ten Greatest Science and Technology Evolving News in China" by 587 academicians, and won the second prize of "the National Science and Technology Progress Prizes" of 2002. Dongbao Human Insulin has the independent property right of our country, and has declared the international patent (The patent number is ZL988139413.

In 2002, "Dongbao" brand trademark was affirmed for "Chinese famous trademark" by the trademark office of State Administration for Industry & Commerce. In the same year, they passed an attestation of the ISO14001 environment management system both domestic and international. In 2004, Dongbao was affirmed for "the Important High-Tech Corporation of the National Torch Plans."

LUYE PHARMA 绿叶制药

绿叶制药集团有限公司
Luye Pharma Group Ltd.

绿叶制药集团是一家以研发为基础的专业制药企业，专注于天然药物、新型制剂和生物技术产品的研发、生产和销售。公司成立于1994年，在烟台、南京、北京、泸州、芜湖等地设有生产和研发基地，现有员工近4000人，其中专业研发人员300余人。绿叶致力于为客户提供高品质的医药产品和专业化的服务，目前集团有50多个上市产品，覆盖抗肿瘤、心血管、内分泌、骨科、消化和中枢神经系统等领域，其中具有自主知识产权的创新药物以及新制剂的销售占90%以上，公司业务遍及国内30个省市区，产品进入4000多家医院，并出口多个国家和地区。目前，绿叶制药已成为中国健康领域的知名企业，进入中国制药工业50强。集团将以自主创新为己任，力争2020年成为世界100强的国际性专业制药企业。

Luye Pharma Group is a leading R&D based pharmaceutical company. With "Professional technology serves human health" as the mission and "customer-oriented, efficiency, and employee achievement" as the corporate philosophy, it focuses on research and development, production and sales of natural drugs, new formulations and biotechnology products. Founded in 1994, the company has established its production and R&D center based in Yantai, Nanjing, Beijing, Luzhou and Wuhu with 4,000 employees, with over 300 R&D specialists. We're committed to provide high quality medical products and professional services for customers and patients. We have launched more than 50 products in oncology, cardiovascular, orthopedics, gastroenterology and central nervous system areas with independent intellectual property. These products marketed in more than 30 domestic provinces and cities, and have encompassed over 4,000 hospitals and exported to a number of foreign countries and regions.

振东制药 ZHENDONG PHARMACEUTICAL

振东制药股份有限公司
Zhendong Pharmaceutical Co., Ltd.

振东制药股份有限公司是山西省首家登陆创业板的上市企业，为高新技术企业，下辖中药材开发公司、北京药物研究院、振东制药、泰盛制药、安特制药、开元制药、家庭护理用品、医药物流等9个子公司。主要生产抗肿瘤、心脑血管、抗感染、消化系统、呼吸系统、维生素营养、解热镇痛、补益中成药等八大用药系列，中西药品、保健食品和家庭护理三大健康系列548个品规。现已形成种植、研发、生产、销售为一体的健康产业链。

振东制药长期与中国医学科学院、中国军事医学科学院、中国中医科学院、中国药科大学等多家科研院所合作，进行新产品的研制开发，并承担了国家重大专项科技项目。

振东制药营销网络覆盖全国400余个城市，与全国数千家医疗单位建立了业务关系，形成了“多渠道，多模式”的销售体系，有完善的学术支持、售后服务与信息反馈渠道。

面向未来，振东制药将以“百年企业，百亿振东”为目标，以“好人好药，好药好人”为理念，全力打造“振东制药”全国知名品牌，为人类的健康事业贡献力量。

The Zhendong Pharmaceutical Co., Ltd., being the first listed high-tech company on the Growth Enterprise Market of Shanxi Province, has 9 subsidiaries like the Chinese herbal medicine development Company, the Beijing Pharmaceutical Research Institute, the Zhendong Pharmaceutical, the Taisheng Pharmaceutical, the Ante Pharmaceutical, the Kaiyuan Pharmaceutical, the Family Care Products Co. and the Pharmaceutical Logistics enterprise. It has 548 kinds of product in eight medicine series—products for antitumor, cardiovascular and cerebrovascular, anti-infection, digestive system, respiratory system, nutrition of vitamin, antipyretic and analgesic and tonic Chinese patent medicine, and three health care series—the eastern and western medicine, health care food and family care products. A health industrial chain with the integration of medicine planting, researching, manufacturing and marketing, has been formed already.

The Zhendong Pharmaceutical Co., Ltd, by seeking long-term cooperation with research institutions like the CAMS (Chinese Academy of Medical Sciences), the Chinese Military Medical Science Academy in the PRC, the CACMS (China Academy of Chinese Medical Sciences) and the CPU (China Pharmaceutical University), is dedicated to the research and development of new medical products, and some of the national key Science and Technology Special Projects.

Zhendong Pharmaceutical Co., Ltd, whose marketing network has covered more than 400 Chinese cities, has established business relations with thousands of medical institutions nationwide, and formed a marketing system of “multiple channels, and multiple modes” with its well-developed academic.mechanism, after-sale service and information feedback channels.

Looking into the future, Zhendong Pharmaceutical will make great efforts to create the national well-known brand “Zhendong Pharmaceutical” and contribute to human’s health industry, by taking the establishment of “century-old enterprise and ten-million invested Zhendong” as the goal, and the idea of “selling proper quality medicine to the right persons” as the philosophy.

美罗药业股份有限公司
Merro Pharmaceutical Co., Ltd.

美罗是以药品研发、制造和销售为核心业务的专业化上市公司，注册资本3.5亿元，占地面积23万平方米，建筑面积10万平方米。“美罗”品牌被认定为中国驰名商标，是国家级高新技术企业。

美罗一直致力于化学药制剂、生物医药、中药、植物药的研究、生产和销售，在行业内具有突出地位。美罗产品的三个方向是：国家基本药物、国际仿制药和生物医药的研发、制造，并在现有300多个产品的基础上重点发展缓控释制剂和生物制剂。美罗积极与国际制药公司合作，不断研发、引进新品种，全力推进国际医药市场产品、技术的广泛合作，不断提升公司创新能力，向专业化、规范化、国际化迈进，把美罗建设成为一个运用科技、服务卓越、精于变化的国际制药公司。

Merro Pharmaceutical Co., Ltd. is a public listed pharmaceutical company specializing in R&D, manufacturing and marketing of pharmaceutical products, with registered capital of 350 million yuan, which covers a land of 230,000 square meters with build-up area of 100,000 square meters. “Merro” is rated as the famous trademark of China and it is a national high-tech enterprise.

Merro has been devoted to the development, manufacture and sales of chemical medicine, biological medicine, Chinese traditional medicine and herbal medicine. Merro is a leading company in the pharmaceutical field. Merro’s core strategies are: developing and manufacturing of National Essential Drugs, Generic drugs and Biomedicines; focusing on ER preparation and biologicals; collaborating widely with international pharmaceutical markets; improving the company’s innovation capability and becoming an international pharmaceutical company with high technology, superior service and adaptability to changes.

国药集团一致药业股份有限公司
China National Accord Medicines Co., Ltd.

国药集团一致药业股份有限公司（简称国药一致）是集医药研发、制药工业、药品分销、医药物流为一体的综合性医药上市公司（A股000028，B股200028），承担着国家、省、市政府药品特储任务，属下企业32家，销售规模超200亿元，分布于广东、广西、江苏等区域。

国药一致工业下属企业三家（致君制药、国药致君（苏州）、深圳中药），产品覆盖抗感染、呼吸系统、消化系统、心脑血管以及抗肿瘤等领域，其中致君制药是国内首家自主产品注册通过欧盟GMP认证的头孢粉针制剂生产厂商，位列中国制药工业50强。

国药一致分销业务涵盖医院纯销、商业调拨、第三方物流、终端配送及疫苗/器械新业务等，拥有完善的全国商业网络和深度渗透的南区终端市场网络，也是华南地区首家获批第三方医药物流资质的企业，名列中国医药商业20强。

未来，国药一致将坚持科工贸协同发展，成为具有国际竞争力的医药健康产品和服务提供商。

China National Accord Medicines Co., Ltd (short as Sinopharm Accord) is a complex of pharmaceutical research and development, industry, distribution and logistics, who is responsible for the special drug storage tasks of national, provincial and municipal governments. A group of 32 affiliated enterprises led by Sinopharm Accord locate in Guangdong, Guangxi and Jiangsu provinces ect, the total sales volume exceeding 20 billion RMB.

Sinopharm Accord industrial division has 3 affiliated companies: Shenzhen Zhijun Pharmaceutical Co., Ltd, Sinopharm Zhijun (Suzhou) Pharmaceutical Co., Ltd.and Shenzhen Traditional Chinese Medicine Co., Ltd. Products of the above three companies cover anti-infective, respiratory system, digestive system, cardiovascular, anti-tumor and other fields. Among them, Shenzhen Zhijun Pharmaceutical Co., Ltd, top 50 of Chinese pharmaceutical industry, is the first EU GMP approved manufacturer of cephalosporin powder for injection in China.

Sinopharm Accord distribution division ranks top 20 for pharmaceutical business all round China. The distribution businesses include hospital sales, commercial allocation, third party logistics, terminal distribution and some new business such as vaccines / medical device ect. With a perfect national commercial network and deeply penetrated terminal market network of the Southern District, Sinopharm Accord is also the first to get the qualification of third-party pharmaceutical logistics in southern China.

In the future, Sinopharm Accord will insist on the simultaneous development of science, industry and trade, aiming at becoming an internationally competitive provider of health products and service.

信 SINE 誼 ®

上海信谊药厂有限公司

Shanghai Sine Pharmaceutical Laboratories Co., Ltd.

上海信谊药厂有限公司是上海医药直属企业。信谊品牌始创于1916，是近代中国最早的民族化学制药企业之一。历经百年传承，不断发展壮大，成为集制造、销售、研发为一体的大型民族制药企业。旗下拥有九大工业生产基地，四大商业公司、一家市级研发中心。信谊具有强大的渠道和终端覆盖能力，营销网络辐射全国30多个省、市、自治区，覆盖了全国近10000 家医院终端、800余家主要经销商、150多个地级市，拥有一支1200多人的高素质、专业化的终端销售队伍。

信谊是中国化学制药企业产品最多、剂型最全的产业实体之一，拥有产品批文1114个，涉及14个治疗领域，覆盖16种剂型，有3个国家一类新药品种，其中“培菲康”是国家一类生物制品，已获得中国、美国、英国、加拿大、澳大利亚等多国专利。2012 年，“培菲康”被选为益生菌制剂“国家标准菌种”，目前正作为自主知识产权产品在申报美国FDA注册。公司在保持处方药领先的基础上，以“培菲康”为主要产品进入OTC业态，将通过未来几年的不懈努力，使之成为中国制药行业最具规模的企业之一，并始终成为引领微生态领域发展的先行者。

信谊品牌已获得“中国驰名商标”、“中国最具历史文化价值品牌”、“上海市著名商标”等多项殊荣，作为上海医药产业的重要组成部分，信谊人将秉承 “以信治厂，以谊为人”的经营理念，立足于品类发展、产业整合、品质提升、职能管控四大创新，提高企业的核心竞争力。

华润双鹤药业股份有限公司
China Resources Double-Crane Pharmaceutical Co., Ltd.

华润双鹤药业股份有限公司拥有70余年制药历史，1997年挂牌上市【股票代码600062】，2010年进入位列世界500强企业的华润（集团）有限公司旗下，成为其医药板块化学药平台的支柱企业。目前拥有17家子公司，万余名员工，年销售收入69亿元，净利润6.1亿元，是“中国驰名商标”企业和“国家高新技术企业”。经济实力、竞争活力和可持续发展能力位居国内制药公司前列。

公司主要产品聚焦大输液、心脑血管、内分泌和儿科等领域；拥有盈源、一君、0号、冠爽、糖适平、儿泻康、珂立苏等多个知名产品；销售网络深入医院、社区医疗卫生服务站、地县卫生院及药店等终端。

公司坚守“关心大众，健康民生”的企业宗旨，秉承华润集团“诚实守信、业绩导向、客户至上、感恩回报”的价值观，正向着“百亿工业”的“十二五”发展战略目标稳步迈进。

China Resources Double-Crane Pharmaceutical Co., Ltd. has over 70 years of history in pharmaceutical industry. The company was listed in 1997 (Share Code: 60006), acquired by China Resources (Holding) Co., Ltd. (Global 500) in 2010 and becoming one of its pillar enterprises in Chemical Pharmaceuticals. Currently, the company has 17 subsidiaries, over 10 thousand employees, with annual revenue of 6.9 billion RMB, and net profit of 610 million RMB. The company is recognized as “China Top Brand” and “National High-tech Enterprise” and its economic strength, competition vitality, and development sustainability are ranked among the highest in the nation.

The company’s main product focuses on four therapeutic areas: IV solution, cardiovascular and cerebrovascular diseases, endocrine diseases, and pediatric pharmaceuticals. The company has developed a wide range of well-known products including Yingyuan, Hypertensive No.0, GuanShuang, Tangshiping, Erxiekang, and Kelisu. Sales network covers hospitals, community health service stations, county hospitals, and pharmacies.

China Resources Double-Crane Pharmaceutical Co., Ltd. has been advocating tenet of the company: “Care for People and Promote Health” and adhering to the enterprise value of China Resources: “Integrity, Pursuing Excellence, Customer Come First, and Return to society.” China Resources Double-Crane Pharmaceutical Co., Ltd. has been moving forward steadily to achieve 10 billion-enterprise and twelfth five-year plan strategic objective.

丽珠医药集团股份有限公司
Livzon Pharmaceutical Group Inc.

丽珠医药正在向国际化迈进

丽珠医药集团股份有限公司是集医药研发、生产、销售为一体的综合性企业集团，创建于1985年。集团所属GMP生产工厂9个，GAP中药生产基地3个，共有员工5000人。

集团拥有完备的现代化产业链和产品群，主要生产原料药、化学药品、中成药、诊断试剂等400多个品种，涉及消化、心脑血管、抗感染、抗肿瘤、生殖内分泌、中药等领域。同时拥有国内规模及技术领先的原料药及中药注射剂生产基地，进行发酵类抗生素、头孢类无菌原料药、他汀类调血脂药及癌症辅助治疗的中药注射剂生产。

集团产品完成多项DMF备案及EDMF评审，部分已获COS/KOSHER证书，或通过FDA现场考察。高标准的质量体系推动了原料药在日本、加拿大、西欧、东南亚、中东、南非等国家和地区的销售。制剂产品也实现了在东南亚、中亚、香港、尼日利亚、巴基斯坦等国家和地区的注册和销售。

近年来，公司实施研发转型战略，研发重点转向抗体药物和疫苗领域，设立抗体药物和疫

苗开发实验室，同时调整化学药研发方向，进行化学药研发转型升级。丽珠以自身科研队伍为核心，聚集500多名高素质研发人才，形成了以国家工程技术中心和国家中药现代化研究中心为骨干的、完整的科研体系，并且与30多家海内外大专院校及科研院所开展长期合作。

生产战略转型——新建国内领先、国际一流的现代化医药生产基地

丽珠工业园位于广东省珠海市金湾区生物医药产业园，占地面积超过42万平方米，总投资为20亿元人民币。2008年7月开始奠基动工，2010年12月一期工程正式投产，2015年三期工程全部完成。一个装备精良、工艺先进、管理规范、环境友好、规模宏大、国际一流的现代化医药药城将矗立在南海之滨！投产后的丽珠工业园将在产能产量、质量、工艺技术、生产装备、节能降耗和环境保护方面达到国内一流、国际领先的水平。

研发战略转型——进军单抗疫苗生物药领域

丽珠集团将研发重点转向抗体药物和疫苗等生物制药领域，2010年引进国际一流人才成立了珠海市丽珠单抗生物技术有限公司、丽珠集团疫苗工程股份有限公司。在丽珠工业园建立了大规模生物反应器疫苗产品生产线、单克隆抗体生物药物生产线、全自动立体仓库、QC实验室、动物房、研发中心等。

Livzon Striding Forward to Internationalization

Livzon Pharmaceutical Group Inc., founded in 1985, is a comprehensive pharmaceutical enterprise integrating development & research, production and sales. Livzon has 9 GMP production plants located in Guangdong, Shanghai, Sichuan, Fujian, 3 GAP planting bases for TCM production located in Shanxi, Gansu, Yunan of China, with total 5,000 employees.

Livzon has modern industrial chain and product group, operates to manufacture APIs, finished dosage forms, diagnostic agents and TCM, with more than 400 products which therapeutically grouped as gastrointestinal, cardiovascular, anti-infective, anti-cancer, reproductive etc. Meanwhile, Livzon possesses production bases as leading manufacturer of TCM injection, and specialist APIs such as fermented antibiotics, sterile cephalosporins, and hypolipidemic “statins”.

All production lines are in compliance with WHO GMP requirements, including some DMFs and EDMFs documentation, as well as USA FDA inspection, COS and KOSHER approvals. Benefited from the regulatory compliance, an extensive overseas market is under robust development, including Japan, Canada, West Europe, South East Asia, Middle East, South Africa for APIs, and South East Asia, Middle Asia, Hong Kong, Pakistan and Nigeria for finished formulations.

In recent years, Livzon implement the strategic transformation of R&D, focusing to antibody medicines and vaccines, and it has already established laboratories of antibody medicines and vaccine development. At the meanwhile, Livzon adjusts R&D direction of chemical pharmaceutical for carrying out transformation and upgrade. Livzon forms a complete research system with the backbone of National Engineer Technical Center and National Research Center on Modernization of Traditional Chinese Medicine (TCM). In addition, Livzon has established long-term cooperative relationship with more than 30 domestic and overseas scientific research institutes.

Transition in Production Strategy——A Newly Established Leading Pharmaceutical Production Base at Home and Abroad

Livzon Industrial Zone, located in Biomedical Industrial Zone,Jinwan, Zhuhai, Guangdong, covering an area of more than 420000 square meters with a total investment of about 2 billion RMB, began to construction at July 2008, whose Phase I Project went into operation formally in Dec 2010 and Phase III Project will be completed in 2015. Along the coast of the South China Sea at that time will stands a modern large-scale international pharmaceutical city with advanced equipments, sophisticated technology, normative management and friendly environment. Livzon Industrial Zone put into production will be in a leading position at home and reach the international standard in technology, equipments, energy saving, environmental protection and capacity, quantity and quality of production.

Transition in R&D Strategy——Enter into the Field of Biomedicine in Monoclonal Antibody and Vaccine

Livzon Group has transferred its R&D focusing on biomedicine like monoclonal antibody and vaccine. In 2010 a team of preeminent talents from all over the world were introduced to found Livzon Monoclonal Antibody Biological Technology Co,. Ltd. and Livzon Vaccine Engineering Co,. There are large-scale bioreactors, vaccine production line, monoclonal antibody bio-medicine production line, full-automatic warehouses, QC laboratory, animal houses, R&D center and so on.

杭州民生药业有限公司
Hangzhou Minsheng Pharmaceutical Co., Ltd.

杭州民生药业有限公司（杭州民生药厂）创建于1926年，是中国最早的四大西药厂之一。80余年来，民生药业一直专注于西药制药产业，见证了中国整个西药制药的历史。2006年被商务部评为第一批“中华老字号”企业。经过多年的积累和发展，民生药业成为了一家专业化、负责任的现代化制药公司。公司在2002年至2006年间成功实施了跳跃式发展战略，从2007年开始全面实施的国际化发展战略将引领企业走向新的辉煌。

民生药业的第一只处方药已于2011年通过美国FDA的认证，产品在美国成功销售，标志着药业制剂产品已取得出口美国的通行证，迈进了制剂产品国际化的门槛，这具有里程碑式的意义。2010年民生药业与法国拉曼公司合作，微生态制剂“普瑞宝”保健产品上市，将打造成为民生继21金维他以后第二个大品牌产品。公司在抗肿瘤及大输液等领域均享有较高的市场声誉。民生药业以传播科学健康观为己任，不断追求卓越，致力于打造充满活力的百年企业。

Hangzhou Minsheng Pharmaceutical Co., Ltd. was established in 1926. It is one of the earliest four chemical pharmaceutical factories in China.and was appraised one of the first approved "China's Time-honored Brand Enterprises" in 2006. The company has been specializing in the pharmaceutical industry for over eighty years, witnessed the entire history of western medicine in China. After years of development, the company has grown as an extremely professional and responsible modernized pharmaceutical company. From 2002 to 2006, the company had implemented the leap-forward development strategy successfully. From 2007, the company has put the international development strategy in practice. Since then, Minsheng has entered a new period of development.

Minsheng has got the first generic drug approval from FDA in 2011, and the product has been sold in USA, which means Minsheng have obtained permits to enter the international market. And it is a milestone during the development of Minsheng. In 2010, Minsheng launched a new product -" Probio'stick ", cooperated with Lallemand. This micro-ecological product will be created as another star brand besides 21 Super-Vita.

In addition, the company has high prestige in anti-oncology drugs and large volume parenterals. The vision of Minsheng is to build an unfailing, dynamic company.

广西梧州中恒集团股份有限公司
Guangxi Wuzhou Zhongheng Group Co., Ltd.

广西梧州中恒集团股份有限公司是一家拥有制药、房地产、保健食品等多产业、现代化的民营控股上市公司，属国家级高新技术企业，广西百强企业，地方龙头企业、第一纳税大户。近几年，中恒集团建成了总占地面积1500亩、亚洲最大的中药现代科技工业基地，2007年到2010年，连续四年保持产值、利润和税收平均增幅超过100%。同时为社会公益事业捐赠价值超过4亿元。从而为社会经济发展及和谐社会建设作出了重要贡献。中恒集团也先后获得了全国五一劳动奖状、全国守合同重信用企业、全国诚信经营企业、中华慈善突出贡献（企业）奖等荣誉称号。在未来发展上，中恒集团将牢抓西部大开发以及广西北部湾经济开发区建设和东盟自由贸易区正式开放带来的历史性机遇，不断做强做大做优。

Guangxi Wuzhou Zhongheng Group Co.,Ltd. holded by the private capital, is a multi-industry and modern company who possesses industries of pharmaceutical, real estate and supplement food. Zhongheng Group became the State-level high-tech enterprise, Fortune 100 of Guangxi, one of the leading companies and the largest tax payer of Wuzhou.

During recent years, Zhongheng Group has built up the Asian’s largest industrial base of Chinese Traditional Medicine with a area of more than 1 million square meters. For the straight four years from 2007 to 2010, the output capacity, profit

and tax payment of the Group have raised at an average rate of more than 100%. Meanwhile, Zhongheng Group has donated over ￥ 400 million to social charity, which makes a great contribution for the economic development and harmonious society. Zhongheng has been awarded the National Labor Model, National Contract Orientational Enterprise, National Honest Enterprise and Prize of Outstanding Contribution to China’s Charity (for Company).

In the future, Zhongheng Group will seize the historical opportunity brought by Western Development of china, construction of the Pan-Beibu Gulf Economic Zone and open of the China-ASEAN Free Trade Area to be bigger and stronger.

浙江佐力药业股份有限公司
Zhejiang Jolly Pharmaceutical Co., Ltd.

浙江佐力药业股份有限公司是一家集科研、生产、销售于一体的国家高新技术企业。2011年2月22日,公司在深圳证券交易所创业板成功上市，成为湖州市第一家创业板上市企业。公司位于德清县莫干山经济开发区，坐落于风景秀丽的避暑胜地莫干山脚下，拥有现代化的原料药、片剂、胶囊剂、颗粒剂和冻干粉针等生产流水线；公司研发中心是省级高新技术研究开发中心、浙江省企业技术中心。

公司坚持以关心、关爱人类健康为己任，努力实践“辅佐人类身体健康，致力祖国医药发展”的宗旨，立足于药用真菌生物发酵技术生产中药产品。通过多年的研发、改进，实现了珍稀中药材——乌灵参的产业化生产，实现了传统中药材和现代生物技术的结合。

乌灵参是生长在地下深处废弃白蚁巢内的一种药用真菌，具有很高的滋补功能和药用价值，极为珍稀。由于生长环境特殊，采获十分困难，且不易人工栽培。

公司利用从天然乌灵参中分离获得的菌种，运用现代生物发酵技术，实现了乌灵参发酵菌粉（乌灵菌粉）的工厂化、规模化生产。

1998年，公司获得了乌灵菌粉和乌灵胶囊两个国家中药一类新药；1999年，“真菌中药乌灵参”通过“浙江省高新科技成果”认定，其研制水平在同行业属国内领先水平；2001年，“一类新药乌灵胶囊的研制”被评为“九五”国家重点科技攻关计划优秀科技成果；2004年，乌灵胶囊进入国家医保目录；2006 年，乌灵胶囊取得《中药保护品种证书》；2010 年，“珍稀药用真菌乌灵参的工业化生产关键技术及其临床应用”被定为“国家秘密技术”。

公司以市场为导向，不断加强对乌灵菌粉的深度研究，围绕乌灵菌粉开发系列产品。目前，公司独家生产且有自主知识产权的乌灵系列产品有：补肾健脑，养心安神，从根本入手调理睡眠的乌灵胶囊；治疗更年期综合症的灵莲花颗粒；治疗前列腺增生的灵泽片。

公司坚持产品创新、市场创新和管理创新，在企业经营取得快速发展的同时，先后荣获“国家级火炬高新技术企业”，“国家高新技术企业”，“全国模范劳动关系和谐企业”，“全国五一劳动奖章”，“浙江省绿色企业”，“浙江省文明单位”，“浙江省创新型试点企业”，“浙江省优秀民营企业”，“中国驰名商标”，“浙江省著名商标”，“浙江省知名商号”，“浙江名牌产品”，“浙江省企业文化优秀单位”、“浙江首届助残爱心企业”等诸多荣誉，树立了良好的口碑。

公司将以乌灵系列产品为起点，以药用真菌药的产业化为己任，打造国内药用真菌制药领域的专业化制药企业。

康弘药业 KANGHONG PHARMACEUTICAL

成都康弘药业集团股份有限公司
Kanghong Pharmaceutical Group Co.,Ltd

成都康弘药业集团股份有限公司是一家致力于中成药、化学药及生物制品的研发、生产、销售及售后服务的专业创新型医药企业集团，自成立以来，始终坚持走专业与创新相结合的发展道路，不断传播专业创新的医药产品和知识，销售网络遍布全国各省、市、自治区。

康弘药业始终坚持创新，研发投入占营业收入中的比例远高于行业平均水平，研发投入力度正向国际水平迅速靠拢。康弘药业坚持以临床需求为导向，在中枢神经系统、消化系统、眼科等重点临床领域建立起独具特色的系列专利产品布局。康弘药业目前申请和授权的专利共计160余项（包括国外专利40余项）。创新成果中，有11个已上市；10余项在研品种中，有5个国家I类“生物药”正处于研发的不同阶段。目前由康弘药业自主研发的国家I类新药康柏西普（Conbercept）已经在2013年11月获得国家食品药品监督管理总局的生产批文，康柏西普眼用注射液（Conbercept，WHO授权的国际非专有名称），是一种VEGF受体与人免疫球蛋白Fc段基因重组的融合蛋白，用于治疗年龄相关性黄斑变性（AMD），目前已经拥有20多项国内外发明专利，是中国第一例被世界卫生组织批准的、拥有自主知识产权国际非专有名称的生物制品。

为实现创新成果的产业化，康弘药业现有4个GMP生产基地与2个GSP医药贸易公司，正在新建1个GAP基地与多个GMP生产基地，现有生产基地将在2014年底前全部通过新版GMP认证，为已上市产品的市场发展提供良好的质量保障。

康弘药业的专业创新发展，在为地方经济发展做出了贡献的同时，也积极参与社会公益事业，获得了政府与社会的认同。康弘药业曾先后获得省市/区/县各级政府重点优势企业、突出贡献企业、纳税大户等荣誉称号；2008年，在全国行业协会组织的首批全国制药企业信用评价中，获得全国仅有的七家“AAA级企业信用等级”的制药企业之一；2009年康弘药业荣获中国医药30年风云会改革开放三十年“创新奖”，商标为“中国驰名商标”；2010年，被列为“全国企事业知识产权试点单位”；2011年，被评为“中国化学制药行业创新型企业品牌十强”；2012年，被国家科技部、国资委和中华总工会联合认定为 “国家创新型企业”，是一二年四川省唯一入选的药企。

南京圣和药业有限公司
Nanjing Sanhome Pharmaceutical Co., Ltd.

蓬勃发展的圣和药业

南京圣和药业有限公司创立于1996年，是集医药研究、药品生产和市场营销为一体的现代化的“高新技术企业”。公司是最早通过国家GMP论证的企业之一，生产基地坐落在南京经济技术开发区，拥有具有国内先进水平的生产和质量检测设备，以及科学严密的生产和质量管理控制体系。公司迄今已获新药证书百余本，拥有国家发明专利和国际发明专利数十项，中西药品种中有国家一类新药，有国家重点新产品，有国家中药保护品种，有全国独家产品。公司还承担了包括国家863计划、重大新药创制专项、国家创新基金、国家火炬计划在内的国家和省级重点科研项目20余项。2008年，国家人力资源和社会保障部批准在公司设立“国家博士后科研工作站”

通过遍布全国的专业化自有销售队伍，圣和以其高质量的产品和一流的服务赢得了客户和患者的信任和赞誉。圣和将继续坚持“高科技、高速度、高效益”的发展战略，为人类的健康事业谱写新的篇章。

Growing Sanhome

Nanjing Sanhome Pharmaceutical Co., Ltd., which was founded in 1996, is an integration of medical research, production and marketing as a modern "high-tech enterprise." Our company is among the enterprises which pass the national GMP certification. Production base is located in Nanjing Economic and Technological Development Zone, with a domestic advanced level of production and quality testing equipment, as well as scientific and strict management of production and quality control system. To date, our company had gained more than a hundred new drug certificates, dozens of national invention patents and international invention patents. Among all varieties of the products, many of which are national newly-invented first-class medicine, national key new product, national protected traditional medicine and national exclusive product. The company has also undertaken more than 20 national and provincial key scientific research projects, including the State 863 Plan, Special Project for New Drugs, the National Innovation Fund and the National Torch Program. In 2008, Ministry of Human Resources and Social Security approved the company to establish "national postdoctoral research station".

Owing to our specialized sales force throughout the country, Sanhome, with its high-quality products and first-class service, has won the trust and praise of clients and patients. We will continue to adhere to the development strategy of "high-tech, high-speed, high-efficiency" and make a new chapter for the health of mankind.

沈阳三生制药有限责任公司
Shenyang Sunshine Pharmaceutical Co., Ltd.

沈阳三生制药有限责任公司成立于1993年，是集研发、生产和销售为一体的生物制药企业。公司被国家科委认定为重点高新技术企业，并被科技部认定为“国家高技术研究发展（863）计划成果产业化基地”。近几年，生物制药更以其先进性和环保优势与新能源等一起成为国家十二五计划最重要的战略性新兴产业。

三生公司是以科技创新为长期目标的中国生物科技公司，目前公司拥有8项国家发明专利授权，10项独家专营权，15个在研产品和6个上市产品。

公司在国内拥有三个生产基地，为了满足日益增长的国内外需求，公司于2010年按照欧盟标准设计和建造了新的生产车间，生产设备全部采用性能优良的国际公认顶级设备。新车间建成后，成为国内最大的EPO生产基地，并于2013年成为首批通过国家新版GMP认证的企业之一。

公司国内市场营销团队由400多名拥有超过十年的蛋白类药物市场推广经验的专业人员组成，遍及国内31个省和主要城市。

在国际营销方面，公司产品已经远销20多个国家，并且已经在智利，马来西亚，摩洛哥，俄罗斯，韩国，委内瑞拉，以及台湾地区提出注

册申请。

2007年2月，三生公司作为中国生物制药的领军企业在纳斯达克成功上市。

公司多次从美国、加拿大、日本等知名生物制药企业收购创新产品和技术，以弥补国内尚未满足的医疗需求。

Shenyang Sunshine Pharmaceutical Co., Ltd., founded in 1993, is an integrated national high-tech company engaged in research, development, manufacture and marketing of biopharmaceutical products in China. It is a industrialization base of National High-Tech Research and Development Program. Recently with its advanced advantage of environmental protection bio pharmaceutical and new energy industry have become the most important stategic emerging industry in national twelfth-five year plan.

3SBio, biotechnology company aims at technology and innovation and has 8 national patients, 10 exclusive franchise, 15 research products, 6 products listed.

3SBio has three production bases. In order to meet the increasing demand home and abroad in 2010, according to EU GMP standard, 3SBio built the new production workshop where all the equipments with excellent performances are the international top. It is the largest domestic production base of EPO. In 2013, it has been approved the first batch company of new version certificate of GMP.

Our sales force in China benefits from over ten years of experience in marketing protein-based therapeutics. We maintain a sales and marketing force in 31 provinces in China.

In international marketing, our products have been exported to over 20 countries, and has applications in progress in Chile, Malaysia, Morocco, Russia, South Korea, Venezuela, and Taiwan.

In February 2007, 3SBio was listed in the NASDAQ.

3SBio purchases drug innovation and technology from USA Canada,Japan and other well-known pharmaceutical enterprises to meet for demand for the domestic medical markets.



贵州信邦制药股份有限公司
Guizhou Xinbang Pharmaceutical Co., Ltd.

贵州信邦制药股份有限公司创建于1995年元月，管理总部设在贵阳市，现有员工1300余名，总资产超过十亿元人民币。

公司以生产中成药为主，下属贵州信邦远东药业有限公司、贵州信邦药业有限公司、贵州信邦药物研究开发有限公司、贵州信邦保健品有限公司、江苏信邦制药有限公司、贵州信邦中药材发展有限公司等六家子公司。公司建成了以罗甸为中心的固体制剂生产基地和以贵阳为中心的注射制剂生产基地，形成了集新药研发、中药材种植、药品生产、市场营销为一体的产业链。

公司现拥有国药准字号品种71个，其中优质优价品种4个，国家中药保护品种3个，独家品种7个，《国家基本药物目录》（2012 年版）品种18个。

2010年4月16日，公司股票在深圳证券交易所成功挂牌上市，股票代码：002390。

十多年来，公司秉承“精诚至信，众志兴邦；健康民众，发展民生”的企业理念，坚持科学发展观，致力于实现中药的现代化和国际化，为人类的健康而努力。

Guizhou Xinbang Pharmaceutical Co., Ltd. was established in January, 1995. The administrative headquarter of it is located in Guiyang City, with 1300 staffs and total assets over 1 billion RMB.

The company mainly produces traditional Chinese medicine and has six subordinate share holding enterprises, including Guizhou Xinbang Yuandong Pharmaceutical Co., Ltd., Guizhou Xinbang Pharmaceutical Industry Co., Ltd., Guizhou Xinbang Medicine Research and Development Co., Ltd., Guizhou Xinbang health care products Co., Ltd., Jiangsu Pharmaceutical Co., Ltd. and Guizhou Xinbang traditional Chinese medicine development Co., Ltd .,where forms a solid preparation production base at Luodian county and an injection preparation production base at Guiyang city. Our

company has formed a relatively complete industrial chain from herbal medicine planting ,research and development of new medicine, drug manufacture to marketing.

The company has 71 products of medicines covering “cardio-cerebral vascular type,” “digestive system type,” which there are 4 high quality and favorable price products, 3 products are listed as national protected species in traditional Chinese medicine, 7 exclusive products of domestic, 18 products have been listed as the country’s basic medical insurance, industrial injury insurance and maternity insurance medicine.

April 16, 2010, the stock of Guizhou Xinbang pharmaceutical company was successfully listed on the Shenzhen Stock Exchange, the code is 002390.

For the last 10 years, with the inheritance of our enterprise idea "absolute sincerity, prospering the motherland with unity, contributing to people's health and developing people's livelihood ", and adhering to the scientific development view, we are devoting ourselves to the realization of modernization and internationalization of traditional Chinese medicine and working diligently for the health of the mankind.

山东步长制药股份有限公司
Shandong Buchang Pharmaceutical Co.,Ltd.

步长公司成立于1993年，是一家集医药研究、生产、销售和诊疗服务、教育为一体的国内知名高科技健康产业公司。

2002年，公司被国家税务总局、全国工商联评定为全国“诚信纳税企业”。2007年，公司获评“百姓放心药企业”。08年，公司董事长赵步长教授、制药总裁赵超两人同时当选第十一届全国人大代表。公司09年位居“中国制药工业百强”第九位。2010年纳税9.6亿元，累计为国家纳税近40亿元。企业为社会公益事业捐款超过3亿元，“2010中国慈善排行榜”评选中位列“十大慈善企业”第二；“2010胡润慈善榜”评选，赵步长和赵涛父子荣列“中国特色慈善家”。

步长致力于“中药现代化、市场国际化”，打造中国中药第一品牌。

Buchang Group, established in 1993, is a modernized and high-tech enterprise focusing on researching, producing and distributing medicines for health care and education in China.

In 2002, Buchang Group was awarded the “sincerity taxpayer enterprise” by National Industry & Commerce Federal Commission and the State General Tax Bureau. In 2007, Buchang Group was awarded the honorable title of "Trusting Pharmaceutical Enterprise for People". In 2008, the Professor Zhao Buchang,Chairman of Buchang Group and ZhaoChao,President of Buchang Pharmacy were elected the representatives of the 11th National People's Congress .In 2009, Buchang Group was ranked 9th of top 100 Pharmaceutical Enterprises in China. In 2010, Buchang Group paid 960 million RMB tax to the country, adding up nearly 4 billion RMB tax in total.

Buchang Group had donated more than 300 million yuan, which was the second from the 2010 China Charity Rank Selection. Professor Zhao Buchang and his son Mr.Zhao Tao,the President of Buchang Group, were rated Chinese characteristic philanthropist in 2010 Charity Chart of Hurun. Buchang Group is dedicated to "the modernization of traditional Chinese medicine and market internationalization",and creates the No.1 brand of Chinese medicine in China.

悦康药业
YUEKANGYAOYE

悦康药业集团有限公司
Youcare Pharmaceutical Group Co.,Ltd.

悦康药业集团有限公司总部位于北京亦庄，是一家集新药研发、制药、流通贸易于一体的医药企业集团。集团相继入选中国制药工业百强企业，研发十强企业，中国制剂国际化先导企业，美国《福布斯》杂志“中国潜力企业”等。2010年入选首批中关村“十百千工程”百亿元重点培育企业和北京生的医药产业跨越发展工程G20规模企业。开发区纳税50强和纳税增长50强企业。

悦康秉持“做老百姓用得起的好药”的经营理念，坚持“药品质量只有一百分，九十九分等于零”的质量原则，关爱病患健康，为患者提供优质、安全检查的药品。公司在奠定头孢类和消化类药品市场领先地位的基础上，着力构建完善的医药产业链，加大药物创新和国际市场开拓力度。现已形成以安徽原料药基地为基础，以北京集团总部管理和创新为驱动，以北京、上海、广州、重庆四大品牌制剂生产基地为依托的全产业发展格局。

目前公司有70多个品规的药品在俄罗斯、巴基斯坦、东南亚、中东、美、非洲等40多个国家进行出口注册并开展出口业务，药品出口金额逐年翻番增长。2011年公司片剂、胶囊剂生产线通过欧盟cGMP认证，打开了悦康药品进入欧美市场的大门。

放眼未来，悦康将继续发扬“合和”文化和“诚信、勤奋”的企业精神，与各界朋友广泛合作，为建设一个创新、国际化的悦康，实现人类共同的健康理想而不懈努力。

Youcare Pharmaceutical Group headquarter locates at BDA,Beijing,China. It’s a diversified pharmaceutical Group integrated with R&D, manufacturing, logistics, sales and trade. We have won the prestigious “Top 100 Leader in Technology of China’s Manufactures”, “Top 10 R&D enterprise ”, “China chemical drug International leading enterprises”,"Forbes China Best Enterprises” awards.

In April,2010,Youcare was nominated as one of the main supported ten-billion-class enterprises(Billion level Enterprise), which was a project by National Demonstration Zone of Zhongguancun Innovation and was selected as "Across Beijing biomedical industry development project” (G20 project) enterprise.

Working in the philosophy of "offering high quality drug with affordable price for people",Youcare insists on "100% Quality,99% equals zero" principle.

The company occupy the market leading position of the cephalosporins and digestive drug, meanwhile, we strive to establish and improve the pharmaceutical industry chains to develop drug innovation and intermational market development. At present, Youcare forms a whole pattern of industrial development base, which is integrated by pharmaceutical API base in Anhui, management and innovation in Beijing headquarter, and four brand drug production faclilities in Beijing-Shanghai-Guangzhou-Chongqing.

With the outstanding quality and reasonable price,there are more than 70 Youcare produchs exporting to Russia,Pakistan,Mali,Peru,Kazakhstan,Venezuela,Vietnam,Thailand,Nigeria,etc.Meanwhile,the export registration work of more products is proceeding smoothly in other countries.In Nov.2011,the solid workshop for tablet and capsule dosage was qualified by the cGMP certificate of European Union,which enables Youcare products to enter EU market soon.

Having global perspective,Youcare will continue to carry forward the enterprise culture of "cooperation and harmony” and enterprise spirit of “integrity,diligence”. Youcare will continuously improve the brand’s popularity,and expand cooperation to construction of an innovative,international Youcare.We are committed to create a great future with all of you who are committed to promote the health and well-being of the entire humanity!

江苏奥赛康药业股份有限公司
Jiangsu Aosaikang Pharmaceutical Co., Ltd.

江苏奥赛康药业股份有限公司（奥赛康药业）是集医药、研发、生产、市场推广和销售为一体的国家级高新技术企业。2011年7月，公司成功实施企业股份制改造，正式更名为：江苏奥赛康药业股份有限公司。

奥赛康药业的主导产品集中于新型质子泵抑制剂药物和抗肿瘤药物。公司目前是全国最大的质子泵抑制剂注射剂生产企业之一、全国拥有质子泵抑制剂品种最多的企业之一和全国抗肿瘤药品种最多的公司之一，同时也是全国冻干粉针剂品种最多的特色企业。

公司已获得“中国医药工业百强企业”、“国家火炬计划重点高新技术企业”、“国内最佳研发产品线十佳”等荣誉；“奥赛康”名称及图标也已被国家工商总局认证为“中国驰名商标”。

Jiangsu Aosaikang Medicinal Group is a high-tech modern pharmaceutical company integrating research, development, manufacture, market promotion and sales of medicine, fine chemicals and health care products. In July 2011, We made a shareholding reform successfully, and changed the name to be “Jiangsu Aosaikang Pharmaceutical Co., Ltd.”.

The leading products of the company are Proton pump inhibitor drugs and antineoplastic drugs. Our company is one of the largest enterprises which produce Proton pump inhibitor drugs, own the most variety of Proton pump inhibitor drugs and antineoplastic drugs. Meanwhile, it is also one of the largest manufacturers for proton pump inhibitors and injections.

The company became the top 100 in industrial enterprises, won “key Hi-Tech enterprises of the National Torch Program” “Best industrial enterprise of China medicine R&D Line”. Our company’s name “Aosaikang” was selected as “China Famous Brand” by the State Administration for Industry & Commerce of P.R .China.

重庆植恩药业有限公司
ZHIEN pharmaceutical Co., Ltd.

植恩药业创办于2001年，是立足于重庆的一家集研发、生产、销售、市场一体化的新兴医药企业。目前已经形成一个以重庆植恩药业有限公司为核心，包含植恩医院管理有限公司、重庆两江药物研发中心有限公司、重庆植恩医药销售有限公司、重庆江岸大药房连锁有限公司等一系列医药医疗健康服务平台的产业集群。

植恩药业每年在新药研发及技术改进方面投入占销售收入的5%以上，目前已经获得新药证书33项、临床批件32项、生产批件51项；申请国家发明专利数十项，其中已获国外专利授权2件，国内专利授权11件。公司目前主打产品有盐酸托烷司琼、奥利司他、盐酸多奈哌齐、盐酸罗匹尼罗、甲磺司特、西洛他唑等。

植恩药业具有强大的一级市场到达终端市场的分销商网络，拥有零售终端及医院终端销售人员500余人。产品覆盖30个城市 2000 多家医院，40000家药店。自有连锁药店600家，并有《药品互联网信息服务资格证》和《药品互联网交易服务资格证》，积极开展药品电子商务业务。外贸方面，原料药出口到全球20多个国家。

木直因心，植药为仁，此即植恩。

木直参天，可庇佑世人，良药施人，可健民强国。

植恩之心，在良药济世，在产业报国；植恩之志，在引领创新，在追求卓越。

植恩药业以“创建中国医药与健康服务的领先企业”为发展目标。在强大的医药研发团队、高效的医学注册能力、广泛坚固的医药渠道网络、专业化的市场销售能力、权威的政府事务及专业机构合作能力支持下，将公司打造成行业内知名的高新技术医药企业。

Founded in 2001, Zein Pharma is a pharmaceutical enterprise in Chongqing, which focused on research, production, sales and market. As a core company, Zein Pharma has formed a series of medical health industries platform including Zein Hospital Management Co., Ltd., Chongqing Liangjiang Medicine Center Co., Ltd., Chongqing Zein Sales Co., Ltd. and Chongqing Riverbank Pharmacy Chain Co., Ltd.

Every year, Zein Pharma invests more than 5% income in drug research and development and has obtained 33 new drug certificates, 32 clinical approvals and 51 production licenses. Zein has already applied dozens of National Invention Patents, in which two foreign patents and 11 domestic patents have been authorized. Now the main products include tropisetron hydrochloride, orlistat, donepezil hydrochloride, ropinirole hydrochloride, suplatast tosilate and cilostazol etc.

Zein Pharma owns a strong distributor network from primary market to terminal one. There are more than 5000 salesman distributed from the retail terminal to the hospital terminal. Zein’s products cover 30 cities, including 2000 hospitals and 40,000 drugstores. It also owns 600 chain pharmacies and has obtained “Drug Internet Information Service Qualification Certificate” and “Internet Drug Transaction Services Certificate”. Zein is developing the e-commerce business. Zein’s APIs are exported to more than 20 countries worldwide. Zein Pharma develops medicines with a beneficent heart and aims to develop

a new image for the Chinese pharmaceutical companies in the contemporary era. Zein Pharma helps our people live longer and healthier by providing them with good medicines. Zein Pharma pursues innovation and strives for excellence. Zein has set up a number of subsidiary companies to develop and manufacture a variety of pharmaceutical products.

Zein Pharma sets goal to be one of the leading company in Chinese medicine and health service. With the supporting of strong pharmaceutical research and development team, efficient medical registration ability, wide selling network, professional market-selling ability, and cooperation with government and professional institutes, Zein Pharma is growing to be a well-known and high-tech pharmaceutical enterprise.

正大青春宝药业有限公司
Chiatai Qingchunbao Pharmaceutical Co.,Ltd.

正大青春宝药业有限公司位于杭州西湖风景区桃源岭下，其前身杭州第二中药厂原来是百年老店胡庆余堂的制胶车间，1972年独立建厂，经过长期的艰苦奋斗和改革创新，逐步发展成为我国中药行业规模最大、经济效益最好的现代化企业之一，现为上海医药集团股份有限公司之核心企业。

公司拥有完善的科研、信息系统、技术中心、产品检测中心和完善的全国销售网络。能生产注射剂、片剂、颗粒剂、胶囊剂等8个剂型近百种产品，参麦注射液、丹参注射液、青春宝抗衰老片等主要产品生产规模大、工艺先进、技术含量高。公司“中药质量计算分析技术及其在参麦注射液工业生产中的应用”项目获国家科技进步二等奖。

Chiatai Qingchunbao Pharmaceutical Co.,Ltd. Is located in Taoyuan Ling of Hangzhou West Lake Scenic Area.

Its predecessor,Hangzhou Second Traditional Pharmaceutical Factory was established in 1972,which came from a former workshop of Hu Qing Yu Tang-"King of Chinese Medicine in the South of Yangtze River".Through long-term hard work and innovation,it has become one of the largest scale and the most profitable TCM pharmaceutical ebterprise in China. Today,the company is a key enterprise member of Shanghai Pharmaceutical Group Co.,Ltd.

It has comprehensive R&D and information systems,technology and inspection center,with sales network throughout the country.The company can produce about 100 kinds of products in 8 docage forms,including injections,tablets,granules,capsules and so on.Among them,Shenma injection,Danshen injection,Qingchunbao Anti-aging tablets are the major products witth large output,high quality level and advanced techonlogy,The research project "Technology of TCA quality evaluation aided by computation,and its application in the manufacture of Shenmai injection" has won the National Science and Technology Progress Award(second prize).

贝达药业股份有限公司
Betta Pharmaceuticals Co.,Ltd.

贝达药业股份有限公司成立于2003 年1月，是一家由海归团队创办的以创新药物研究和开发为核心，集研发、生产、营销于一体的国家级高新制药企业。公司总部设立于杭州，在北京拥有自己的研发中心。公司成立10年来已启动新药项目20多项，成功研发我国第一个小分子靶向抗癌新药盐酸埃克替尼（凯美纳）。2011年7月，盐酸埃克替尼（凯美纳）获批上市，目前已有近2万名晚期肺癌病人服用凯美纳，实现累计销售约6亿元，其中2012年全年销售约3.6亿，堪称中国新药史上的一个奇迹。

公司现有人员500多位，包括6位留学归国博士，他们有深厚的专业造诣和国际化的新药开发理念，其五位博士已成为国家"千人计划"专家。

贝达药业将继续秉承创新、开拓为发展理念，在保持研发优势的同时，力求建立一支国际化的市场、营销队伍，将创新的成果、福音带给所有有需要的病人，真正造福国人。

BettaPharmaceuticals Co.,Ltd. is a leading innovative pharmaceutical company in China with fully integrated capabilities that include R&D, GMP manufacture, sales and marketing. It was founded in January 2003 by a group of returnees and is headquartered in Hang-Zhou with R&D operation in Beijing. Over the last 10 years, we have established a robust R&D portfolio with more than 20 innovative R&D programs. In July 2011, we successfully launched Icotinib (ConmanaTM), the 1st small molecule targeted anti-cancer drug with independent intellectual property developed by a Chinese company. Nearly 20,000 Chinese patients have taken Icotinib so far that resulted into more than 600 million RMB in total accumulated sales. In the year of 2012 alone, the sales of Icotinib has reached 360 million RMB ,a grownd-breaking event in the history of Chinese pharmaceutical industry.

Currently, we have more than 500 colleagues with 6 doctors trained and returned from USA who have world class expertise on pharmaceutical R&D. Among the 6 doctors, 5 of them have already been selected to join the prestigious China Global Expert Recruitment program, the so called "Thousand Talents Program".

Going forward, we will continue to focus on pharmaceutical innovation through maintaining and enhancing our core competence on R&D. We will also strive to establish a world-class marketing and sales team following global standard so that we can bring hope and achievements from our innovation to every single patient in need, and to truly benefit the people in China.

深圳奥萨制药有限公司
Shenzhen AUSA Pharmaceuticals Ltd.

深圳奥萨制药有限公司是一家面向国内外市场，产学研一体化的，从事创新药物以及生物标记物的科研、开发和商业化的企业。公司的研发策略是主要针对严重影响健康的慢性复杂性疾病，以药物基因组学研究为先导，对疾病发生、发展和治疗的分子生物学机理进行深入研究，设计并开发出更为安全有效的治疗方案和相关的诊断产品，以获得更大市场潜力和社会效益。

公司位于广东省深圳市南山区科技园国家高新技术产业带，拥有固体制剂、体外诊断试剂、医疗器械等符合国家GMP规范的生产车间。并承担国家发改委“深圳国家生物产业基地复方创新药物实验中心”，现已经建成设备齐全、功能完善的药理研究中心、药学研究中心、分子生物学实验室。

公司目前已经上市I类新药一个，医疗器械（含体外诊断试剂）产品3个，在研创新产品20余项。其中I类新药“依叶”是我国过去6年来批准上市的心血管系统唯一的国家I类（化学）新药；“依叶”的研发成果分别在2008年和2010年被欧洲和美国脑卒中防治指南列入为重要证据；2009年进入国家医保目录（乙类）；2010年被列入国家重大专项重大战略新品种（全国一共5项，广东省唯一的一项）。“依叶”还与我公司自主开发的MTHFR基因诊断试剂盒组成了世界上首个应用于常见心脑血管疾病的个体化诊疗产品对，能更有效,更经济地预防脑卒中。

Shenzhen AUSA PharmaceuticalsLtd.. is a research-based pharmaceutical company and committed to improve quality of health care for patients with cardiovascular diseases and diabetes through the research, development and commercialization of genomic-based diagnositic tools, clinical laboratory services and innovated new drugs. To that end, the company conducts sophisticated genomic research to develop clinicallyvalidated molecular diagnostics which provide individualized information on response to certain types of therapy, as well as the likelihood of disease occurrence. These diagnostic technologies generate information that healthcare providers and patients can use in making treatment decisions. AUSA R&D has two distinct research departments. The PharmaTherapeutics Group focuses on discovery of new drugs and related modalities; and The Diagnostics Group focuses on development of genomic-based diagnosis tool and service. AUSA´s management team has extensive experience in a variety of cutting-edge technical fields including molecular diagnostics, information technology, biotechnology, pharmaceutical and genomic research and industries. Team members have demonstrated continued success in starting businesses, researching and developing novel drugs, launching products, building successful organizations and delivering value to patients.

百济神州（北京）生物科技有限公司
BeiGene (Beijing) Co., Ltd.

百济神州是一家总部设在中关村生命科学园内的中国生命科学生物科技公司，致力于探索和开发对中国和亚太地区常见癌症有效的新型抗肿瘤药物。我们的研发策略将包括开发我们自己在中国实验室发现的新药和从合作伙伴引进的对中国和亚太地区常见癌症有潜在疗效的新药。为完善我们的研发能力，百济神州正在中国创造一个从实验室到临床试验的强大整合研发平台，包括生物标志物和生物信息平台，用于识别癌症患者中最有可能受益于相关药物或治疗方法的病人亚群。

BeiGene is a Chinese life sciences biotechnology company based in the Zhongguancun Life Science Park in Beijing that is focused on discovering and developing innovative oncology drugs that encompass novel small molecules and biologics. BeiGene is pursuing this through its own internal discovery laboratories in China and by in-licensing from pharmaceutical partners investigational therapeutics that address unmet medical needs for Chinese and Asian patients with cancer. BeiGene is also creating a robust biomarkers and bioinformatics platform to enable the identification of specific subsets of patient populations who will most likely benefit from the use of specific drugs or treatments.

广州市香雪制药股份有限公司
Xiangxue Pharmaceutical Co.,Ltd.

广州市香雪制药股份有限公司总部位于广州经济技术开发区科学城，是一家专注于现代中药生产和研发，集生物医学工程与健康饮料于一体的现代化高新技术医药企业。

公司秉承“厚生，臻善，维新”的企业理念，坚持“崇尚品质关爱健康”的质量方针，坚持自主创新、自主品牌，在品质、技术、研发、品牌和规模等多方面成长为行业领先者，得到消费者、行业和社会各界的高度评价和广泛认可，其中“香雪”商标获评“中国驰名商标”，“香雪抗病毒口服液”获评广东省名牌和广州市名牌产品。香雪制药获评“《福布斯》中国成长企业潜力榜100强”前五位，香雪制药获评“广东省医药产业50强企业”和“广州2010年亚运会药品供应商”。

公司首创抗病毒口服液指纹图谱，在抗病毒口服液用于红眼病、手足口病等新适用症方面的研究工作已经取得了重大的突破。公司是2010版国家药典中抗病毒口服液的标准制定者与参与者。公司在质控、给药技术、先进制造技术、提取分离技术等方面充分发挥了集成创新的优势。

公司正赶上中药发展的黄金时期，现代中药制剂技术改造项目、中药提取生产线建设技术改造项目、区域营销中心建设技术改造项目、中药饮片标准化技术改造项目、工程技术研发中心技术改造项目和抗病毒口服液循证医学、药物经济学评价技术改造项目等6个项目的实施将使公司在扩大产能的基础上完善中成药制造的产业链，进一步增强公司在所属行业的竞争优势，优化公司产品结构，提高公司的核心竞争力。

亚宝药业集团股份有限公司
YaoBao Pharmaceutical Group Co., Ltd.

亚宝集团集药品研发、生产、物流于一体，主要研发、生产、经营中西药制剂、原料药、化妆品、保健品、药用包装材料，兼营中药材种植加工和房地产开发业务。

集团下设5个分公司、12个子公司，有员工5000余人，是山西省医药行业首家股票上市公司，“亚宝”商标为“中国驰名商标”。

集团公司以现代中药和化学新型给药系统为主要发展方向，已在心脑血管病用药、儿童用药、妇科用药方面形成强势，努力打造全国心脑用药第一品牌。

目前，集团公司正按照欧美标准建设生产线，引进国际先进管理系统，不断做精产品、做优服务、做大品牌、做强企业，打造“世界亚宝、百年亚宝”。

With a whole network of R&D, manufacture and logistics, Yabao Pharmaceutical Group Co., Ltd mainly focus on the R&D, manufacture and operation of Chinese and western medicines, APIs, cosmetics, health care products, packing materials for medicine, and also engages in the planting and processing of medicinal materials and real estate development.

Consisting of 5 branch companies and 11 subsidiaries, with more than 5000 staffs, Yabao is the first listed company of pharmaceuticals in Shanxi Province (stock code: 600351). The brand Yabao has been rated as the Chinese Famous Brand.

The group company has been mainly developing modern Chinese medicine and new chemical drug delivery system, having a dominant position in drugs for CCVD (Cardiac Cerebral Vascular Disease), children and women, striving to be the top brand of CCD (Cardiac Cerebral Disease) drugs of the nation.

The Group Company is now constructing production lines according to the standards of USA and EU, importing internationally advanced management system to produce better products, provide better service, enlarge our brand and strengthen our company, making Yabao an international and centenary company

河南太龙药业股份有限公司
HeNan Taloph Pharmaceutical Stock Co.,Ltd.

企业简介

河南太龙药业股份有限公司位于郑州高新技术产业开发区，是集生产、经营、科研于一体，以中西药产品为主，生产口服液、片剂、胶囊、输液、原料药等多种剂型共100多种产品的现代化制药企业。公司注册资本4.12亿元，现有职工1200多人，年销售收入10亿元人民币，主要经济指标在河南省医药行业中名列前茅。

企业荣誉

公司是河南省高新技术企业，2001年经国家科学技术部认证，公司被认定为国家火炬计划重点高新技术企业。近年来，公司多次被郑州市国家税务局评为"国税免检企业"，2003年获"郑州市优秀企业称号"，被国家发改委评为"国家高技术产业化示范工程"；2006年被国家人事部批准为博士后工作站分站；2009年获得郑州市"2009年度药品规范化管理先进集体"称号；2010年，公司获得河南省"实施以品种为单元GMP管理工作先进企业"和郑州市"A级纳税信用单位"光荣称号；公司注册商标也被认定为"中国驰名商标"、"河南省著名商标"。2011年，公司荣获 “食品药品规范化管理工作”先进集体称号。

发展历程

1992年底，公司前身——众生制药厂在郑州高新技术产业开发区奠基；1998年10月，公司进行股份制改造，设立河南竹林众生制药股份有限公司；1999年8月，公司股票在上海证券交易所发行上市（股票代码：600222），成为河南省医药行业首家上市公司；2006年3月，公司更名为河南太龙药业股份有限公司；2007年，太龙药业在巩义市生态经济园区投资建立大容量注射剂生产基地，一期投资1.6亿元；2009年，太龙药业大容量注射剂项目高速玻璃瓶生产线一次通过国家GMP认证，顺利投产；2011年，公司新的LOGO启用。

常州方圆制药有限公司
Changzhou Fangyuan Pharmaceutical Co., Ltd.

常州方圆制药有限公司其前身是江阴方圆制药有限公司，始创建于 1994年4月，仅为研发代号“8907”（后定名硫酸依替米星）的科技型孵化企业。为形成产业化生产，江阴方圆制药有限公司于2000年4月迁址常州国家高新技术产业开发区“三药”科技产业基地，更名常州方圆制药有限公司。目前，常州方圆制药有限公司已成为常州市生物医药行业骨干企业,国家重点高新技术企业，江苏省高新技术企业。企业注册资本5233万元，资产总额4.2亿元。2008年以来，公司年销售收入、上交国家税收和实现利润，均以30%以上的比例递增。

常州方圆制药有限公司主导产品是商标名为“创成”的硫酸依替米星。该产品是我国唯一拥有自主知识产权的抗生素类一类新药，为半合成抗生素领域的新一代半合成氨基糖苷类抗生素，具有高效、低毒、抗耐药菌等优点。该产品同时获得中国、英国、美国、俄罗斯、哈萨克斯坦、日本等国家专利， 2002年分别被评为国家科技进步二等奖，江苏省科技进步一等奖。目前，硫酸依替米星产品已拓展到包括原料药、小容量注射剂、冻干粉针剂等，且均被列为国家重点新产品、江苏省高新技术产品、江苏省名牌产品和江苏省优秀新产品。由于产品学术水平和生产工艺达到国际先进水平，2011年入选“国家十二五重大专项（大品种改造）”。公司已有覆盖全国的医药营销网络。

常州方圆制药有限公司坚持“以人为本”理念， 制定政策，鼓励、选拔和引进各类人才；建立“我以服务方圆为责任，我以方圆发展为荣誉” 的企业文化，以创新为核心驱动力，通过技术创新、产品创新、商业模式创新和管理创新，融和全体员工，努力将公司发展成为生物医药行业的新锐企业。

Changzhou Fangyuan Pharmaceutical Co., Ltd whose predecessor is Jiangyin Fangyuan Pharmaceutical Co., Ltd was established in April 1994. It was a technical incubate enterprise with its research code “8907” (late named after the Etimicin Sulfate). For industrialization product, Jiangyin Fangyuan Pharmaceutical Co., Ltd moved to Changzhou National Hi-tech Technology Industrial Develop Distinct — “Pesticide, Veterinary medicine and Drug” Technology Industrial base, and changed its name into Changzhou Fangyuan Pharmaceutical Co., Ltd. Now Changzhou Fangyuan Pharmaceutical Co., Ltd is a professional pharmaceutical enterprise in Changzhou, and it’s also the National key high-tech enterprise and Jiangsu Province Hi-tech enterprise. The company’s registered capital is 52.33 million RMB and the total assets is 420 million RMB. Since 2008, our annual sales income, national tax revenue and profits are all increased as 30% proportion.

Changzhou Fangyuan Pharmaceutical Co., Ltd’s leading product— “ChuangCheng” Etimicin Sulfate is the only National-level Class I New Drug of antibiotic with independent intellectual property rights, which is the latest generation of Semi-synthetic aminoglycoside antibiotics. It owns advantages such as high efficiency, low toxicity and anti resistant bacteria. This product has been granted patent in several countries which includes China, US, British, Russia, Kazakhstan and Japan. Etinmicin Sulfate has been awarded the Second Grade Prize of National Advancement in Science and Technology and First Grade Prize of Advancement in Science and Technology of Jiangsu Province in 2002. Now the product model has been expanded to API, small capacity injection and freeze-dries powder injection. All these forms have been listed as the National-level Major New Products, High-tech Products of Jiangsu Province and Excellent New Product of Jiangsu Province. Its academic level as well as the production process has reached the international advanced level, so it was selected by the “National twelfth five-year major projects” (major variety transformation) in 2011. The company has the medicine marketing network covering the whole country.

Changzhou Fangyuan Pharmaceutical Co., Ltd insists “People First” as the principle, sets up policy to encourage, selects and introduces all kinds of talents; establishes “To serve Fangyuan as our responsibility, takes Fangyuan”s development as our proud” as culture of the company, takes innovation as the core driving force, with all staff’s efforts, through technical innovation, product innovation, business model innovation and management innovation, making Fangyuan to be the new prominent enterprise of biopharmaceutical industry.

上海东富龙科技股份有限公司
Shanghai Tofflon Science and Technology Co., Ltd.

上海东富龙科技股份有限公司成立于1993年，是一家以医用冻干机及冻干系统的研发、设计、生产、销售和服务为一体的高新技术企业。东富龙公司自创立以来，一直专注于冻干系统的行业发展，为制药企业提供专业化、个性化、定制化的冻干系统解决方案。东富龙公司为国内最大的冻干机设备制造商，是我国替代进口冻干系统产品的代表企业，冻干机产销量居国内行业首位，从设立至今已有超过3000台冻干机产品服务于全球制药领域。2011年2月1日，东富龙公司正式在深圳证券交易所创业板上市，发行新股2000万股，股票名称东富龙，股票代码300171。

东富龙在冻干系统领域拥有国内领先的研发、设计能力。2005－2007年连续三年进入上海市高新技术成果转化项目百佳企业行列，并获得中国制药装备科技成果一等奖、中国医药设备工程协会AAA级企业信用等级、国家重点新产品企业、上海市自主创新产品企业、上海市装备制造业与高新技术产业自主创新品牌企业、上海市最具活力科技企业（成长型）、上海科技企业创新奖、上海名牌、上海市著名商标等多项奖励和荣誉证书。公司产品还通过了UL、CE、ASME、PED、21 CFR PART11等多项国际权威机构认证。

东富龙凭借领先的技术创新能力、高素质的员工团队，公司业绩取得了高速增长，在冻干系统行业已取得了有利的领导地位。

齐鲁制药有限公司
QILU PHARMACEUTICAL CO., LTD.

齐鲁制药有限公司总部位于山东省济南市，是中国大型综合性现代化制药企业，专业从事治疗肿瘤、心脑血管、抗感染、精神系统、神经系统、眼科疾病的制剂及其原料药的研制、生产与销售。

公司始终坚持创新发展战略，以市场需求为核心，以产品创新为先导，广泛拓展国内外科研开发合作，注重人才的引进与培养，建有一支高素质的科研队伍，具备专业而高效的研发能力，已先后研制成功了近百个国家级新药，为公司未来的发展建立了合理的在研产品线，多项研究被评为国家、省级科技进步奖，并创造了良好的社会效益。

公司在快速发展的同时，切实履行各项社会责任，扶危救困，奉献爱心，以辉煌的成就，傲人的气魄展示了中国民族医药企业的发展与腾飞。

Located in Jinan, Qilu Pharmaceutical is one of the leading pharmaceutical companies in China. It focuses on developing, manufacturing and marketing of generic drugs and active pharmaceutical ingredients in the therapeutic areas of Oncology, Cerebrovascular & Cardiovascular, Infections, Psychological and Neurological System, Respiratory System, Ophthalmological Diseases, etc.

Always committing itself to meet the needs of the patients and the society, Qilu pharmaceutical provides high-quality products by adopting advanced technology. Oriented by market demands, Qilu Pharmaceutical adopts a strategy of innovation & development. The company widely cooperates with domestic and international partners on R&D projects. Qilu enrolled many qualified personnels and have a highly qualified research team. With state-of-the-art R&D facilities and substantial expenditure, Qilu developed and launched up to 160 generics in China and many other products are in the pipeline. Many projects are awarded State or Provincial Scientific and Technological Progress Award and benefit greatly to the society.

北京科信必成医药科技发展有限公司
CoSci Med-Tech Co., Ltd.

北京科信必成医药科技发展有限公司总部位于北京中关村科技园区海淀园区，成立于2003年，是一家拥有多项国内外自主知识产权的高新技术企业，被北京市人民政府、科技部、中国科学院共同认定为“中关村科技园区创新型试点企业”，获评中关村20周年突出贡献企业，2010年-2012年连续三年获得德勤高科技、高成长中国50强及亚太500强等荣誉。

科信必成是专注于口服固体制剂产业化的药品研发机构，坚持以市场为导向、产业化为目标，以获得独立知识产权和商业价值作为衡量创新成果的标准，致力于药物制剂领域的研究开发与技术创新，构建国内先进的口服药物速、缓、控释等制剂技术创新体系，实现中国药物制剂技术和产品达到国际水平，助推中国医药产业实现国际化。研发中心拥有国内一流的研发设备，掌握了多项具有独立自主知识产权可产业化的共性关键技术，建立可达到FDA、EMA药物制剂标准的化学药物速释、缓释、控释口服固体制剂技术平台。开发品种涵盖心脑血管、呼吸系统、神经系统、退行性疾病、解热镇痛等多个领域，在每个领域均有系列产品满足不同治疗时期的需求。科信必成为国内 40 多家制药企业提供服务，其中包括 32 家上市公司以及中国前10强制药企业中的 9 家。

公司成立至今，先后承担了一批政府重大技术项目，包括：主持国家“十二五”重大新药创制-创新型口服药物制剂中试及产业化技术基地、主持国家“十一五”重大新药创制-新型口服缓控释制剂及工艺技术平台、中关村科技园区国际化药物制剂技术公共技术平台、中关村药物创新制剂技术研发与产业化公共服务平台、承担多项国际化合作项目列入中关村科技园区海淀园专项发展资金。截至目前申请药物制剂国家发明专利128项，获得67项授权，申请国际PCT专利6项。

发展方向和目标：紧跟国际制剂发展新趋势，结合国内市场发展需要，培育核心技术、打造创新管理团队，将科信必成公司发展成为拥有核心技术的专业化、国际化的技术服务上市公司。

CoSci Med-Tech Co., Ltd, is a burgeoning innovative high-tech enterprise subordinated to Beijing Zhongguancun Science and Technology Park. It has focused on R&D and industrialization of oral fest modified-release formulations for 10 years, and successfully developed many products and technology platforms in drug delivery system. Currently 118 products are in our pipeline, and we’ve achieved 30 clinical trial approval and 25 manufacture approval from SFDA, as well we’ve developed products that were successfully launched on EU and US markets. Company has 128 patent applications, 66 of which got approved 7 international PCT applications and 1 was approved by 35 EU member states. During the last 5 years CoSci has been very active in international business development and has achieved many cooperations and partnership.

CoSci has developed 13 technology platforms regarding drug delivery system, including: Milti-Porous Osmotic Pump Controlled-Release Tablet; Complete Dissolution of Drug Content From Osmotic Pump Formulations; Enteric-Coated Pellet; Tablet Matrix Using Water as Wetting-Agent; Double-Layer Wex-based Matrix; Sustained-Release Pellet; Industrial Production of Solid Dispersions; Microencapsulation of Cellulose Acetate Dispersables; Extended-Release Drug Delivery System; Oral Dipersable Pellets; Mirco-Teblet; Colon-Release Formulations; Multi-Unit Sustained-&Controlled-Release Formulations (Mirco-Pellet Compression). We’ve launched more than 30 products on the market, also more than 30 products under clinical trial. Currently 63 products are under development, and 118 products are in our portfolio, including around 60 first generics to SFDA, and 10 innovative drugs. The product list of CoSci covers circulation disease, respiration disease, nerve system, age-related disorders, pain and infect relief, etc. In each therapeutic area, CoSci has a series of products that suits for various therapeutic phases and needs.

Mission and Value: Focus on innovation and development of DDS technologies, and use the well-established technology platforms to develop therapeutically preparations to meet the patients' needs in China and Global, especially focus on improving the convenience and compliance of the medication of patients, as well as improving the BA of pharmaceuticals with subsequent improvement of the efficacy and safety of medicines.

上海中信国健药业股份有限公司
Shanghai CP Guojian Pharmaceutical Co., Ltd.

上海中信国健药业股份有限公司（以下简称“中信国健”）是由中国中信集团有限公司旗下香港上市公司中信泰富有限公司投资控股的生物医药高新技术企业。公司自2002年创建以来，专注于抗体药物的研发、中试和产业化，现已发展成为国内抗体制药领域的领军企业，提供覆盖治疗肿瘤、自身免疫性疾病、抗器官移植排斥反应等重大疾病领域的靶向药物。

作为一家以研发为基础的生物制药公司，中信国健已成功构建了抗体药物开发和产业化平台并掌握核心技术，具备持续开发新药的创新能力。公司生产规模位居行业前列，产品在国内抗风湿生物制剂市场占有率稳居首位。

Shanghai CP Guojian Pharmaceutical Co., Ltd. (CPGJ) is a high-tech bio-pharmaceutical company which is co-invested and led by China International Trust and Investment Corporation(CITIC)Group. CPGJfocuses on R&D, pilot development, industrialization and commercialization of monoclonal antibody drugs. Established in 2002 and going through more than ten years of growth, CPGJ has become a leading player in China’s domestic therapeutic Mab area. It has built up the largest production capacity for monoclonal antibody drugs in China and further expansion is undergoing within CPGJ’s strategic planning.The company’s product pipeline has covered the therapeutic solutions for critical diseases in Oncology, Transplantation andAutoimmune Disorders. Its drug for rheumatic disease has maintained a leading domestic market share in thebiological anti-rheumatic drugs field in China.

Dedicated to sharpening its Research & Development capability, CPGJ has successfully produced key technological know-hows for the development and industrialization of monoclonal antibody drugs. As CPGJ’s wholly owned R&D organization, Biotechnology Institute of Shanghai CP Guojian focuses on discovery and early development of therapeutic antibodies and proteins, as well as innovation of technologies and processes to support drug development. The institute has established a comprehensive technological platform with a strong capability to take a drug development program from early discovery through CMC stage.

深圳微芯生物科技有限责任公司
Shenzhen ChipsCreen Bioscien Co.,Ltd.

原创 安全 优效 中国

微芯生物是一家以研发为驱动力，以市场为中心，原创新药进入国际主流市场的现代生物医药企业。

微芯生物由留美归国团队创立，专长于原创小分子药物研发，现已具备完整的从药物靶点研究到临床候选药物开发及产业化的能力。

以自主创建的“基于化学基因组学的集成式药物发现及早期评价平台”为企业核心竞争力，微芯生物已奠定了在中国医药行业创新研发的领军地位，也赢得了国际同行的认可。

通过专利授权、合作研究和产品最终上市销售实现盈利和发展的创新发展模式——改变了中国本土医药企业缺乏原创药这一实质性缺陷，开创了从“中国仿制”到“中国创制”的先河。

专注于肿瘤、代谢性疾病和自身免疫性疾病等治疗领域，微芯生物已建立了十几个不同研发阶段的原创化学新药。至今，微芯生物已申请60项化合物全球发明专利，32项已获授权。

“质量源于设计”是微芯生物GMP生产及质量管理始终坚持的原则和实践。

微芯生物是国家首批“创新药物孵化基地”，获得多项国家“863”及重大科技专项支持.并积极参与国家医药行业技术政策制定，荣获2009年SFDA颁发的“特殊贡献奖”，作为中国医药行业创新的代表受到国内外专业媒体广泛关注，提升了中国药企在国际制药领域的影响力。

药品是一种特殊商品，关系人命，应立足于科学而非政治、宗教和商业利益。这一理念将一直铭记在微芯人心中。

Constant Innovation for Life

Chipscreen is a leading integrated biotech company specialized in discovery and development of novel small molecule

pharmaceuticals. The company has utilized its proprietary chemical genomics-based discovery platform to successfully develop a portfolio of commercial, clinical and preclinical stage programs in a number of therapeutic areas including oncology, metabolic disease and autoimmune/inflammatory diseases. Our core competence is the science-driven approach in discovery, strong pipeline building capability, experience with IP, and regulatory expertise.

Chipscreen's business strategy is to generate differentiated drug candidates across multiple therapeutic areas. Drug candidates are either developed by Chipscreen or co-developed and commercialized in a partnership at the research, preclinical and clinical stages.

Chipscreen was established as Sino-foreign joint venture in 2001 by several highly regarded Chinese returnees from the United States with academic, scientific, and industrial experience. Our founders established our company out of a common vision to create the leading drug discovery and development firms, and to provide affordable innovative pharmaceuticals in China.

中国中医科学院
China Academy of Chinese Medical Sciences

中国中医科学院(原名为中国中医研究院)成立于1955年，位于北京，是国家中医药管理局直属的集科研、医疗、教学为一体的综合性研究机构。现任院长为曹洪欣教授。

中国中医科学院是目前我国规模最大、学科齐全、设备先进、科研力量雄厚的中医药研究机构，下设13个研究所、6所医院及研究生部、中医古籍出版社、中医杂志社等学术单位；有职工4000余人，各类专业技术人员3200多人，其中高级职称者800多人；与世界卫生组织（WHO）共同建立了临床与信息、针灸、中药三个传统医学合作中心；世界针灸学会联合会、中国中西医结合学会、中国针灸学会均设在中国中医科学院。

中医药科学研究是中国中医科学院的中心任务，50年来，中国中医科学院在中医药基础理论研究和重大疾病防治及中药新药开发研究等方面均取得了显著成就。截止2004年底，全院共获得科研成果近900项，其中获国家级、部局级奖近300项；现有院级以上在研课题482项，其中国家级课题200项、部局级课题258项；拥有国家新药（中药）临床试验研究中心（GCP）、国家规范化中药药理实验室、中国中医药文献检索中心和BSL－3实验室， 是国家中药安全性评价中心（GLP）与中药复方药物开发国家工程研究中心建设单位。

中国中医科学院是培养高层次中医药人才的重要基地，现有中医学、中药学、中西医结合三个一级学科所涵盖的所有学科专业的博士、硕士授予权，具有临床医学专业学位授予和在职人员申请学位的资质；设有中西医结合、中医学、中药学三个一级学科的博士后工作站。 中国中医科学院图书馆是全国藏书最多的中医药专业图书馆，其中珍本、善本、孤本书籍2万余册。中国医史博物馆是我国收藏文物最多的中医专业博物馆，收藏文物3000余件。

中国中医科学院主办多种全国性的中医药专业期刊，其中在国内外影响较大的有《中医杂志》、《中国中西医结合杂志》、《中国中药杂志》、《中国针灸》、《针刺研究》、《中国骨伤》、《中华医史杂志》、《中国中医药信息杂志》、《中国中医基础医学杂志》等。

作为我国传统医药对外合作与交流的重要窗口，中国中医科学院与世界上100多个国家和地区的医药界、科研院所、高等院校、企业及民间团体有广泛友好的联系与交流，在国际传统医学界有较大的影响。

中国药科大学
China pharmaceutical university

中国药科大学是教育部直属国家“211工程”和“985优势学科创新平台”建设高校，是我国首批具有博士、硕士学位授予权的高校。始建于1936年，是中国历史上第一所由国家创办的高等药学学府。学校现已成为以药学为特色，理、工、经、管、文等学科协调发展的多科性大学。

学校下辖11个院部系，24个本科专业，26个博士点，35个硕士点，3个专业学位授权点，2个博士后流动站，23个学科专业可招收博士后。药学学科为国家一级重点学科，中西医结合为江苏省一级重点学科。学校药理与毒理学、化学两个学科领域的ESI排名位列全球前1%，进入国际先进行列。

学校现有“天然药物活性组分与药效”国家重点实验室，已建成临床前创新药物研发各节点相关的国家和省部级重点实验室、技术平台、工程技术中心13个，江苏省高校协同创新中心1个，为各类新药的研发提供全方位服务。学校获“十一五”国家“重大新药创制”科技重大专项项目数40余项，经费资助2.15亿元，获批项目数、经费数位居全国高校之首。

学校现有江宁、玄武门两个校区，占地2200余亩。全日制在校生15000余人，本专科生12000人，研究生3200余人。在职教职工1400余人，其中中国工程院院士1人、德国科学院院士1人、“国家杰出青年科学基金”获得者5人、“长江学者”4人、“国家级教学名师”2人、“全国优秀教师”3人、“百千万人才工程”国家级培养人选2人、教育部新世纪优秀人才支持计划12人、享受国家政府特殊津贴48人、江苏省教学名师3人、省级以上各种人才培养工程遴选命名93人次。

学校连续三届获得国家级教学成果一等奖。“十一五”期间，在国家“本科教学质量与教学改革工程”项目建设中，获批项目数在全国医药院校中名列前茅，获全国药学类项目经费总数的1/5。

我校是教育部最早指定接收外国学生和港澳台地区学生的定点院校之一。与57个国家和地区的有关院校和科研机构建立了学术联系。

学校的中长期发展目标是：至2036年建校100周年时，将学校建成国际知名的，以药学为特色，理、工、经、管、文等学科协调发展的高水平、多科性、研究型大学。

北京大学药学院
Peking University school of Pharmaceutical Sciences

北京大学药学院始建于1941年，至今已走过了半个多世纪的历程，在学科建设、师资培养、教学、科研等方面都得到巨大的发展。曾培养出一大批科学家，是国内外药学科学家培养的摇篮。至今药学院已有四名教授遴选院士。

北京大学药学院，现设药学、应用药学二个专业，其中药学专业为国家级、北京市级高等学校特色专业建设点，是“国家理科基础科学研究和教学人才培养基地”。药学院由六系（化学生物学系，药物化学系，天然药物学系，药剂学系，分子与细胞药理学系，药事管理与临床药学系）、一室（天然药物与仿生药物国家重点实验室）、一所（应用药物研究所）、一中心（药学实验教学中心）组成。下设四个委员会：教学委员会、学术委员会、药物研究与开发委员会、对外合作交流委员会。

目前学院承担着多项国家自然科学基金重点项目、国家“863”项目、“973” 项目、国家科技攻关项目以及省部级科研项目，参与了“211工程” “985工程”“九五” “十五”“十一五”的重大项目的建设，在全体师生的共同努力下，近五年来，学院获国家自然科学奖、省部级奖多项，获得国内国际专利授权多项；发表论文千余篇，大部分被SCI收录；并有数个国家级1类新药及创新药物获得国家批准进入临床研究或生产。由学院为牵头单位，联合学校有关新药研发机构和企业，利用药学、基础医学、生命科学、化学、计算机科学等综合学科的优势和坚实的研究基础，整合北大优势资源，构建的“北京大学综合性创新药物研究开发技术大平台”被列入国家“十一五”科技重大专项“重大新药创制”计划资助项目。学院将依托此平台的建设，构建从创新药物发现至新药研发整体环节，包括化学药、中药/天然药、生物技术药在内的创新药物发现与研发体系，以提高学院新药研究的自主创新能力。

药学院与国际国内科研院所、制药企业有着广泛的合作与交流。与美国 、英国、法国、德国、日本、荷兰等国家及港、澳、台地区等十几所大学或公司建立了友好合作关系，积极开展新药科研和技术协作及科技成果推广，促进医药科技的商品化，专业化，为国家实现从医药大国到医药强国的转变贡献力量。

沈阳药科大学
Shenyang Pharmaceutical University

沈阳药科大学是一所具有光荣革命传统的学校，1931年诞生于江西瑞金，是我国历史最悠久的综合性药科大学。学校占地面积21万平方米，建筑面积28万平方米，教职工1108名。

学校目前已发展成为多学科、多层次、多形式教育的高等药学学府。设有药学院、制药工程学院、中药学院、生命科学与生物制药学院、工商管理学院、基础学院、高等职业技术学院、继续教育学院、国际药学合作研究中心以及测试中心、计算机中心、现代教育中心、中药资源中心等。

学校是国家批准有权授予博士学位、硕士学位和招收港、澳、台地区学员及外国留学生、国内高中保送生的院校。有药学博士后流动站1个，一级学科博士学位授权点2个，二级学科博士学位授权点19个，硕士学位授权点26个，硕士专业学位授权点3个，本科专业21个(含专业方向)，高职专业8个，成人本专科专业14个。本科教育中有国家理科基础科学研究和教学人才培养基地 、国家生命科学与技术人才培养基地。药剂学科是国家级重点学科，药学和中药学一级学科为省级重点学科。药剂学、天然药物化学、药物化学、药物分析学、药学概论、分析化学、化学制药工艺学、生物技术制药等8门课程为国家级精品课程，药学实验教学中心为国家级实验教学示范中心，药剂学教学团队、药理学教学团队和药物分析学教学团队为国家级教学团队，药学专业、制药工程专业和药物制剂专业为国家级一类特色专业。现有在校研究生2139名（博士402、硕士1737）、本科生5701名、高等职业技术教育学生1741名、成人教育本专科生4000余名。

学校荟萃了众多的专家学者。有教授84名，副教授186名，其中中国工程院院士1名，国家新世纪百千万人才工程百层次人才3名，国家级教学名师1人，省级教学名师7人，省级以上各种人才培养工程遴选命名80人次。建校近八十年来已为国家培养了4万余名高级药学、制药人才，他们遍布祖国各地，其中有很多已成为国内外知名的专家、教授、企业家和优秀领导者。

学校学术氛围浓厚，科研工作深入扎实。在药物新剂型设计与评价、创新药物的合成与筛选、中药与天然药物药效物质基础和质量标准、药物代谢和药物动力学、药理与毒理学、药物经济学等领域的研究均居国内领先水平。学校是国家中成药工程技术中心、沈阳国家新药安全性评价研究中心的重要组成单位，教育部创新药物研究与设计重点实验室1个，有4个国家中医药管理局批准的中药三级实验室、1个中药二级实验室，18个省市级工程技术研究中心或重点实验室。我校于2008年成功申报国家级综合性新药研究开发技术大平台项目，该综合平台是唯一由地方院校承建的国家综合平台，获得经费8000万元。近5年来，承担各级各类科研项目310余项，获各级各类科技成果奖120项，申请发明专利300项，获得专利证书50项，获得新药证书42个，发表学术论文6000余篇，其中SCI收录论文1000余篇，出版专著、译著180部，仅2009年发表论文1105篇，SCI收录论文366篇。学校主办的《沈阳药科大学学报》和《中国药物化学杂志》现已成为国家药学类核心期刊。《亚洲社会药学》等三种国际学术期刊于2005年创刊。

学校仪器设备先进，图书馆藏丰富。拥有可供教学科研使用的核磁共振波谱仪、气—质联用仪、高效液相色谱—质谱联用仪等现代高精设备；学校图书馆建筑面积11000平方米，现有藏书80余万册（件），国内外重要期刊2300余种。目前已建立了数字图书馆，通过Internet，使师生很快了解国内外最新科技信息。

学校积极开展国内外学术交流与合作，先后与国内一些知名大学签订了合作办学协议，实现资源共享；与美国、日本、英国、俄罗斯等 30 多个国家和地区的高等院校、科研院所建立了校际交流与科研协作关系。

学校坚持“团结、勤奋、求实、创新”的校训精神，立足辽宁、面向全国，建设药学教育领域国内一流、国际知名的教学研究型大学。

Shenyang Pharmaceutical University is a university with glorious revolutionary traditions and was born at Ruijin, Jiangxi Province in 1931. It grew from the Medical School of the Chinese Workers’ and Peasants Red Army. Now it is situated on the banks of the Hun River in Shenyang. It was formerly subordinate to the State Pharmaceutical Administration of the People’s Republic of China and is one of the two comprehensive pharmaceutical universities. From February, 2000, it was put under the leadership of the People’s Government of Liaoning Province.

Now Shenyang Pharmaceutical University covers an area of more than 220000 square meters with building area of 180000 square meters. The university has a staff of 846, among them there are 342 full-time teachers.

At present the University has developed into a multidisciplinary, multilevel and multiform pharmaceutical institute of higher learning. It consists of Schools of Pharmacy, Pharmaceutical Engineering, Traditional Chinese Medicines, Business Administration, Basic Courses and Adult Education. The University has been authorized to confer Master’s and Doctor’s Degrees and to enroll students from areas of Hong Kong, Macao, Taiwan, foreign countries and recommended students from senior middle schools for admission to the University as well. In 1996 with the approval of the State Education Commission of China, the University began to run a “National Training Base for Science Talents of Basic Science and Research and of Science Teaching”

as a test. There is 1 postdoctoral scientific research center for pharmacy, 1 doctor's degree-conferring unit of the first class of disciplines, 6 doctor's degree-conferring units of the second class of disciplines, 8 master's degree-conferring units, 9 specialities of undergraduate courses. The English class of pharmacy and the Japanese class of pharmacy (with a 5-year period of schooling) are a speciality which has greater influence at home. At the University specialities of the pharmacy class are complete. Pharmaceutics is the only national key discipline and the specialities of medicinal chemistry and pharmaceutical analysis are provincial key disciplines. Now the total students of all levels are more than 7000.

At the University there is an Institute of Materia Medica, an Institute of Pharmaceutical Education of Higher Learning, a computer center, an audio-visual education programme center, a center of instrumental analysis, a botanic garden of medicinal herbs, a subsidiary pharmaceutical factory, etc. The National Medicine Engineering & Technique Research Center of the Former SPAC and the Laboratory of Pharmacokinetics and Drug Matabolism were all set up at the University. The University is an important component unit of The Engineering Technique Center of the National Patent Medicines and the Shenyang National New Drug Safety Evaluation Center.

There is one academician of the Chinese Academy of Engineering, over 170 professors and associate professors (nearly 1/4 of them are personnel studying abroad, nearly 20 of them have gained doctor's degrees abroad). They enjoy higher prestige at home and abroad. Some of them are holding important posts. For example, the leader of the appraisal group of pharmacy of the academic degree committee of the State Council, the convener of the first medical expert group of the national postdoctor's management committee, a member of the standing experts' committee of new drug research of the State Science and Technology Commission, a consultant of the "Industrial Development Organization of the United Nations", an appraisal member of the National Prize for the Development of Science and Technology, a member of the Commission of the State Pharmacopoeia, etc. The University has trained nearly 20000 senior talents of pharmacy and pharmaceutical engineering. They are scattered all over China. Some of them have become well-known experts, scholars, enterprisers and outstanding leaders.

There is dense academic atmosphere in the University and active scientific research work. In the field of theory research and practice of new dosage forms of pharmaceutical preparations-polyphase liposomes and solid preparations, in the field of research on chemical components and search for active components of traditional Chinese medicines and natural drugs, in the field of distinguishment of chemical models or chemical models of the quality of traditional Chinese medicines and the study on their quality control, all the achievements are in the leading position in China, more than 3000 academic papers have been published. This had brought great influence internationally. In recent years hundreds of projects for study from the State, Province or City have been completed. The University has gained hundreds of national, provincial and ministry prizes for development of science and technology. It has also gained more than 50 certificates of new drugs. Some research results have brought outstanding economical and social benifits.

The instruments in the University are advanced and the books in the library are plentiful. The University possesses modern, high-grade precision instruments for teaching and studies, e.g. NMR, GC-MS, HPLC-MS. The building area of the library is 11000m2 and a collection of over 26000 books, over 2300 kinds of important magazines and periodicals. Now a computer search system has been set up. Teachers and students can learn the latest scientific and technical information very quickly via the Internet.

The University actively develops internal and international academic exchange and collaborations. The University has signed cooperative agreements for running Schools with Jilin University and China Medical University to achieve common use of the resources and supplement superiority of each other, cross disciplines and develop commonly. The University has also established friendly intercollegiate relationship with over 20 countries and areas, including America, Japan, Britain, Korea, Hong Kong, Taiwan, etc. In February 1997, Tokyo University signed intercollegiate cooperative relationship with our university. In the field of training talents and academic exchange, etc. cooperation will be carried out. Our University has become the fifth university which signed the agreement after Beijing University, Tsinghua University, Fudan University, China Science and Technology University.

The University insists on the spirit "Be united and diligent, Be practical and dedicative", bases ourselves upon Liaoning Province, serves the whole country and strives for the establishment of a teaching and scientific research type of a university which suits the need of development of our country, pharmaceutical economy, with distinguishing features, makes focal points and enjoys better quality and prominent benefit.

复旦大学药学院
School of Pharmacy, Fudan University

历史溯源

复旦大学药学院创建于1936年，时称国立上海医学院药学专修科，后分别更名为国立上海医学院药科、国立上海医学院药学院、上海第一医学院药学系、上海医科大学药学院。2000年，原上海医科大学与原复旦大学合并后定名为复旦大学药学院，是我国最具影响力的五所高等药学院校之一。

2008年8月，药学院整体搬迁至浦东新区张江高科技园区内的复旦大学张江校区，占地面积80亩，工作用房面积为2.5万平方米，由科研楼、化学楼、实验动物楼、本科生实验教学楼等建筑群构成。

组织结构、学科布局、人才培养

药学院下设药物化学、药剂学、药理学和临床药学四大学科群，其中：药物化学学科群由合成药物化学、生物合成药物化学、天然药物化学和生药学组成；药剂学学科群由药剂学、物理化学、放射药学组成；药理学学科群由药理学、生物化学和药物分析组成；临床药学学科群由临床药学和药事管理学组成。

具有药学一级学科博士学位授予权，拥有药学博士后流动站1个，二级学科博士点和硕士点各7个，国家生命科学与技术人才培养基地—生物医药点，国家重点学科（药剂学）和上海市重点学科（药理学）各1个。设有药学研究所和《中国临床药学杂志》社。

按药学一级学科专业招收本科生，分为药学和临床药学方向。已培养本科生5500余名、硕士生600余名、博士生120余名，受到了社会和用人单位普遍欢迎，其中6人已成为“两院”院士。目前在读研究生300余名、本科生（含留学生）260余名。获得国家精品课程1项（药理学）、全国百篇优秀博士学位论文2篇（药剂学）。

师资力量

现有教职员工130人，其中：正高职称33人，副高职称38人；博士生导师39名，硕士生导师32名。拥有国家“千人计划”特聘教授3名、入选上海市“千人计划”特聘教授2名、973项目首席科学家3名、国家“杰出青年基金获得者”2名和“优秀青年基金获得者”1名、教育部“长江学者”特聘教授1名、教育部新世纪优秀人才5名、上海市领军人才1名、上海市优秀学科带头人4名等。

研究领域

学院以药学基础及应用基础研究为主，兼顾新药开发，侧重于抗感染药物、抗肿瘤药物、心脑血管药物的新理论、新技术、新方法、新产品等研究。拥有智能化递药教育部和全军重点实验室，国家中医药管理局三级实验室（中药制剂、中药生药分析）。设有仪器分析测试、计算机辅助药物设计、动物实验、药物筛选与药效评价、放射药学与分子影像、药物制剂中试等多个技术支撑平台。

科研经费、论文、成果

2007年以来，承担国家重大科学研究计划（973）、国家重大创制新药技术专项、863计划项目、国家自然科学基金等国家及省部级项目多项，到位科研经费约达2亿元；授权专利128项；年均发表SCI论文100篇以上；获得教育部自然科学一等奖2项等。

国内外交流合作

连续承办了“国际药物制剂论坛”等大型国际会议，多名教授在国内外重要学术组织、学术期刊上担任重要职务，并活跃在国际重要学术会议讲坛上，国际合作研究成果多次在国际著名学术刊物上发表等，药学院国内外影响力逐年提升。

发展目标、愿景

药学院致力于发展高、精、尖的复旦药学一级学科，争取进入国家一级重点学科行列，并建成完整的药物研发链，产出一类新药。通过5-10年建设，在药学和临床药学教育、药学应用基础研究和新药开发方面进入国内领先行列，并在国际上拥有较高知名度。

History

Founded in 1936, School of Pharmacy Fudan University (SPFDU, former School of Pharmacy, Shanghai Medical University) has a long history. After the merge of the original Shanghai Medical University and Fudan University in 2000, she was named School of Pharmacy Fudan University and now is one of five most influential pharmacy schools in China.

In August 2008, SPFDU moved into the new campus which is located at Zhangjiang Hi-Tech Zone in Shanghai Pudong New District with a total area of about 80 acres. The campus is composed of four major buildings with a total construction area of 25,000 square meters, including research building, chemical laboratory buildings, experimental animal building and experimental teaching building for undergraduates.

Organization

SPFDU is organized into four main academic departments: Pharmaceutical Chemistry (including Synthetic Medicinal Chemistry, Biological Synthesis of Medicinal Chemistry, Natural Medicinal Chemistry, and Pharmacognosy), Pharmaceutical Science (including Pharmaceutical Sciences,

Physical Chemistry, Radiation Medicine, and Pharmaceutical Analysis), Pharmacology (including Pharmacology and Biochemistry), and Clinical Pharmacy (including Clinical Pharmacy and Pharmacy Administration).

SPFDU is awarded the right to grant doctoral, master and bachelor degree of 7 disciplines. It has one postdoctoral station, and one national base of life science and technology education –biology medicine, collaborated with College of Life Science. At present, the Pharmaceutical and Pharmacological Science are selected as national and Shanghai key discipline respectively. The school is also one of Research and Training Centers of Shanghai Clinical Pharmacy with a peer-reviewed journal titled "Chinese Journal of Clinical Pharmacy" in its charge.

SPFDU has undergraduates majored in pharmacy and clinical pharmacy. So far, about 5500 undergraduate students, 600 masters and 120 PhD have graduated from SPFDU and 6 of them have been awarded as national Academicians. Currently students of SPFDU consist of almost 300 graduate students and over 260 undergraduates including foreign students. Besides, Pharmacology was awarded as national excellent course and 2 theses about pharmaceutical science were selected as the national excellent Ph.D. Thesis.

Faculties

The SPFDU has 130 faculties, with 33 professors and 38 associate professors, which include 39 doctoral supervisors and 32 master supervisors. There are 3 "Thousand Person Plan" distinguished professors from the national project and 2 elected "Thousand Person Plan" distinguished professors from Shanghai project, 3 chief scientists of national key scientific research project (973), 1 Yangtze Distinguished Professor recognized by the Ministry of Education, 2 National Outstanding Youth Foundation Winners and other 5 cross-century talents recognized by the Ministry of Education, 1 leading figure in Shanghai, and 4 outstanding academic leaders in Shanghai.

Research

Based on pharmaceutical basic research and applied basic research, and taking account into the development of new medicine, SPFDU focuses on research about the new theories, new technologies, new methods and new products of anti-infective drugs, antineoplastic drugs and cardiovascular drugs. The School has Smart Drug Delivery laboratory, Key Laboratory of Ministry and Three-level laboratories of Traditional Chinese Medicine (TCM) and the TCM crude drug analysis of the State Traditional Chinese Medicine Administration. It also includes several supporting technical platforms: Specialized Integrated Platform of National New Drugs Development, Screening and Efficacy Evaluation Platform for Antivirals, Technology Platform for the development of New Formulation and New Drug Delivery System, GLP Laboratory Animal Center, Instrument Test Center.

Achievements and Honors

Since 2007, SPFDU has accomplished national key scientific researches (973), major projects of national development of new drugs, 863 and national and provincial projects of the national natural science foundation. Also, SPFDU achieved funding about 2 billion, 128 patents, over 100 publications on SCI annually and 2 first prize of natural science from the Ministry of Education.

Collaboration

SPFDU has undertaken "the International Forum of Pharmaceutical Preparation" and other large international conferences for several years. Many professors have been appointed as the editor or associate editor of some prestigious peer-reviewed journals. Many international collaboration research results have been published on authoritative publications, which show the increasing influence of SPFDU in the international academia.

Future

With the state-of-the-art research and cutting-edge technology, SPFDU works for national key disciplines and has established the pipeline of drug development. In 5-10 years, we believe that SPFDU will make greater achievement in pharmaceutical science and clinical pharmacy education, drug applied research and new drug development, with higher reputation in the international academia.

中国医学科学院药物研究所
Institute of Materia Medica , Chinese Academy of Medical Sciences

中国医学科学院药物研究所成立于1958年，是国家重点药物研究机构之一。现有科技人员400 余人，其中正副研究员99 人，中国科学院院士2 人，中国工程院院士1 人。

建所五十多年来，共获科研成果奖266项，已研制上市新药百余种,获新药证书129 项，其中以人工麝香、丁苯酞、双环醇、艾瑞昔布等为代表的一类创新药物19项。自1986 年国家设立基金制以来，共承担各类科研课题1000余项，发表论文6600 余篇，编写专著326 本，申请国内外专利700 余项。

药物所学科齐全，下设合成药物化学、天然药物化学、药理学、药物分析、生物合成、新药开发等研究科室，具有很强的药物研发能力，还建有国家药物及代谢产物分析研究中心、国家新药开发工程技术研究中心、国家药物筛选中心、科技部药效学平台、院校新药安全评价研究中心、药物所药物晶型研究中心等多个新药研发技术平台，以及1个国家重点实验室，7个省部级重点实验室.

药物所始终坚持走产学研相结合的发展道路，现有2 家全资企业：北京协和药厂、北京协和制药二厂，以及3 家控股企业：北京联馨药业有限公司、北京协和建昊医药技术开发有限责任公司、北京科莱博医药开发有限责任公司。形成了药物所“产-学-研”相结合一体化优势格局。

The Institute of Materia Medica (IMM), Chinese Academy of Medical Sciences & Peking Union Medical College, founded in 1958, is currently accommodating more than 400 research scientists and technicians, and among them more than 90 person are holding full and associate professorships, two person are Academician of Chinese Academy of Sciences and one is Academician of Chinese Academy of Engineering.

Since its establishment, researches in this institute have resulted in more than 100 marketed drugs, 129 new drug certificates including level-A novel pharmaceuticals, and 266 governmental and social awards and prizes. Since the inception of the new research funding system in China in 1986, more than 1000 grant applications from this institute have been approved in total.

These studies have resulted in more than 6600 published papers, 326 monographs and more than 700 domestic and international patent applications.

IMM comprises of several departments: Department of Synthetic Medicinal Chemistry, Department of Natural Medicinal Chemistry, Department of Pharmacology, Department of Drug Analysis, Department of Biosynthesis, Department of Drug Development Research. Being a full-range-disciplined research institution, IMM’s extraordinary capacity in drug research and development is well recognized.

In addition, the institute also hosts a number of government-sponsored special research centers, including the National Research Center for Analysis of Drugs and Metabolites, the National Engineering Research Center for Development of New Drugs, the National Center for Pharmaceutical Screening, the Ministry of Technology Research Platform for Pharmacodynamics, the Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC) New Drug Safety Evaluation Center, and 8 key laboratories.

军事医学科学院毒物药物研究所
Institute of Pharmacology and Toxicology Academy of Military Medical Sciences

军事医学科学院毒物药物研究所成立于1958年，是由1951年组建的军事医学科学院药物系、药理系、化学系合并组成，原名药理毒理研究所，1958年更名为毒物药物研究所。

经过50年的建设与发展，该所现已形成以防化医学为重点，新药研究为主体，基础医学和生物高技术为支撑的科研布局.现设有10个研究室、1个编辑部，并拥有国际实验室1个，国家级研究中心或技术平台6个，全军性研究中心和重点专业实验室6个。主要任务是化学武器损伤医学防护研究、军队特需药及重大疾病防治药物研究开发。

毒物药物研究所是我国、我军防化医学研究的牵头单位和核心力量。50年来，始终坚持军事医学研究方向，经过几代科学家的共同努力，建立起比较齐全完备的防化医学科研体系，研究提出“侦、检、消、防、诊、救、治”等一整套医学防护综合措施，取得了以国家科技进步特等奖“战时特种武器伤害的医学防护” 为标志的一大批高水平科研成果，出色完成了防化医学卫勤保障和突发化学事件的应急救援任务，为提高部队卫勤保障能力，保障官兵和人民的身体健康，维护国家安全做出了重要贡献。

毒物药物研究所是我国国家级新药研发主要机构和骨干力量。50年来，在开展防化军队特需药物研究基础上，建立了新药设计合成、质量控制、制剂研究、药物代谢、药理学评价和药物安全性评价等衔接配套的新药研发技术链，共获得国家新药证书67个。其中，一类新药证书7个，一大批新药研究成果成功转让上市，取得了良好的社会效益和经济效益。“十五”以来，共承担了国家科技重大专项、“973”、“863”、科技支撑计划等国家级重大、重点科研项目332项。其中，“综合性新药研究开发技术大平台”获“十一五”国家“重大新药创制”重大科技专项重点支持，显示出研究所在新药研发领域的实力和水平，已成为国家创新药物研发体系的重要组成部分。

毒物药物研究是培养防化医学和新药研究高级专业人才的重要基地。现有国家重点学科3个，博士授权学科7个，硕士授权学科8个，博士后流动站3个。拥有中国科学院院士1名，中国工程院院士1名，21人次中青年学术带头人获得国家杰出人才基金、“长江学者”、“求是”杰出青年奖等各类荣誉称号，已形成了以院士领衔、知名中青年科学家为骨干、结构合理的科技人才群体，为研究所可持续发展奠定了坚实的基础。1978年以来，共培养博士后，博士、硕士研究生两千余人。

50年的发展和积淀已成为研究所新的历史起点，面对新形势，我们有信心抓住新机遇，迎接新挑战，全面推进研究所健康协调发展，努力把研究所建设成为国际先进的综合性研究所。

天津药物研究院
Tianjin Institute of Pharmaceutical Research

天津药物研究院始建于1959年，原是国家食品药品监督管理局直属的全国综合性医药科研单位之一。目前是以新药研究为主业的国有独资高新技术企业，汇聚了中国工程院院士、享受国务院特殊津贴专家等专业人才，设立了药学硕士点和博士点，建立了博士后科研工作站。

院学科整体优势强，可进行药物创新研究、化学制药研究、现代中药研究、新药评价（GLP）、新型制剂技术及工程化研究、药品质量及分析测试研究、医药信息研究，涵盖了整个药学研究领域。2009年被科技部、国务院国资委、全国总工会三部委确定为“创新型企业”，2010年入选“第二批全国企事业知识产权示范创建单位”。

近年来，承担了100多项国家重大新药创制专项等国家课题，共获得200多件新药证书和生产批文，申报专利超过460项，还负责编辑出版四种学术期刊。

Tianjin Institute of Pharmaceutical Research (TIPR) was originally founded in 1959, and was one of affiliated research institutes of State Food and Drug Administration, P.R.China (SFDA).Now the institute is a national key hi-tech enterprise focusing on the development of new drugs . The institute has a research team, including academician of Chinese Academy of Engineering, specialists receiving state allowance and senior research fellows. In addition, the institute provides Master programs in Chinese Medicine, pharmaceutical science and PhD program in pharmacology, as well as post-doctoral training center.

Tianjin Institute of Pharmaceutical Research leads the research in pharmaceutical areas and has seven major research divisions, including center for drug innovation, department

of medicinal chemistry, department of traditional Chinese medicine, center for drug evaluation (GLP), center for pharmaceutical formulation technology and engineering research, department of analytical testing of pharmaceutical quality, and center for medical intelligence, covering the entire field of pharmaceutical research. In the meanwhile, the institute was awarded "the innovative enterprises" by administrative agencies in 2009, and "second batch of national demonstration units of intellectual property" in 2010.

In the past years, Tianjin institute of Pharmaceutical Research has engaged in over 100 special projects of national key novel drug innovation; the number of new drug certificates and licenses for production granted by central authority is over 200, and patent application is over 460. Tianjin Institute of Pharmaceutical Research also hosts publication of a series of academic journals in pharmaceutical research field.

中国医学科学院医药生物技术研究所
Institute of Medicinal Biotechnology Chinese Academy of Medical Sciences

中国医学科学院医药生物技术研究所（原名抗生素研究所）成立于1958年，是我国抗感染药物的主要研发单位，也是我国第一支青霉素的诞生地，为我国抗生素的研发、人才培养及工业化生产起到了奠基的作用，在我国重大疾病、尤其是传染病的防控中作出了突出贡献。随着生物学理论与技术进步和社会的发展，药物研究的范围扩展至肿瘤、心血管、免疫调节等领域，1986年研究所更名为医药生物技术研究所。

研究所现有在职人员近500人，包括中国工程院院士，国家（部）级"突出贡献中青年专家，长江学者特聘教授，国家杰出青年基金获得者，硕、博士生导师，客座教授及在读研究生等。

进入21世纪后，研究所被国家确立为公益性研究机构，加强了药学基础研究平台的建设和国际合作，研究所的"微生物与生化药学"成为国家重点学科，是我国药物研究、硕博士研究生教学和科学技术产业化的核心基地之一。

Institute of Medicinal Biotechnology (IMB),Chinese Academy of Medical Sciences,initially named as Institute of Antibiotics founded in 1958,was a national key institute for discovery and development of anti-infective agents.As the place of giving birth to the first ampule of penicillin in China,the Institute laid a solid foundation for discovery and development of antibiotcs,nurturing professional talents and industrial production of antibiotics and made great contribution to prevention and therapy of seriouis disease,especially,infectious disease.Wih he social advance and scientific development in theory and technology of biology,the research fields of the institute were extended to areas of cancer,cardio-vascular system and immunoregulation,etc. In 1986,the institute was renamed as Inatitute of Medicinal Biotechnology.

Today,there are more than 500 employees in IMB,including Academician of Chinese Academy of Engineering,National Outstanding Scientists,Cheung-Kong Scholars,National Distinguished Young Scholars founded by NSFC,Supervisors for Doctoral Degree,Visiting Professors and Postgraduate Srudents,etc.

In the 21st century,as the social commonwealth research institute,IMB strengthened platform building for basic research of pharmacology and international cooperation. Meanwhile,microbial and biochemical pharmacy in IMB was evaluated and authorized as national key subject by Ministry of Education,P.R.China.Now IMB becomes one of the central primary bases for drug research,postgraduate education and industrialization of scientific and technology in China.

中国医药工业研究总院
China State Institute of Pharmaceutical Industry

中国医药工业研究总院（以下简称“医工总院”），缘起于国家于1957年创建的上海医药工业研究院，现隶属于中国医药集团总公司。

医工总院现有6家所属单位：上海医药工业研究院、四川抗菌素工业研究所、上海现代制药股份有限公司（上市公司）、药物制剂国家工程研究中心、国家上海新药安全评价研究中心、中国医药工业信息中心。

目前，总院从业人数3000余人，科研团队近500人，其中，中国工程院院士2人，享受国务院特殊津贴专家110人。

医工总院在国内医药类应用型科研院所中居引领地位，是我国医药行业的技术创新基地之一，在国内医药界乃至海外享有盛誉。目前，沪深股市医药板块中30余家上市公司，以医工总院输出的成果作为主要产品。医工总院先后获国家科技发明奖14项，国家科技进步奖15项，上海市科技进步奖等省部级科技进步奖360余项。尤其是2005年以来，医工总院连续5年获得国家技术发明奖、国家科技进步奖，连续7年获得上海市技术发明奖、科技进步奖一等奖。

未来，医工总院将加快实现重大成果的研究突破，真正体现其作为“医药行业技术创新基地、国药集团科技创新平台”的地位和责任，为医药事业的进步和民众生活水平的提高做出贡献。

北京天坛医院
Beijing Tiantan Hospital

首都医科大学附属北京天坛医院始建于1956年，是一所以神经外科为先导，神经科学为特色，集医、教、研、防为一体的大型现代化三级甲等综合教学性医院。经过半个多世纪的艰苦创业和奋发努力，医院实现了跨越式发展，医疗技术水平以及医院的知名度跻身于国内一流医院的行列。

目前医院现有床位1150张，设有30余个临床科室和11个医技科室，年门诊量达百万以上、年住院病人近3万人次，拥有各类先进的医疗设备。

Founded in 1956, Beijing Tiantan Hospital affiliated to the capital medical university, a quaternity consisting of medical treatment, scientific research, medical education and disease prevention, is a large upper first-class general hospital with the characteristic of neuroscience especially associated with neurosurgery serving as a precursor. Through hard work and strenuous efforts for more than half a century, the hospital has already achieved leap-and-bound development and ascended into the top-level hospitals in China in terms of medical technology and hospital fame.

There are 1150 beds with 30 clinical departments and 11 adjunct departments at present in hospital equipped with various advanced medical equipments, and furthermore, annual patient visits steadily increased tallying up to over I million and 30,000 inpatient admissions per year.

重要活动
Important Events

中国药促会在上海召开2013年第一次会长会议
1st SINO-PhIRDA Chairman Board Meeting in Shanghai on February 21, 2013



桑国卫副委员长与全体与会代表合影。（2013年2月21日·上海）

Group photo of representatives with Academician Sang Guowei, Vice Chairman of the Standing Committee of the Eleventh National People's Congress (February 21, 2013, Shanghai).

2013年度兼职副秘书长第一次会议（2013年4月18日·重庆）

1st Deputy Secretary-General Meeting of SINO-PhIRDA in 2013 (April, 18, 2013, Chongqing)

2013年会员单位联络秘书工作会议（2013年9月4日 内蒙古·赤峰）

2013 Annual Meeting of SINO-PhIRDA Contact Secretary (September 4, 2013, Chifeng, Inner Mongolia)

宋瑞霖执行会长作“当前热点问题给企业带来的机遇与挑战”的报告

Speech by Executive President Song Ruilin on “Hot Topics, Opportunities and Challenges in Pharmaceutical Industry”.

张清奎部长作“知识产权保护与企业创新”的报告

Speech by Zhang Qingkui on “IPR Protection and Innovation”.

联络秘书工作会议会场

Plenary meeting

第九届会员大会第四次会议(2013年10月17日·北京)

4th Meeting of SINO-PhIRDA Ninth General Assembly (October 17, 2013, Beijing)

2012–2013年度轮值会长陈启宇主持会议

Address by Chen Qiyu, SINO-PhIRDA's Annual Chairman of 2012-2013.

执行会长宋瑞霖做工作报告

Address by Executive President Song Ruilin.

副会长孙飘扬宣读桑国卫院士贺信

Sun Piaoyang, SINO-PhIRDA's Vice- President, delivered congratulatory letterfrom Academician Sang Guowei, Vice Chairman of the Standing Committee of the Eleventh National People's Congress.

总监票人中国药科大学邵蓉教授宣读
我会2013–2014年度轮值会长选举结果

Total scrutineer Shao Rong, Professor of China Pharmaceutical University, declared the election result of SINO-PhIRDA's Annual Chairman of 2013-2014.

2012–2013年度轮值会长陈启宇为2013–2014年度
轮值会长闫希军颁发证书

Chen Qiyu, SINO-PhIRDA's Annual Chairman of 2012-2013, presented certificate to Yan Xijun, SINO-PhIRDA's Annual Chairman of 2013-2014.

常务副秘书长陈昌雄宣读
《关于优化我国医药创新生态环境的建议书》

Chen Changxiong, Executive Deputy Secretary-General of SINO-PhIRDA, delivered speech on Proposal on Optimizing Pharmaceutical Innovative Eco-system in China.

副秘书长冯岚做
《中国药促会2012年度会费收支情况报告》

Feng Lan, Deputy Secretary-General of SINO-PhIRDA, made a report on Income and Expenditure of SINO-PhIRDA Membership Fee in 2012.

清华大学教授李稻葵做学术报告

Address by Li Daokui, Professor of Tsinghua University.

会议主席台

Representatives from SINO-PhIRDA Chairman and Vice-President members.

会场全景

Plenary meeting

第三届中国医院药学论坛（2012年8月4日 青海·西宁）

3rd Forum of China's Hospital & Pharmacy (August 4, 2012, Xining, Qinghai Province)

大会开幕式
Opening ceremony

天坛医院王拥军副院长
主持会议开幕式

Wang Yongjun, Deputy-Dean of Tiantan Hospital, hosted the opening ceremony.

卫生部医疗服务监管司何红副司长

He Hong, Deputy DG of Department of Medical Service Supervision of Ministry of Health

发改委药品价格审评中心卢凤霞主任

Lu Fengxia, DG of Evaluation Center of Drug Pricing National Development and Reform Commission.

卫生部医政司医疗管理处王斐

Wang Fei, Director from Medical Administration and Medical Service Supervision Division of Ministry of Health.

北京大学人民医院药剂科冯婉玉主任

Feng Wanyu, Director of Pharmacy, Peking University People's Hospital.

北京大学第三医院药剂科翟所迪主任

Zhai Suodi, Director of Pharmacy, Peking University Third Hospital.

北京天坛医院药剂科赵志刚主任

Zhao Zhigang, Director of Pharmacy, Tiantan Hospital.

大会会场

Plenary meeting

国家创新药物政策专家座谈会（2012年9月22日·北京）

Experts Seminar on Policies Promoting Development of Innovative Drugs (September 22, 2012, Beijing)

桑国卫副委员长（中）、
国家食品药品监督管理总局副局长吴浈（左）、
时任卫生部科教司司长何维（右）

Academician Sang Guowei, Vice Chairman of the Standing Committee of the Eleventh National People's Congress (middle); Wu Zhen, Vice Commissioner of CFDA (left); He Wei, DG of Department of Science and Technology and Education of Ministry of Health (right).

参加座谈会的有关领导
Officials attended this conference.

会场全景
Plenary meeting

创新药物市场环境建设政策座谈会（2013年1月11日-北京）

SINO-PhIRDA held the seminar on Construction of Innovative Pharmaceutical Drugs Market Environment in Diaoyutai State Guesthouse (January 11, 2013, Beijing).

桑国卫副委员长发表重要讲话

Academician Sang Guowei, Vice Chairman of the Standing Committee of the Eleventh National People's Congress, Honorary Chairman of SINO-PhIRDA, delivered important speech.

执行会长宋瑞霖主持会议

Executive President Song Ruilin hosted the meeting.

北京市卫生局方来英局长做报告

Addressed by Fang Laiying, Secretary of Party Leadership Group and Director of Beijing Municipal Health Bureau

青岛社保局刘军帅处长做报告

Addressed by Liu Junshuai, Director of Health Insurance Division of Qingdao Human Resources and Social Security Bureau.

复旦大学陈文教授做药物经济学演讲

Addressed by Chen Wen, Professor of Fudan University.

部分参会领导合影

Photography of officials during this meeting

国家重大新药创制专项项目成果应用汇报会(凯美瑞IV期临床研究总结会)（2013年4月16日·北京）

Report Meeting of National Major New Drug Application Project – Summary of Conmana IV Phase Clinical Research (April 16, 2013, Beijing).

执行会长宋瑞霖率调研组在重庆药品交易所调研
（2013年4月17日·重庆）

Led by Executive President Song Ruilin, the expert group visited Chongqing Medicine Trade Center.
(April 17, 2013, Chongqing).

调研组与重庆药品交易所总经理敖荣峰合影

SINO-PhIRDA investigation working group met with Ao Rongfeng,
General Manager of Chongqing Drug Trading Office

研讨《广东省药品交易规则（征求意见稿）》座谈会（2013年5月22日-北京）

Seminar on Pharmaceutical Trading Rules in Guangdong Province (Draft) (May 22, 2013, Beijing)

高值药品医保报销方式研究结题报告会（2013年5月23日·北京）

Closing Seminar on Research of High-value Drug Reimbursement Systems (May 23, 2013, Beijing)

桑国卫院士（右2）、人社部姚宏司长（左2）、
协和医院李大魁教授（右1）、宋瑞霖执行会长（左1）

Academician Sang Guowei, Vice Chairman of the Standing Committee of the Eleventh National People's Congress(second from right); Yao Hong, DG of MOHRSS(second from left); Li Dakui, professor of Peking Union Medical College Hospital (first from right); Song Ruilin, Executive President of SINO-PhIRDA (first from left).

会议现场

Plenary meeting

中国药促会赴青岛调研长期护理保险制度（2013年6月13日-6月14日.青岛）

SINO-PhIRDA working Group went to Qingdao to have an investigation on long-term care insurance system (June 13-14, 2013, Qingdao)

青岛市济南军区第二疗养院负责同志向
宋瑞霖执行会长介绍有关情况

Introduction by 2nd Sanatorium in Jinan Military Region of Qingdao

调研组、青岛社保局的领导与青岛市四方区红会
养老护理院的同志合影

Photography of working group with representatives from Red Cross Nursing Home in Sifang District.

药品注册审评工作座谈会（2013年8月1日-南京）

Seminar on Drug Registration and Approval (August 1, 2013, Nanjing)

上海市医保药品“带量采购“实施方案座谈会（2013年8月6日·北京）

Seminar on Implementation Plan for Drug Purchase with Required Amount in Shanghai. (August 6, 2013, Beijing)

第四届中国医院药学政策论坛（2013年8月9日 辽宁·丹东）

4th Forum of China's Hospital & Pharmacy (August 9, 2013, Dandong,Liaoning)

中国药学会医院药学专业委员会
主任委员朱珠主持开幕式

Zhu Zhu, Director of Hospital Pharmacy Professional Committee of Chinese Pharmaceutical Association, hosted the opening ceremony.

中国药学会李少丽副理事长致辞

Address by Li Shaoli, Deputy Director of Chinese Pharmaceutical Association in the opening ceremony.

执行会长宋瑞霖致辞

Address by Executive President Song Ruilin.

北医三院翟所迪主任作报告

Address by Zhai Suodi,
Peking University Third Hospital.

天坛医院赵志刚主任
主持分论坛

Zhao Zhigang, Director of Tiantan Hospital, hosted the meeting.

上海交大附属第一人民医院
刘皋林主任作报告

Address by Liu Gaolin, Director of Shanghai First People's Hospital.

2012年11月30日，我会与中国外商投资企业协会药品研制和开发行业委员会（RDPAC）、美国药品研究与制造商协会（PhRMA）联合举办的“2012国际医药创新峰会”，峰会的主题为“全面提升中国生物医药产业创新能力”。

On November 30, 2012, “2012 International Pharmaceutical Innovation Summit” was co-hosted by RDPAC, SINO-PhIRDA and PhRMA in Beijing, under the theme “Improving innovative capability of pharmaceutical enterprises in China”.

桑国卫副委员长主题演讲

Address by Academician Sang Guowei, Vice Chairman of the Standing Committee of the Eleventh National People's Congress.

执行会长宋瑞霖主持峰会

Executive President Song Ruilin hosted the summit.

PhRMA主席、礼来全球CEO李立达致辞

Address by Li Lida, PhRMA Chairman and CEO of Eli Lilly.

中外企业家午餐会

Working Luncheon.

桑国卫副委员长会见PhRMA主席

Academician Sang Guowei, Vice Chairman of the Standing Committee of the Eleventh National People's Congress, met with PhRMA Chairman.

大会会场

Plenary meeting

执行会长宋瑞霖率团赴美国进行考察访问（2013年7月6日–13日·美国）

Led by Executive President Song Ruilin, SINO-PhIRDA delegation visited US (July 6-13, 2013)



代表团与美国哥伦比亚大学专家合影

SINO-PhIRDA delegation with experts from Columbia University.

与美国专利商标局专家合影

The visit to US Patent Trademark Office (USPTO).

代表团访问辉瑞公司总部并与辉瑞公司高管合影

SINO-PhIRDA delegation met with senior executives at Pfizer headquarter.

执行会长宋瑞霖率团赴加拿大进行考察访问（2013年7月14日–21日·加拿大）

Led by Executive President Song Ruilin, SINO-PhIRDA delegation visited Canada (July 14-21, 2013, Canada)

与西安大略大学校领导会谈现场

Meeting with President and representatives from The University of Western Ontario.



在西安大略大学校园

Group photography at The University of Western Ontario.

宋瑞霖执行会长与BC省
生命科学技术协会主席Don Enns
Executive President Song Ruilin met with
Don Enns, President of LSBC.

与LSBC会员企业开展项目洽谈
Meeting with LSBC member companies.

与BC省政府会谈现场
Meeting with BC government.

亚太经合组织医药产业伦理准则会议（2013年8月26–30日.马来西亚·吉隆坡）

APEC Workshop for Voluntary Codes of Business Ethics in Biopharmaceutical Sector
(August 26-30, 2013, Kuala Lumpur, Malaysia)

王鑫副总监代表中国药促会出席APEC医药产业伦理准则会议，并作报告

Wang Xin, Deputy Senior Director – International Affairs, attended APEC event and delivered speech on Ethical Business Practices Code in Biopharmaceutical Industry on behalf of SINO-PhIRDA.

王鑫副总监与美国商务部高级贸易顾问（大会主席）Lynn Costa

Wang Xin, Deputy Senior Director – International Affairs, met with Ms. Lynn A. Costa (Program Overseer, Senior Trade Development Advisor, US Department of Commerce).

2013国际医药创新大会(2013年10月18日·北京)

2013 International Pharmaceutical Innovation Forum (October 18, 2013, Beijing)

上午全体大会

Plenary meeting in the morning

执行会长宋瑞霖主持会议

Executive President Song Ruilin hosted the forum.

北京市食品药品监督管理局副局长
丛骆骆宣读桑国卫院士的贺信

Cong Luoluo, Deputy Director of Beijing Food and Drug Administration delivered the congratulatory letter from Academician Sang Guowei, Vice Chairman of the Standing Committee of the Eleventh National People's Congress.

北京市卫生局局长方来英致辞

Address by Fang Laiying, Secretary of Party Leadership Group and Director of Beijing Municipal Health Bureau

2013–2014年度会长、
天士力控股集团董事局主席闫希军致辞

Address by Yan Xijun, Chairman of the Board of Tianjin Tasly Group and Annual Chairman of SINO-PhIRDA (2013-2014).

中国国际商会秘书长林舜杰致辞

Address by Lin Shunjie, Secretary-General of CCOIC.

波兰药品注册局副局长
MarcinKolakowski作报告

Speech by MarcinKolakowski, Vice President of Polish Office for Registration of Medicinal Products, Medical Devices and Biomedical Products.

国家食品药品监管总局党组成员孙咸泽致辞

Address by Sun Xianze, Member of Party Leadership Committee of CFDA.

美国FaegreBD咨询公司卫生与生物科学部主任Timothy Franson作“医药创新与医药政策之间关系”的演讲

Timothy R. Franson, Principal in FaegreBD Consulting's Health and Biosciences Sector, gave a keynote speech on Relationship between Drug Innovation and Policy.

国家卫生和计划生育委员会药物政策与基本药物制度司司长郑宏作“关于巩固完善基本药物制度的若干思考”的报告。

Zheng Hong, Director-General of Department of National Drug Policy and Essential Medicine System of NHFPC, gave a speech on Drug Biding and Procurement Policy in China.

国家食品药品监管总局药品化妆品注册司稽查专员许嘉齐作“中国药品注册制度与鼓励医药创新”的报告。

Xu Jiaqi, Inspector-General of Department of Drugs and Cosmetics Registration in CFDA, gave a presentation on Current Drug Registration Policy and Drug Innovation in China.

大会会场
Plenary meeting

下午各分会场
Sessions in the afternoon

分会场一：创新政策论坛
Session1：Pharmaceutical Innovation Policy Forum

完善审批制度促进创新药物尽快上市
Improving the drug approval system to promote innovative drug to enter the market

许嘉齐作报告
Speech by Xu Jiaqi

邵蓉作报告
Speech by Shao Rong

张连山作报告
Speech by Zhang Lianshan

Ms Anna Cieslik作报告
Speech by Ms Anna Cieslik

王波作报告
Speech by Wang Bo

武志昂作报告
Speech by Wu Zhiang

姚宏作报告
Speech by Yao Hong

郭剑英作报告
Speech by Guo Jianying

傅鸿鹏作报告
Speech by Fu Hongpeng

朱恒鹏作报告
Speech by Zhu Hengpeng

分会场二：研发技术论坛
Session 2. R&D Technology Forum

“新药临床试验优化设计”
主持人、讲者和嘉宾
（从左至右分别为：周贤忠、王印祥、盖文琳、何伟）
Optimizing design for new drug clinical experiment.
Panelists with the audience
(From left: Eric Chi, Wang Yinxiang, Gai Wenlin and He Wei).

刘川主持“新药临床数据论坛”
Liu Chuan hosted the data management session

“新药临床数据管理”，讲者、嘉宾
（从左至右分别为：黄钦、韩少梅、李卫、石远凯）
Data management for new drug clinical experiment.
Panelists with the audience
(From left: Huang Qin, Han Shaomei, Li Wei and Shi Yuankai).

苏玲主持研发技术论坛

Su Ling hosted the forum.

“新药研发与知识产权保护” 主持人、讲者和嘉宾

Drug innovation & Intellectual property protection.Panelists.

“欧盟美国生物仿制药相关政策”
主持人、讲者和嘉宾

Biosimilar related policies in EU/US. Host and panelists.

分会场三：商业桥企业“1对1”洽谈
Session 3. “One on One” Business Bridge Forum

2012–2013年度轮值会长陈启宇致辞
Address by Chen Qiyu, SINO-PhIRDA's Annual Chairman of 2012-2013.

副秘书长冯岚
主持“商业桥”项目推介会
Feng Lan, SINO-PhIRDA's Deputy Secretary-General, hosted the session.

泰州工业园区项目推介
Introduction by China Medical City

英国MRCT项目推介

Introduction by Medical Research Council Technology from UK

加拿大西安大略大学项目推介

Introduction by WorlDiscoveries of The University of Western Ontario

丹麦投促局项目推介

Introduction by Invest in Denmark

台湾东洋制药项目推介

Introduction by TTY Biopharm from Taiwan

中国药促会大事记

（2012年7月-2013年10月）

1. 2012年7月24日，由“经济学人”等单位主办，中国药促会等单位协办的2012中国卫生圆桌会议在北京举行。
2. 2012年8月4日，第三届中国医院药学论坛在青海省西宁市成功 召开。
3. 2012年9月19日，中国药促会与美国PhRMA在京共同举办“2012 中美医药产业知识产权专家工作组会议”。
4. 2012年9月20日，受波兰共和国驻华大使馆的邀请，中国药促会执行会长宋瑞霖在京会见了波兰驻华大使Tadeusz Chomicki，并与来华访问的波兰卫生部代表就中波两国医药产业间的合作举行会谈。
5. 2012年9月22日，中国药促会在北京举办了“促进创新药物发展政策专家座谈会”。
6. 2012年10月10日，中国药促会与美国PhRMA代表团在北京共同举办了“2012中美峰会第二次专家工作组会”。
7. 2012年11月1日，中国药促会与辉瑞公司在北京召开“补充医疗保险制度”结题会。
8. 2012年11月30日，由中国外商投资企业协会药品研制和开发行业委员会（RDPAC）、中国医药工业科研开发促进会（Sino-PhIRDA）、美国药品研究与制造商协会（PhRMA）共同举办的“2012国际医药创新峰会”在北京隆重举行。全国人大常委会副委员长、中国药促会荣誉会长桑国卫院士出席会议并发表重要讲话。400余位来自政府、行业及相关组织的中外医药界代表参加了会议。
9. 2012年12月4日，中国药促会搬迁至朝阳门外大街26号朝外们写字中心A座 2005室。
10. 2013年1月11日，中国药促会与中国药学会在北京联合举行“创新药物市场环境建设政策研讨会”，全国人大常委会副委员长桑国卫出席会议并发表重要讲话。
11. 2013年1月25日，中国药促会执行会长宋瑞霖与美国药品研发与制造商协会（PhRMA）国际事务高级副总裁Rod Hunter在京举行会晤，就两协会今年的合作以及双方所共同关心的问题进行了深入、友好交流，并达成诸多共识。
12. 2013年2月21日，中国药促会在上海召开 2013年第一次会长会议。全国人大常委会副委员长、中国药促会荣誉会长桑国卫院士出席了本次会议并发表重要讲话。中国药促会10位会长、副会长参加了会议。
13. 2013年2月22日，由中国药促会、沈阳药科大学主办，沈阳三生制药有限公司承办的“中国生物医药研发政策和产业发展高端研讨会”在沈阳召开。
14. 2013年3月4日，民政部批准了中国药促会第九届会员大会第三次会议做出的本会章程修正案，并以书面形式给我会发来了“社会团体章程核准通知书”，这意味着即日起我会新章程正式生效。
15. 2013年4月17日，中国药促会执行会长宋瑞霖率领调研组在重庆开展了考察会员企业和重庆药品交易所的调研活动。
16. 2013年4月26日，中国药促会执行会长宋瑞霖与来京访问的加拿大西安大略大学副校长John Capone等举行会晤。双方就生物医药创新技术和政策研究领域的合作进行了深入友好的交流。
17. 2013年4月28日，中国药促会执行会长宋瑞霖走访了会员企业常州方圆制药有限公司。
18. 2013年5月9日，中国药促会执行会长宋瑞霖走访了会员企业齐鲁制药有限公司。
19. 2013年5月21日，中国药促会执行会长宋瑞霖受加拿大阿尔伯塔大学（University of Alberta）商学院副院长黄礼民的邀请，在京与阿尔伯塔大学的20余位EMBA学员举行座谈。
20. 2013年5月22日，中国药促会执行会长宋瑞霖走访了会员企业北京科信必成医药科技发展有限公司。
21. 2013年5月23日，《高值药品医保报销方式研究》课题结题会在京举行。十一届全国人大常委会副委员长桑国卫院士出席了会议。
22. 2013年5月23日，针对在业内引发广泛争论的广东省药品交易相关规则（试行）（征求意见稿），中国药促会提出了三点意见，并将意见发送广东省药品采购工作领导小组并同时报送国家有关部委。
23. 2013年6月13—14日，中国药促会执行会长宋瑞霖率领调研组赴青岛开展调研活动，主要考察青岛市长期护理保险制度的主要内容与实施情况。调研组还走访了青岛市四方区红十字老年护理院及济南军区青岛第二疗养院。
24. 2013年6月20—21日，中国药促会执行会长宋瑞霖走访了会员企业丽珠集团有限公司。
25. 2013年7月6日-21日，由宋瑞霖执行会长率领的中国药促会代表团赴美国、加拿大进行考察访问。在美期间，就美国医药产业创新发展问题进行考察，专门访问了美国商务部、专利商标局等部门，与美国药品研究与制造商协会（PhRMA）、美国食品药品研究所（FDLI）、哥伦比亚大学等机构的专家进行座谈，详细研究了美国医药产业的发展历程、美国促进医药产业创新发展的主要法律制度等。在加期间，代表团走访了加拿大的2个省级政府机构和行业协会、2所大学、4个科研机构，并对接了50余项医药创新项目。
26. 2013年7月18日，中国药促会代表应邀赴台，参加“2013台湾生技大会（BioTaiwan 2013）”暨“杰出产业看生技未来”研讨会。
27. 2013年8月1日，由中国药促会主办，中国药科大学国家药物政策与医药产业经济研究中心和中国药科大学国际医药商学院承办的“药品注册审评工作企业座谈会”在中国药科大学举行。
28. 2013年8月6日，中国药促会在北京组织有关专家和会员企业代表对上海市医保药品试行“带量采购”的实施方案进行了讨论研究。医药行业的有关专家及药促会的部分会员企业派代表参加了座谈会。
29. 2013年8月9日，第四届中国医院药学政策论坛在辽宁省丹东市召开。本次会议的主题是：药师在医疗服务中的责任和地位。
30. 2013年8月19日，中国药促会执行会长宋瑞霖一行赴上海拜会上海市人力

资源与社会保障局。双方就上海药品招标有关工作进行了坦率而富有建设性的交流，

31. 2013年8月20日，中国药促会执行会长宋瑞霖一行走访了药促会新近会员企业上海中信国健药业股份有限公司，双方进行了亲切友好的交流。
32. 2013年8月26-30日，“2013亚太经合组织医药产业伦理准则会议”在马来西亚吉隆坡举行。中国药促会代表参加了会议，并做了题为“Ethical Business Practices Code in Biopharmaceutical Sector – A View from SINO-PhIRDA”的报告。
33. 2013年9月6日，中国药促会在内蒙古赤峰市召开了2013年会员单位联络秘书工作会议。中国药促会30多家会员单位联络秘书及特邀专家近40人参加了会议。
34. 2013年10月17日，中国药促会在北京召开了第九届会员大会第四次会议。会议以无记名投票方式选举天士力控股集团董事局主席闫希军为我会2013-2014年度轮值会长，选举江苏恒瑞医药股份有限公司董事长孙飘扬为我会2014-2015年度轮值会长候选人，并通过了将我会更名为“中国医药创新促进会”的议案。
35. 2013年10月18日，由中国国际商会、中国药促会、药物信息协会、中国医疗保险研究会、北京市卫生局、北京市食品药品监督管理局共同主办的“2013国际医药创新大会”在北京隆重举行。十一届全国人大常委会副委员长、中国药促会荣誉会长桑国卫院士给大会发来贺信。来自国家发改委、卫生计生委、工信部、社保部、药监总局等有关部门的领导、专家学者出席了会议。

Remarkable Events of SINO-PhIRDA

(July 2012 – October 2013)

1. On July 24, 2012, Healthcare Round-table Conference hosted by Economist, co-organized by SINO-PhIRDA, was held in Beijing.
2. On August 4, 2012, Third Forum of China’s Hospital & Pharmacy was successfully held in Xi'Ning, Qinghai Province.
3. On September 19, 2012, SINO-PhIRDA and PhRMA co-hosted the 2012 Experts Working Group Seminar on IPR in Pharmaceutical Industry in Beijing.
4. On September 20, 2012, upon the invitation of Embassy of the Republic of Poland in Beijing, Executive President Song Ruilin met with Ambassador Tadeusz Chomicki, and had discussion on the bilateral collaboration in pharmaceutical industry between China and Poland together with representatives of Polish Ministry of Health.
5. On September 22, 2012, SINO-PhIRDA held Experts Seminar on Policies Promoting Development of Innovative Drugs in Beijing.
6. On October 10, 2012, SINO-PhIRDA and PhRMA co-hosted 2012 Second Experts Working Group Seminar for SINO-US Pharmaceutical Industry Summit in Beijing.
7. On November 11, 2012, SINO-PhIRDA and Pfizer co-hosted the closing seminar on Supplementary Medical Insurance System in Beijing.
8. On November 30, 2012, 2012 International Pharmaceutical Innovation Forum was co-hosted by RDPAC, SINO-PhIRDA and PhRMA in Beijing. Academician Sang Guowei, Vice Chairman of the Standing Committee of the Eleventh National People's Congress, Honorary President of SINO-PhIRDA, attended this conference and delivered important speech. More than 400 representatives from government, industry and relevant organizations wordlwide participated in this event.
9. On December 4, 2012, SINO-PhIRDA moved to Room 2005, Suite A, Chaoyang MEN Business Center, 26 Chaowai Street.
10. On January 11, 2013, SINO-PhIRDA and Chinese Pharmaceutical Association co-hosted Policy Seminar on the Construction of Innovative Drug Market Environment. Academician Sang Guowei, Vice Chairman of the Standing Committee of the Eleventh National People's Congress, Honorary President of SINO-PhIRDA, attended this event and delivered important speech.
11. On January 25, 2013, Executive President Song Ruilin met with Mr. Rod Hunter, Senior Vice President of International Affairs of PhRMA, and had warm discussion on bilateral collaboration and common interests in Beijing,.
12. On February 21, 2013, SINO-PhIRDA held the 1st Chairman Board Meeting in 2013 in Shanghai. Academician Sang Guowei, Vice Chairman of the Standing Committee of the Eleventh National People's Congress, Honorary President of SINO-PhIRDA, attended this event and delivered important speech. SINO-PhIRDA Chairman and Vice-Presidents participated in this meeting.
13. On February 22, 2013, Biopharmaceutical R&D Policies and Industrial Development Forum co-hosted by SINO-PhIRDA and Shenyang Pharmaceutical University, co-organized by Shenyang Sunshine Pharmaceutical Co., Ltd, was held in Shenyang.
14. On March 4, 2013, Ministry of Civil Affairs approved the Amendments of SINO-PhIRDA Constitution made by the 3rd meeting of SINO-PhIRDA Ninth General Assembly, and sent Approval Notice of Regulations on Social Organizations Constitution, indicating that the new constitution came into force since this day.
15. On April 17, 2013, Executive President Song Ruilin led an investigation working group to Chongqing and visited member companies and Chongqing Drug Trading Office.

16. On April 26, 2013, Executive President Song Ruilin met with Dr. John Capone, Vice President of University of Western Ontario in Canada, and had warm discussion on pharmaceutical innovative technology collaboration and policy research.
17. On April 28, 2013, Executive President Song Ruilin visited SINO-PhIRDA member company Changzhou Fangyuan Pharmaceutical Co., Ltd.
18. On May 9, 2013, Executive President Song Ruilin visited SINO-PhIRDA member company Qilu Pharmaceutical Co., Ltd.
19. On May 21, 2013, upon the invitation by Dr. Edy Wong, Vice Dean of Business School at University of Alberta in Canada, Executive President Song Ruilin gave a lecture and had warm discussion with more than 20 EMBA students from University of Alberta.
20. On May 22, 2013, Executive President Song Ruilin visited SINO-PhIRDA member company Beijing CoSci Med-Tech Co., Ltd.
21. On May 23, 2013, the closing seminar on Research of High-value Drug Reimbursement Systems was held in Beijing. Academician Sang Guowei, Vice Chairman of the Standing Committee of the Eleventh National People's Congress, Honorary President of SINO-PhIRDA, attended this event.
22. On May 23, 2013, focusing on the "Pharmaceutical Trading Rules in Guangdong Province (Draft)", which caused wide controversy among the industry, SINO-PhIRDA proposed three revising suggestions and sent comments to Guangdong Drug Purchasing Leading Group, meanwhile submitted to the relevant state ministries and commissions.
23. During June 13-14, 2013, Executive President Song Ruilin led a working group to Qingdao for investigation on main contents of long-term care insurance system and its implementation. The working group visited Red Cross Nursing Home in Sifang District and the 2nd Sanatorium in Jinan Military Region.
24. During June 20-21, 2013, Executive President Song Ruilin visited SINO-PhIRDA member company Livzon Pharmaceutical Group Inc.
25. During July 6-21, 2013, led by Executive President Song Ruilin, SINO-PhIRDA delegation visited US and Canada. During the visit to US, the delegation met with representatives from US Department of Commerce, US Patent and Trademark Office, PhRMA, FDLI, University of Columbia, etc., discussing common interests on the development history of US Pharmaceutical industry and major laws and regulations, as well as the main factors to promote the innovative development of the industry.
    During the visit to Canada, the delegation visited governments and industry organizations in Ontario and British Columbia, University of Western Ontario, University of British Columbia, four research institutes with more than 50 innovative projects introduced.
26. On July 18, 2013, SINO-PhIRDA representatives attended 2013 BioTaiwan Conference.
27. On August 1, 2013, Enterprises Seminar on Drug Registration and Approval hosted by SINO-PhIRDA, co-organized by Research Center of National Drug Policy & Ecosystem and International Pharmaceutical Business College of China Pharmaceutical University, was held in China Pharmaceutical University.
28. On August 6, 2013, SINO-PhIRDA organized relevant experts and member companies for a discussion on Implementation Plan for Drug Purchase with Required Amount in Shanghai. Representatives from SINO-PhIRDA members and experts in pharmaceutical industry attended this event.
29. On August 9, 2013, 4th Forum of China's Hospital & Pharmacy, under the theme of role and responsibility of pharmacists in medical services, was held in Dandong, Liaoning Province.
30. On August 19, 2013, Executive President Song Ruilin visited Shanghai Office of Human Resource and Social Security, and had a productive discussion on drug biding activities in Shanghai.
31. On August 20, 2013, Executive President Song Ruilin, visited SINO-PhIRDA member company Shanghai Zhongxin Guojian Pharmaceutical Co., Ltd.
32. During August 26-30, 2013, invited by Asia-Pacific Economic Cooperation (APEC), SINO-PhIRDA representative attended APEC Workshop at Malaysia Anti-Corruption Academy (MACA) in Kuala Lumpur, Malaysia, delivered speech on Ethical Business Practices Code in Biopharmaceutical Industry, and shared views with audience during panel discussion session.
33. On September 6, 2013, SINO-PhIRDA held 2013 Secretary Working Meeting of Member Companies in Chifeng, Inner Mongolia Province. Nearly 40 secretaries from SINO-PhIRDA member companies and invited experts attended this event.
34. On October 17, 2013, the 4th Meeting of SINO-PhIRDA Ninth General Assembly was held in Beijing. Mr. Yan Xijun, Chairman of the Board of Tianjin Tasly Group, was elected as the Annual Chairman of SINO-PhIRDA (2013-2014). Mr. Sun Piaoyang, Chairman of the Board of Hengrui Medicine Co., Ltd, was elected as the candidate of the Annual Chairman of SINO-PhIRDA (2014-2015). The meeting approved the renaming proposal to China Pharmaceutical Innovation Association.
35. On October 18, 2013, 2013 International Pharmaceutical Innovation Forum, co-hosted by China Chamber of International Commerce (CCOIC), China Pharmaceutical Industry Research and Development Association (SINO-PhIRDA), Drug Information Association (DIA), China Health Insurance Research Association (CHIRA), Beijing Municipal Health Bureau, Beijing Food and Drug Administration, was held in Beijing. Academician Sang Guowei, Vice Chairman of the Standing Committee of the Eleventh National People's Congress, Honorary Chairman of SINO-PhIRDA, sent a congratulatory letter to the event.Relevant officials, scholars and experts from NDRC, NHFPC, MIIT, MHRSS,CFDA attended this event.

地址：北京市朝阳区朝外大街26号朝外们写字中心A座2005　邮政编码：100020
Add: Room 2005,Suite A,Chaowai MEN Business Center,26 Chaowai Street,Chaoyang District,Beijing,P.R.China,100020
电话(Tel): (8610) 85654830　传真(Fax)：(8610) 85654833
Web:www.phirda.com